TNF-α inhibitor treatment and the risk of cardiovascular events in patients newly diagnosed with rheumatoid arthritis by Desai, Rishi J.
TNF-α INHIBITOR TREATMENT AND THE RISK OF CARDIOVASCULAR 
EVENTS IN PATIENTS NEWLY DIAGNOSED WITH RHEUMATOID ARTHRITIS 
 
 
Rishi J Desai 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Division 
of Pharmaceutical Outcomes and Policy in the Eshelman School of Pharmacy 
 
 
Chapel Hill 
2013 
 
 
                                                                                                        Approved by: 
                                                                                         Joel F Farley, PhD 
                                                                                       Jaya K Rao, MD  
                                                                                      Gang Fang, PhD 
                                                                                                  Richard A Hansen, PhD  
                                                                                                        Matthew Maciejewski, PhD 
ii 
 
ABSTRACT 
RISHI J DESAI: TNF-α inhibitor treatment and the risk of cardiovascular events in patients 
newly diagnosed with rheumatoid arthritis 
(Under the direction of Dr. Joel Farley) 
 
Rheumatoid arthritis (RA) is an autoimmune disease that is mainly treated with 
various non-biologic and biologic disease modifying anti-rheumatic drugs (DMARDs). RA 
patients experience cardiovascular diseases (CVD) at a higher rate compared to the general 
population. Biologic DMARDs that inhibit the effects of the pro-inflammatory cytokine, 
tumor necrosis factor (TNF)-α which is implicated in various atherosclerotic processes, may 
reduce the risk of CVD. Very little evidence exists evaluating the association between TNF-
inhibitors (TNF-Is) and CVD in early RA patients. 
Using data from Truven’s MarketScan claims database for the period of 2007-2010, 
we first examined the factors influencing treatment with biologics in RA patients in a 
retrospective cohort study. We observed that treatment initiation with biologics in RA 
patients is associated with patient age, RA severity, RA type, pre-index non-biologic 
DMARD and steroid use, health insurance type, and drug benefit generosity. Neither the 
presence of cardiovascular risk factors, hypertension, hyperlipidemia or diabetes nor the
 history of CVD, including acute myocardial infarction, chronic heart failure, stroke or other 
CVD, were found to be associated with the initiation of biologic treatments.  
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We then evaluated the impact of treatment with TNF-Is on the risk of incident CVD 
events in patients newly diagnosed with RA using a nested case-control design with 
incidence density sampling. We observed that the risk of an incident CVD event was reduced 
by current treatment with TNF-Is and non-biologic DMARDs compared to no treatment with 
DMARDs. Further, we observed that this protective effect was found to be associated with 
the duration of TNF-I and non-biologic DMARD use in a linear manner. Finally, we 
examined the independent effects of infliximab, adalimumab and etanercept on the risk of 
CVD in the same cohort. We observed that treatment with adalimumab, but not with 
infliximab and etanercept, was found to be associated with a reduced risk of incident CVD 
events compared to no treatment with DMARDs.  
In conclusion, we observed that early TNF-I or non-biologic DMARD treatment may 
play a vital role in reducing the increased CVD burden in RA patients, potentially by 
producing favorable changes in traditional cardiovascular risk factors and RA risk factors.   
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   CHAPTER 1 
1. INTRODUCTION  
 
1.1 Overview: 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of 
the synovium, a membrane that lines the joint capsule and produces lubricating fluid in the 
joint, leading to disability in most cases (1). Data from 2008 suggest that RA affects 
approximately 1.3 million adults in the United States (2). Disease onset generally occurs 
between ages 30 and 50 years, and the incidence is higher in women and older adults. During 
the past 20 years, pharmacotherapy of RA has evolved to include treatment with one or more 
disease modifying anti-rheumatic drugs (DMARD) with a goal of controlling inflammation 
and preventing joint damage (3). DMARDs are generally classified into non-biologic 
(traditional) and biologic agents. Non-biologic DMARDs include orally-administered 
medications such as methotrexate (MTX), sulfasalazine hydroxychloroquine, and 
leflunomide. These agents halt the progression of RA through reducing inflammation by 
suppressing systematic immune response; however their suppression of the immune system 
is non-selective. Biologics differ from non-biologic DMARDs because they target specific 
components of the immune system, specifically cytokines such as Tumor necrosis factor 
(TNF)-α and interleukins. Biologics are administered intravenously or subcutaneously.
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Patients with RA experience cardiovascular diseases (CVD) at a higher rate compared 
to general population (4, 5). CVD is believed to contribute to as much as half of the deaths in 
RA patients (6). The increased rate of CVD in RA patients is driven by accelerated 
atherosclerosis that occurs as a result of increased inflammation (7). Structural damage to 
joints is known to occur aggressively within first few years of RA diagnosis (8, 9), so it is 
possible that acceleration of atherosclerosis may also be more aggressive during early stages 
of RA. Supporting this hypothesis, data from two small studies indicate that atherogenic lipid 
profile and subclinical atherosclerosis can be seen in RA patients at very early stages of the 
disease (10, 11). Therefore, it is important to evaluate the impact of various RA treatments on 
CVD events in early RA patients from a clinical standpoint.   
The first step in evaluating outcomes of biologics treatment is to understand the 
factors that play a role in the treatment initiation in RA patients with biologics. The current 
literature lacks studies that specifically evaluate the factors influencing biologic treatment 
initiation. Identifying predictors of biologic treatment may in turn help to access and target 
the most important factors that facilitate treatment initiation. After understanding the patient 
characteristics that influence treatment initiation with biologics, the next logical step is to 
examine their association with CVD outcomes in RA patients. Among all of the currently-
available treatments, TNF- α inhibitors (TNF-Is) are of special interest because of the 
involvement of TNF-α in the development and acceleration of atherosclerosis. Although, 
several observational studies have attempted to evaluate this association, most of these 
studies are conducted in patients with established RA and very limited information is 
available specific to early RA cases. The literature also lacks evidence for the independent 
effects of different individual TNF-I agents on CVD outcomes in RA patients. TNF-Is are a 
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heterogenous class of drugs and therefore it may not be appropriate to assume a class effect 
of TNF-Is in terms of their effects on reducing the risk of CVD.  
Thus, the main goal of this dissertation is to understand the predictors of biologic 
treatment initiation in RA patients and to examine the effect of TNF-I treatment on the risk of 
CVD events in early RA patients.  
1.2 Specific Aims: 
This dissertation has the following Specific Aims.  
Specific Aim 1: To identify factors influencing biologic treatment initiation in RA patients  
We designed a retrospective cohort study to evaluate the influence of sets of various 
population characteristics on biologic treatment initiation using the Andersen’s behavioral 
model (ABM) for health services use (11). ABM posits a process of health care use in which 
predisposing factors influence the ability (measured through enabling factors) of a person to 
obtain health care which, when adding the need for treatment, predicts the use of health care 
services. Predisposing factors included the variables that may influence the likelihood of 
need for health services. Patients’ age, gender and geographic location were included in this 
set. Enabling factors included variables suggesting patients’ ability to secure healthcare 
services. We included the following variables in this set: visit to a rheumatologist, health plan 
type, type of insurance and drug benefit generosity. Need factors included health conditions 
of patients that necessitate the utilization of health services. In this set, we included RA 
related factors such as RA type, RA severity, RA drug use in pre-index period, and other 
comorbid conditions. To understand the impact of various predictors on the initiation of a 
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biologic agent after controlling for other predictors in a multivariate manner, hierarchical 
logistic regression models were used in which the predictors were entered in 3 sets.  
Specific Aim 2: To examine the effect of TNF-I treatment on incident CVD event in 
patients newly diagnosed with RA 
In this specific Aim, we evaluated the association between TNF-I treatment and 
incident CVD events in patiently newly diagnosed with RA using several different 
definitions of treatment exposure to account for the timing and history of treatment with all 
the DMARDs. A nested case-control study was designed to evaluate this association. The 
outcome of interest was defined as a composite measure consisting of acute myocardial 
infarction, unstable angina, angina pectoris, chronic heart failure, other forms of chronic 
heart diseases, ischemic stroke; and transient ischemic stroke. Three unique exposure 
definition schemes were used. First classified TNF-I use as ever vs never use, second 
definition considered current use indicators for TNF-Is and other RA treatments, third 
definition considered current and past use indicators for TNF-I and other RA treatments. The 
estimates of the association between TNF-I use and CVD events were derived from 
conditional logistic regression models.  
Specific Aim 3: To assess independent effects of individual TNF-Is (adalimumab, 
etanercept, infliximab) on the risk of incident CVD events in patients newly diagnosed with 
RA 
In this specific Aim, we examined the association between the use of individual TNF-
Is, infliximab, etanercept and adalimumab, and incident CVD events in patients newly 
diagnosed with RA. The outcome of interest was defined as a composite measure consisting 
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of acute myocardial infarction, unstable angina, angina pectoris, chronic heart failure, other 
forms of chronic heart diseases, ischemic stroke; and transient ischemic stroke. A nested 
case-control study design was used for this specific Aim.  
We analyzed data from Truven's MarketScan Commercial Claims and Encounters 
(CCAE) and Medicare Supplemental and Coordination of Benefits (COB) for the years 2007-
2010 for this study. The Marketscan database contains claims submitted from health plans 
which have contracts with large private employers or public organizations in the United 
States (12). This longitudinal database covers all inpatient, outpatient, and prescription 
claims for individual patients as long as they remain enrolled in the health plan.  
The results of of our Aim 1 can improve our understanding of the predictors of 
biologic treatment initiation in RA patients. This can help identify factors and target patient 
subgroups for biologic treatment initiation to maximize treatment benefit from these agents. 
Results from Aims 2 and 3 can add unique information to the literature by providing 
information on whether TNF-I therapy has an effect on improving CVD outcomes among 
newly diagnosed RA patients. These findings could guide therapeutic decision-making to 
improve the quality of care provided to patients with RA. 
 
 CHAPTER 2 
2 BACKGROUND AND LITERATURE REVIEW 
 
 In section 2.1, we provide an overview of rheumatoid arthritis (RA) and current 
treatment options. Section 2.2 provides a review of the literature on the relationship between 
RA and cardiovascular diseases (CVD). In section 2.3, we present a review of the current 
evidence regarding TNF-α inhibitor (TNF-I) treatment and CVD events in RA patients. In 
section 2.4, we describe the limitations of previous studies and provide a rationale for the 
proposed study. Finally in section 2.5, we propose a theoretical framework for this study.  
2.1 Rheumatoid arthritis overview: 
RA is an autoimmune disease characterized by inflammation of the synovium, a 
membrane that lines the joint capsule and produces lubricating fluid in the joint. 
Uncontrolled synovial inflammation, or synovitis, leads to progressive erosion of bone and 
cartilage and, ultimately results in joint malalignment and secondary osteoarthritis (1). As the 
inflamed synovium destroys the joint, the surrounding muscles and tendons become weak, 
leading to disability in most cases. According to a 2008 estimate, RA affects approximately 
1.3 million adults in the United States and is associated with substantial morbidity and 
mortality (2). Disease onset generally occurs between ages 30 and 50 years. and the 
incidence is higher in women and older adults. 
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Annually, approximately 9 million physician office visits and more than 250,000 
hospitalizations occur as the result of arthritis and other rheumatic conditions (13, 14).The 
mean total annual direct cost to patients with RA is estimated to be $9,519 per person (15), 
and according to most studies, the indirect costs of RA are approximately twice the direct 
costs associated with this condition (16). The average number of days absent from work due 
to RA has been reported to be in the range of 2.7 to 30 days annually (17).  
Patients with RA are typically treated with a combination of medications from one or 
more of the following therapeutic classes: 1) non-steroidal anti-inflammatory drugs 
(NSAIDs), 2) corticosteroids, and 3) disease modifying anti-rheumatic agents (DMARDs) 
(18). The overarching goal of pharmacological therapy in RA is to control inflammation and 
prevent joint damage.  NSAIDs and corticosteroids provide symptomatic relief in RA 
patients while DMARDs halt the progression of the disease.   
DMARDs are generally classified into non-biologic (traditional) and biologic 
treatments. Non-biologic DMARDs are orally-administered medications and include agents 
such as MTX, SSZ, HCQ, azathioprine, penicillamine and leflunomide. Non-biologic 
DMARDs halt the progression of the disease by suppressing inflammation, but they do not 
interfere with the functioning of specific components of the immune system. On the other 
hand, biologics are intravenously or subcutaneously administered and target specific 
components of the immune system, such as T cells, B cells, and cytokines, that play an 
important role in the pathogenesis of RA (19).  
The US Food and Drug Administration (FDA) approved the first biologic (infliximab) 
for treatment of RA in 1998. Since that time, nine more agents have been approved: 
etanercept (1998), anakinra (2001), adalimumab (2002), abatacept (2005), rituximab (2006), 
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certolizumab pegol (2008), golimumab (2009), tocilizumab (2010), and tofacitininb (2012). 
Infliximab, adalimumab, golimumab, etanercept and certolizumab produce their primary 
effect by blocking TNF-α from interacting with cell surface TNF receptors, thereby blocking 
the inflammatory effects of TNF- α (20); these medications are classified as TNF-Is. Other 
biologic agents act on different components of the immune system.  Anakinra and 
Tocilizumab block interleukins (IL), abatacept inhibits T-cell activation by binding to CD80 
and CD86 surface antigens, tofacitinib,is a janus kinase inhibitor. and rituximab causes 
depletion of B-cells by blocking CD 20 surface antigen (21).   
Since the 1990s, treatment of RA has evolved from a traditional pyramid approach in 
which treatment with DMARDs was reserved for patients with refractory disease to an 
“inverted pyramid” approach in which patients with early RA symptoms are treated with a 
combination of DMARDs in an attempt to control inflammation and prevent joint damage 
(3). Non-biologic DMARDs are recommended for all the RA patients while the use of TNF-
Is is recommended in RA patients with moderate to high disease activity with features of 
poor prognosis (22). If the patients do not respond to TNF-Is, then they may be moved to 
other biologic agents. For RA patients with low disease activity, TNF-Is are reserved for 
patients who fail to respond to non-biologic DMARDs. 
2.2 Rheumatoid arthritis and cardiovascular diseases: 
The association between RA and CVD has been the focus of recent attention, primarily 
because of the increasing recognition of the major role that inflammation plays in the 
development of atherosclerosis in the general population (7, 23, 24).  
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2.2.1 The role of inflammation and the development of cardiovascular disease 
The pathway leading to CVD-related events begins with the development of 
atherosclerosis (25). RA is hypothesized to be associated with early initiation of 
atherosclerosis through endothelial cell dysfunction (26). TNF-α, a pro-inflammatory 
cytokine involved in the pathogenesis of RA, may mediate endothelial cell dysfunction by 
inducing expression of leukocyte adhesion molecules that facilitates the penetration of 
monocytes into the vessel wall (27). After entry, the monocytes differentiate into 
macrophages that ingest lipoproteins to form “Foam cells” and fatty streak (25). Foam cells 
express pro-inflammatory cytokines, including TNF-α that promotes proliferation of smooth 
muscle cell into the intima of blood vessels and formation of a fibrofatty plaque (28). TNF-α 
is also synthesized in the plaque (29) and is thought to increase collagen breakdown and 
facilitate plaque rupture (25). Nearly three-quarters of all acute MIs are believed to be caused 
by plaque rupture (25).  Several reports suggest that endothelial functioning may improve 
with TNF-I treatment (30-34).   
TNF-α also has an effect on traditional CVD risk factors such as insulin resistance 
and dyslipidemia (35). TNF-α is considered to be an important mediator of insulin resistance 
because it decreases tyrosine kinase activity of insulin receptors and impedes insulin-
mediated uptake of glucose in skeletal muscle (36). TNF-α also directly interferes with the 
metabolic pathways of triglycerides and cholesterol (35)resulting a higher level of low-
density lipoprotein (25). Numerous studies have shown a positive impact of TNF-I treatment 
on these traditional CVD risk factors in RA patients (37-40).  
Thus, TNF-α may play an important role in the development and acceleration of 
atherosclerosis in RA patients. Therefore, it is plausible to hypothesize that treatment with 
 10 
 
TNF-Is in RA patients may be able to halt the progression of atherosclerosis, ultimately 
leading to reduction in risk of CVD events.     
2.2.2 Data on the relationship between rheumatoid arthritis and cardiovascular disease 
Several epidemiological studies indicate that RA patients have an increased risk of 
CVD-related morbidity and mortality compared to the general population (4, 5, 41).  A case-
control study of data from the UK General Practice Research Database showed that RA 
patients had a 47% higher odds of developing a first episode of acute myocardial infarction 
(AMI) compared to non-RA patients (41). Maradit-Kremers et al.(4) also reported that 
patients with RA have a significantly higher risk of chronic heart diseases (CHD) and are 
more likely to suffer an unrecognized myocardial infarction (MI) compared to patients 
without RA. Data from the Nurses Health Study showed that women with RA had a two-fold 
increase in the risk of AMI compared to women without RA (5). A meta-analysis reported 
that CVD-related mortality is approximately 50% higher in RA patients compared to the 
general population(6). 
Studies indicate that the increased risk of CVD-related morbidity and mortality in RA 
patients cannot be satisfactorily explained by traditional risk factors such as hypertension, 
dyslipidemia, smoking and diabetes mellitus. Gonzalez et al.(42) reported that traditional risk 
factors imparted significantly less risk for the development of CVD in RA patients compared 
to patients without RA. This finding suggests that extraneous RA-related risk factors may 
also play a role in the development of CVD.  Solomon et al. (43) observed an improvement 
in the prediction of CVD events in RA patients when RA-related risk factors such as disease 
duration > 5 years, the presence of radiographic joint erosions, the presence of subcutaneous 
nodules, a prior total joint replacement, modified health assessment questionnaire (HAQ) 
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score ≥ 2, a Clinical Disease Activity Index score > 22, and seropositivity were added to 
traditional CVD risk factors.  
Thus, the increased CVD risk in RA patients is well demonstrated in the literature. This 
increased risk is believed to be driven by sustained inflammatory activity in these patients. 
2.3 Current evidence for the impact of anti-rheumatic agents on cardiovascular 
events in rheumatoid arthritis patients: 
Because of the increased burden of CVD in RA patients, investigators have focused on 
examining the effect of various RA drug treatments on reducing CVD events. In general, 
randomized controlled trials (RCTs) lack sufficient power to study rare CV outcomes.  Thus, 
most of the evidence for the effect of different RA treatment options on the risk of CVD 
events is based on observational data. In the following sections, we review the previous 
observational studies that evaluated the effect of traditional DMARDs (Section 2.3.1) and 
biologic DMARDs (Section 2.3.2) on the risk of CVD events in RA patients. 
2.3.1 Non-biologic DMARDs and cardiovascular events in rheumatoid arthritis patients: 
Non-biologic DMARDs are believed to exert a cardio-protective effect by its ability 
to control inflammation in RA. In addition some more specific mechanisms for specific 
agents are also suggested. For instance, it is reported that through adenosine A2A receptor 
activation, methotrexate (MTX) promotes reverse cholesterol transport and limits foam cell 
formation in THP-1 macrophages and thus hinders the process of atherosclerosis (44). By 
contrast, some authors have argued that MTX can in fact promote atherosclerosis by 
increasing circulating levels of homocysteine (45). Nine studies have examined the 
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association between non-biologic DMARDs and CVD events in RA patients (46-54) . Table 
2.1 summarizes these studies.  
These studies varied considerably with respect to the study populations and outcomes 
evaluated. Three studies used data from nationwide registries (46, 52, 54), 2 studies used data 
from RA patients registered at a single outpatient RA clinic (47, 50), 2 studies used 
administrative claims data (49, 51), 1 study used electronic medical records from department 
of Veterans Affairs (VA) integrated service network (48) and 1 study used data from an 
international collaboration project that recruited patients in 15 different countries (53). Eight 
of these 9 studies evaluated were conducted in cohorts of established RA patients, and the 
duration of RA varied from 6-15 years in these studies. Only one study (51) was conducted 
in a cohort of new RA patients. Two studies used mortality due to CVD as the primary 
outcome (46, 47), 5 studies used a composite CVD outcome (48, 50, 51, 53, 54), 1 study used 
stroke (52) and 1 study used AMI (49) as the outcome of interest.  
All the 9 studies evaluated the association between MTX treatment and CVD 
outcomes. Five of these nine studies found significant reduction in the risk of CVD outcomes 
with MTX treatment (Range: 15% to 89% reduction) (47, 48, 50, 51, 53). Three studies 
reported no significant association between MTX treatment and CVD outcomes (49, 52, 54). 
One study reported a significant increase in the risk of CVD mortality with MTX treatment 
(46). Association between non-MTX DMARDs and CVD events were reported less 
frequently in these studies. However, two studies documented statistically significant 
reduction in the risk of CV endpoints with SSZ treatment compared to no treatment with SSZ 
(50, 53). Two studies reported significant reduction in risk of CV outcomes with leflunomide 
treatment (49, 53).  
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Table 2.1: Summary of studies evaluating impact of traditional DMARD therapy on cardiovascular outcomes in RA patients 
Study Population RA duration Exposure Comparison Outcomes  Effect size 
Landewe et al., 
2000 (46) 
623 RA patients from 
11 rheumatology  
outpatient clinics  in 
hospitals  that  are 
geographically distrib-  
uted throughout  The  
Netherlands 
NR but prevalent 
cases not excluded 
MTX treatment in 
patients with CVD 
history 
Other DMARD 
treatment in 
patients without 
CVD history 
CVD mortality RR 3.40 (p=0.0054) 
Choi et al., 2002 
(47) 
1,240 RA patients at a 
single arthritis 
outpatient clinic in 
Wichita, KS 
9 years 
 
 
MTX use  MTX use never 
(May use other 
DMARDs) 
CV mortality HR 0.3 (0.2-0.7) 
Prodanowich et 
al., 2005 (48) 
6,707 RA patients at the 
Veterans Integrated 
Service Network 8 
(Florida and Puerto 
rico) 
NR but prevalent 
cases not excluded 
MTX use No use of MTX Composite endpoint 
(CVD, CVA and 
atherosclerosis) 
OR 0.73 (0.55-0.98) 
Suissa et al., 
2006 (49) 
107,908 RA  patients 
identified between 1999 
and 2003 from a US 
administrative claims 
data source 
NR but prevalent 
cases not excluded 
MTX 
LEF 
Other DMARDs* 
No current  
DMARD use 
First AMI RR 0.81 (0.60-1.08) 
RR 0.28 (0.12-0.65) 
RR 0.67 (0.46-0.97) 
Van Halm et al., 
2006 (50) 
613 RA patients 
randomly sampled from 
a larger RA population 
registered 
in the Jan van Breemen 
Institute, a large 
rheumatology outpatient 
clinic in Amsterdam, 
the Netherlands 
7-10 years MTX only 
SSZ only 
HCQ only 
MTX & SSZ 
MTX & HCQ 
SSZ & HCQ 
MTX, HCQ & SSZ 
Never use of 
MTX, SSZ or 
HCQ 
Composite endpoint 
(MI, CVA, TIA, 
PAD) 
OR 0.11 (0.02-0.56) 
OR 0.37 (0.14-0.99) 
OR 0.47 (0.15, 1.46) 
OR 0.16 (0.06-0.42) 
OR 0.19 (0.04-1.02) 
OR 0.37 (0.11-1.24) 
OR 0.16 (0.06-0.43) 
 
Hochberg et al., 
2008 (51) 
16,752 incident RA 
patients identified 
0 years MTX 
Other DMARDs** 
No use of 
DMARDs 
Composite endpoint 
(AMI, CHF, CVA, 
HR 0.74 (0.69-0.80) 
HR 0.99 (0.93-1.05) 
  
 
1
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*Other DMARDs in this study included HCQ, CQ, SSZ, gold, azathioprine, minocycline, penicillamine, chlorambucil, cyclophosphamide, cyclosporine 
List of abbreviations used:  
** The list of individual agents is not reported in the study 
†CORRONA (Consortium of Rheumatology Researchers of North America) registry includes a network of 268 participating academic and community 
rheumatologists at 103 sites and 35 states within the USA 
 
AMI Acute myocardial infarction 
CAD Coronary artery disease 
CHF Chronic heart failure 
CQ Chloroquine 
CVA Cerebrovasculr accident 
CVD Cardiovascular disease 
DMARD    Disease modifying anti-rheumatic agent 
GC Glucocorticoid 
HCQ Hydroxychorloquine 
HR Hazard ratio 
IHD Ischemic heart disease 
LEF Leflunomide 
MTX Methotrexte 
OR Odds ratio 
PAD Peripheral arterial disease 
RA Rheumatoid arthritis 
RR  Risk ratio 
SSZ Sulphasalazine 
TIA Transient ischemic attack
between 1999 and 2006 
from a US 
administrative claims 
data source 
angina, IHD) 
Nadareishvili et 
al., 2008 (52) 
5,765 RA patients 
registered in the 
National Data Bank 
(NDB) for Rheumatic 
Diseases within the 
USA 
15 years MTX No use of MTX Stroke OR 0.77 (0.39-1.54) 
Naranjo et al., 
2008 (53) 
4,383 RA patients from 
48 sites in 15 countries 
11 years MTX 
GC 
Antimalarials 
(HCQ, CQ) 
SSZ 
Gold 
LEF 
No use of that 
particular 
DMARD  (May 
use other drugs 
other DMARD) 
Composite endpoint 
(AMI/Stroke/ 
angina/ CAD) 
 
HR 0.85 (0.81-0.89) 
HR 0.95 (0.92-0.98) 
HR 0.98 (0.94-1.02) 
HR 0.92 (0.88-0.97) 
HR 0.96 (0.92-1.00) 
HR 0.55 (0.41-0.75) 
Greenberg et al., 
2010 (54) 
10,156 RA patients 
registered in the 
CORRONA registry† 
6 years MTX Non-biologic 
DMARDs** other 
than MTX 
CVD composite 
endpoint (AMI, 
stroke, TIA) 
HR 0.94 (0.49-1.80) 
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2.3.2 TNF-α inhibitors and cardiovascular events in rheumatoid arthritis patients: 
Given the role that TNF-α plays in facilitating the development and acceleration of 
atherosclerosis in RA patients, it is plausible that TNF-I treatment may halt the progression 
of atherosclerosis and ultimately lead to a reduction in the risk of CVD events.  Several 
observational studies have been conducted to test this hypothesis. In this section, we briefly 
summarize the studies testing this hypothesis available in the literature.  
Table 2.2 summarizes the 12 studies that evaluated the impact of use of TNF-Is on 
CVD events (49, 51-61). These studies differ significantly in terms of the data sources, 
population included, exposure definitions, and outcomes evaluated. Six of these studies used 
data from nationwide registries (52, 54, 55, 57, 59, 61), 1 study used data from an 
international collaboration project that recruited patients in 15 different countries (53), 1 
study used data from a statewide registry (58), 1 study used a cohort of Medicare enrollees 
from Pennsylvania (56),1 study used electronic medical records from department of VA (60), 
and 2 study used administrative claims data (49, 51). Five studies evaluated composite CVD 
outcomes,(51, 54-56, 61), 4 studies evaluated AMI (49, 57-59) while 1 study evaluated 
stroke (52) and 2 studies evaluated cerebrovascular accident (CVA) and AMI individually in 
addition to a composite CVD outcome as the outcomes of interest (53, 60). Seven studies 
used non-exposure to TNF-Is as the comparison group (49, 51-53, 55, 59, 61) , while 5 
studies used active comparators (54, 56-58, 60). Two studies compared TNF-I therapy with 
MTX monotherapy (56, 58), one study used non-biologic DMARDs other than MTX as the 
comparison (54), one study used only non-biologic DMARDs as comparison (57) and one 
study compared use of TNF-I with use of any other DMARD, pooling traditional and 
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biologic drug users in a single group (60). Only 2 studies evaluated the impact of TNF-I 
treatment on the risk of CVD events in early RA patients (51, 61).  
Two studies comparing TNF-I use vs no use in established RA patients reported 
significant reduction in the risk of composite CVD outcome with TNF-I treatment (54-58% 
reduction) (53, 55). Two other studies using same definition and population did not find a 
significant associations between TNF-I treatment and evaluated outcomes (52, 59). One 
study reported increasing trend of AMI with biologic treatment including TNF-Is compared 
to no DMARD use in established RA cases, but the estimate was not statistically significant 
(OR: 1.30, 95% CI: 0.92-1.82) (49). Three studies reported that treatment with TNF-I was 
significantly better in improving CVD outcomes (17-80% reduction) against a variety of 
active comparators (54, 58, 60) in established RA patients. Two studies found no difference 
in the risk of CVD outcomes between TNF-I treatment and comparator groups (56, 57) in 
similar population. One analysis reported an increase in trend of CVA with TNF-Is, but the 
results were not statically significant (HR: 1.07, 95% CI: 0.997-1.155) (60).  The two studies 
that only included early RA cases reported a statistically non-significant reduction in the risk 
of CVD events after TNF-I treatment compared to no use of these agents (51, 61).  
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Table 2.2: Summary of studies comparing the impact of TNF-I therapy with no use of TNF-I therapy on cardiovascular 
outcomes in RA patients 
Study Poulation RA 
duration 
Exposure Comparison Outcomes Results 
Jacobsson et 
al., 2005 (55) 
983 RA patients from 
rheumatology outpatient 
clinics in South Sweden. 
Uses historical 
comparison cohort of 543 
patients from 1997 (pre-
tnf period) as comparison 
group 
11 years TNF-Is (Etanercept 
and Infliximab)  
Never treated with  TNF-
Is 
Composite 
CVD event 
(ICD 401-448) 
RR 0.46 (0.25-0.85) 
Solomon et 
al., 2006 (56) 
3,501 RA patients from 
Medicare enrollees who 
were also beneficiaries in 
the PACE program in 
Pennsylvania 
NR but 
prevalent 
cases not 
excluded 
Current use of 
Biologics  
(Etanercept, 
Adalimumab, 
Infliximab, 
Anakinra) defined 
as a filled 
prescription 90 
days prior to the 
event 
1. Monotherpay 
2. Biologic+MTX 
3. Biologic+other 
DMARDs 
MTX monotherapy Composite 
endpoint (AMI 
and stroke) 
OR 1.00 (0.5-1.9): biologics 
monotherapy vs MTX 
monotherapy  
 
OR 0.8 (0.3-2): Biologics+ 
MTX vs MTX monotherapy 
 
OR 1.2 (0.7, 2.2): Biologics+ 
other DMARDs* vs MTX 
monotherapy 
Suissa et al., 
2006 (49) 
107,908 RA  patients 
identified between 1999 
and 2003 from a USA 
administrative claims data 
source 
NR but 
prevalent 
cases not 
excluded 
Current use of 
Biologics (Defined 
as a filled 
prescription of 
Etanercept, 
infliximab, 
anakinra in 30 days 
prior to event) 
No current use of any 
DMARD 
First AMI RR  1.30 (0.92-1.83)               
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Dixon et al., 
2007 (57) 
10,755 RA patients 
registered in the BSRBR*  
7-12 years TNF-Is 
(Etanercept, 
Adalimumab, 
Infliximab) 
Non-biologic DMARDs 
(list of agents not 
reported) 
First AMI IRR 1.44 (0.56-3.67) 
Singh G et al., 
2007 (58) 
19,223 RA patients from 
a registry of medical 
assistance patients in 
California (MediCal 
database) 
NR but 
prevalent 
cases not 
excluded 
TNF-Is +MTX MTX monotherapy First AMI RR 0.20 (0.05-0.88) 
Hochberg et 
al., 2008 (51) 
16,752 incident RA 
patients identified 
between 1999 and 2006 
from a US administrative 
claims data source 
0 years Biologics use 
(defined as a filled 
prescription of 
etanercept, 
adalimumab, 
infliximab or 
anakinara in the 
pre-index period 
No use of biologics Composite 
endpoint (AMI, 
CHF, CVA, 
angina, IHD) 
HR 0.99 (0.83-1.18) 
Nadareishvili 
et al., 2008 
(52) 
5,765 RA patients 
registered in the National 
Data Bank (NDB) for 
Rheumatic Diseases 
within the USA 
15 years TNF-Is 
(Etanercept, 
Adalimumab, 
Infliximab) 
1. In the 6 months 
pre-index period 
2. In the baseline 
period 
Not treated with  TNF-Is 
in the respective time 
periods 
Stroke OR for TNF-I use in 6 months 
pre-index Vs no use in that 
period: 0.8 (0.34-1.82)  
 
OR for TNF-I use at baseline 
Vs no use in that period: 0.37 
(0.18-1.66) 
Naranjo et al., 
2008 (53) 
4,383 RA patients from 
48 sites in 15 countries 
9 years TNF-Is exposure 
time (in years) 
Not treated with  TNF-Is 
(exposure time to tnf=0) 
Composite 
AMI 
Stroke 
HR 0.64 (0.49-0.83) 
HR 0.42 (0.21-0.81) 
HR 0.64 (0.39-1.05) 
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Wolfe and 
Michaud, 
2008 (59) 
17,738 RA patients 
registered in the National 
Data Bank (NDB) for 
Rheumatic Diseases 
within the USA 
NR but 
prevalent 
cases not 
excluded 
TNF-Is 
(Etanercept, 
Adalimumab, 
Infliximab)  
1. Ever use &  
2. Current use (6 
months prior to 
event) 
Not treated with  TNF-Is 
in the respective time 
period 
 
First AMI OR: 1.1 (0.8-1.6): Ever use  vs 
Never use 
 
OR: 1.3 (0.9-1.6): Current use 
vs no current use 
Greenberg et 
al., 2010 (54) 
10,156 RA patients 
registered in the 
CORRONA registry** 
  
8 years TNF-Is  
1. New+prevalent 
use 
2. Only new use 
Non-biologic DMARDs
†
 
other than MTX 
  
CV composite 
endpoint (AMI, 
stroke, TIA) 
  
HR  0.39 (0.19-0.82) for new 
and prevalent use of TNF-I vs 
non-biologic DMARDs 
 
HR 0.45 (0.13-1.56) for only 
new users ot TNF-I vs non-
biologic DMARD use 
Al-aly et al., 
2011 (60) 
20,811 RA patients from 
Veterans Administration 
EMR (USA) 
NR but 
prevalent 
cases not 
excluded 
TNF-Is 
(Etanercept, 
Adalimumab, 
Infliximab) 
  
Other DMARDs (HCQ, 
Gold, Penicillamine, 
SSZ, MTX, LEF, 
Azathioprine, 
Cyclophosphamide, 
Cyclosporine, 
Anakinara) 
Composite  
CVA                         
CHF                          
PAD                          
CAD 
HR 0.96 (0.89-1.04) 
HR 0.83 (0.74-0.89)     
HR 1.05 (0.91-1.22)            
HR 0.85 (0.69-1.05)   
HR 1.07 (0.99-1.15) 
Ljung et al., 
2012 (61) 
6,496 patients with early 
RA in the Swedish 
Rheumatology Register 
< 1 year Exposure to TNF-
Is (First time use) 
Never exposed to TNF-
Is 
Composite 
endpoint (ACS 
events) 
HR 0.80 (0.52–1.24) 
  
  
 
2
0
 
* Other DMARDs in this study included HCQ, CQ, SSZ, gold, azathioprine, minocycline, penicillamine, chlorambucil, cyclophosphamide, cyclosporine 
List of abbreviations used:  
*CORRONA (Consortium of Rheumatology Researchers of North America) registry includes a network of 268 participating academic and community 
rheumatologists at 103 sites and 35 states within the USA 
† 
List of individual agents not reported  
 
AMI Acute myocardial infarction 
BSRBR British Society for Rheumatology Biologics Register 
CAD Coronary artery disease 
CHF Chronic heart failure 
CQ Chloroquine 
CVA Cerebrovasculr accident 
CVD Cardiovascular disease 
DMARD    Disease modifying anti-rheumatic agent 
GC Glucocorticoid 
HCQ Hydroxychorloquine 
HR Hazard ratio 
IHD Ischemic heart disease 
LEF Leflunomide 
MTX Methotrexte 
OR Odds ratio 
PAD Peripheral arterial disease 
RA Rheumatoid arthritis 
RR  Risk ratio 
SSZ Sulphasalazine 
TIA Transient ischemic attack
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Thus, very limited information exists in the literature for the association of TNF-I 
treatment with incident CVD events in patients with early RA. It is known that structural 
damage to joints occur aggressively within first few years of RA diagnosis (8, 9), so it is 
possible that acceleration of atherosclerosis may also be more aggressive during early stages 
of RA. A couple of small studies have indicated that atherogenic lipid profile and subclinical 
atherosclerosis are features of early RA (10, 11). The epidemiological evidence of the effect 
of TNF-Is on early RA CVD events is limited to only two studies limited to modest sample 
sizes (61) and mixed treatment exposure with TNF-Is and other biologics, which could bias 
results (51).  
2.4 Significance of this research: 
The first step in evaluating outcomes of biologics treatment is to understand the factors 
that play a role in the treatment initiation of RA patients with biologics. The current literature 
lacks studies that specifically evaluate the factors influencing biologic treatment initiation. 
Only 2 studies have looked at this issue and both have important limitations. The study by 
Bonafede et al. (62) used insurance claims data to study the predictors of DMARD treatment 
initiation in patients with newly diagnosed RA. This study provides limited information 
regarding biologics specifically since the factors were not differentially evaluated for non-
biologic and biologic DMARDs. It is well-understood that these two subgroups of DMARDs 
differ drastically in their mechanism of actions, effectiveness and cost of treatment. So to 
study those as a single group may not give us estimates that are relevant to biologic agents. 
DeWitt et al. (63) studied specific predictors of biologic initiation in 1,545 RA patients in an 
observational database using patient self-reported data. However, this study suffers from 
limitation of very small sample size and lack of generalizability, given its inclusion of only 7 
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centers for patient recruitment in the entire nation. They also did not consider patient 
enabling factors such as drug benefit coverage and insurance type, which are important from 
a policy perspective to understand biologic treatment initiation. Moreover, they used data up 
to 2006, at which point there were only 5 biologics compared to 10 which are available 
currently. Therefore, our study addressed limitations by addressing the important 
phenomenon of biologic treatment initiation in RA patients with the help of a theoretical 
framework using recent data from a large insurance claims database in Aim1.  
After understanding the patient characteristics that influence treatment initiation with 
biologics, the next logical step is to examine their association with CVD outcomes in these 
patients. Among all of the currently-available treatments, TNF-Is are of special interest 
because of the involvement of TNF-α in the development and acceleration of atherosclerosis. 
Although, several observational studies (discussed in section 2.3) have attempted to evaluate 
this association, limited information is available specific to early RA cases. The first of these 
two studies that evaluated the association in new RA patients had a small sample size (198 
acute coronary syndrome cases only) and hence may be underpowered to detect treatment 
effect (61). The second study did not differentially define exposure to TNF-Is form other 
biologics (51). Since these agents differ vastly in their mechanism of actions, we believe that 
categorizing them into a single group may produce biased estimates. Therefore, in Aim 2 of 
our study we evaluated the association between TNF-I treatment and CVD events in early 
RA cases to contribute new knowledge to the literature for this specific population. We have 
tried to overcome these limitations by ensuring sufficient sample size and detailed exposure 
classification. 
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Additionally, precise exposure definition is extremely important in evaluating any 
exposure-outcome association. It is especially important for RA since the use of treatments in 
these patients is complex and patients are known to stop and switch DMARDs frequently. No 
study to our knowledge has systematically tried to evaluate the impact of exposure definition 
on the association of RA treatment and CVD events. Therefore, in our Aim 2 we take up that 
challenge to provide some justification to the contrasting estimates of the RA treatment-CVD 
outcome association available in the literature. In this study we use 3 different exposure 
definitions that are summarized below and compare the resulting estimates.  
The first approach that is used in a couple of studies (51, 55) is to define the use of 
TNF-Is or biologic DMARDs as ever-treated vs never-treated, meaning once a patient begins 
therapy with TNF-Is he or she is considered to be treated for the entire follow-up period. This 
over-simplified definition of exposure into a binary variable leads to non-differential 
misclassification of exposure by ignoring the recency of exposure as well as the frequency of 
exposure. For example, in this scheme, a patient who uses the treatment only for 1 day would 
be considered no different than a patient who uses the treatment for 1 year and 
pharmacologically this makes little sense because these patients are likely to have different 
treatment effects. Although, some authors argue that such non-differential misclassification 
of the exposure would produce a bias towards the null and hence provide a conservative 
estimate of the treatment-outcome association (47), there is also evidence in the literature that 
this may not be true under all circumstances (64). Therefore, it is complicated to predict the 
direction of the bias produced by such misclassification. The best way to address this issue is 
to avoid the misclassification by using finer exposure definitions.  
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Another approach used by several studies (49, 54, 56) is to classify the use of TNF-Is 
as ‘current use’ vs ‘no current use’ based on a prescription filled within a certain time period 
prior to the event. This approach addresses some of the misclassification by considering the 
recency of the exposure, which may be closely associated with the outcome. However, this 
definition still ignores the treatment history of the patients. In other words, if a patient has 
used the treatment in the past before discontinuing it and the reason for discontinuation is 
associated with the outcome, we are likely to miss out on this important finding because 
these patients would not be classified as drug users in this exposure scheme. Therefore, it is 
also important to consider treatment history while defining exposure.  
Because of the reasons discussed above, for this research we also added the 
determinants of past DMARDs use, along with current use while defining exposure. This 
approach has been advocated previously as the most effective in reducing the non-differential 
exposure misclassification (65). This definition however, does not take into account the 
cumulative exposure to the treatment and therefore to quantify the impact of duration of drug 
use, we defined the duration of TNF-Is as cumulative days of use in to derive estimates of the 
association between TNF-I duration and CVD events. 
The literature also lacks evidence for the independent effects of different individual 
TNF-I agents on CVD outcomes in RA patients. TNF-Is are a heterogenous class of drugs. 
These agents include a chimeric [IgG.sub.1] monoclonal antibody (infliximab); monoclonal 
antibodies with fully human amino acid sequences produced by phage display (adalimumab) 
or from mice transgenic for the human immunoglobulin locus (golimumab); an engineered 
p75 TNFRII dimer with a fully human amino acid sequence linked to the Fc portion of 
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human [IgG.sub.1] (etanercept); and a pegylated Fab' fragment that lacks an Fc portion 
(certolizumab) (20).  
Certolizumab and golimumab have been on the market for approximately two years 
and there are limited pharmacological and epidemiological data for these agents. Therefore, 
we limit our discussion to differences among etanercept, infliximab and adalimumab. These 
agents possess unique pharmacokinetic and pharmacodynamic properties (66). The p75 
TNFRII dimer, Etanercept, has been shown to bind with lymphotoxin B and does not induce 
neutralizing antibodies, unlike the monoclonal antibodies, adalimumab and infliximab. 
Infliximab has been reported to form more stable complexes with soluble TNF compared to 
etanercept (67). These three agents have not been compared head-to-head in RCTs for their 
efficacy in RA. However, recent evidence from a mixed treatment comparison using data 
from RCTs reported that the odds of achieving ACR50 response (American College of 
Rheumatology response criteria for 50% improvement in joint function), were higher with 
etanercept compared to infliximab and adalimumab both (etanercept vs infliximab OR: 4.17, 
95% CrI 2.00-11.17, etanercept vs adalimumab OR: 3.50, 95% CrI 1.37-7.63) (68).  
They also differ with respect to their effectiveness in treating other rheumatologic 
diseases. Unlike adalimumab and infliximab, etanercept lacks efficacy in treating 
granulomatous diseases, such as Crohn's disease, Wegener's granulomatosis and sarcoidosis 
(69, 70). These agents are also reported to have differences in their safety profiles. 
Infliximab, but not etanercept, is found to be associated with an increased risk of 
granulomatous infections such as mycobacterium tuberculosis and histoplamosis (71). 
Evidence from mixed treatment comparisons using withdrawals due to adverse events 
reported in RCTs as an outcome suggest that etanercept has more favorable tolerability 
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profile compared to infliximab and adalimumab (etanercept versus infliximab OR:0.30, 95% 
CrI 0.16-0.62, etanercept versus adalimumab OR: 0.50, 95% CrI 0.25-0.91) (72).  
No study has provided estimates for the independent effects of these individual TNF-I 
agents for their effects on the risk of CVD events in RA patients. Because these agents differ 
with respect to their pharmacological properties, effectiveness profiles in various 
rheumatologic diseases and tolerability, we believe that it is not appropriate to assume a class 
effect in terms of these agents’ effect on the risk of CVD events in RA patients. Therefore, in 
Aim 3 of the proposed study, we added novel information to the literature by providing 
estimates for the independent effects of these 3 TNF-Is on the risk of CVD events.  
This dissertation used the data from administrative claims submitted from health plans 
which have contracts with large private employers or with public organizations in the United 
States for the years between 2007 and 2010. The use of this recent data from ‘real-world’ 
strengthened the external validity of the study by inclusion of patients with multiple 
comorbid conditions in the study cohort, which can not be achieved with RCTs. In addition, 
RCTs examining the efficacy of TNF-Is in RA patients are usually under-powered for 
studying CV outcomes. The accelerated onset of atherosclerosis in RA patients often leads to 
events such as AMI and stroke that can be detected in observational studies using 
administrative data. This provided us with a valuable opportunity to evaluate the effect of 
TNF-I treatment on the risk of CVD events in RA patients using secondary databases that 
document the use of medications and clinical events. 
Results from our Specific Aim 1 may be useful in accessing and targeting the most 
important factors that facilitate treatment initiation. Results from Specific Aims 2 and 3 may 
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help in guiding therapeutic decision-making to improve the quality of care provided to 
patients with RA. 
2.5 Theoretical model: 
A conceptual model forms the basis for the consideration of appropriate variables in 
any research study. For our Specific Aim 1,  we used a conceptual framework based on 
Andersen’s Emerging Behavioral Model of Health Services Use (73). This model posits that 
the use of healthcare services and subsequent health outcomes are influenced by a set of 
population characteristics. More specifically, these characteristics are divided in to three 
groups,  
1) Predisposing factors: include patient characteristics that predisposes them to the utilization 
of health services (eg, age, sex, geographical factors)  
2) Need factors: include health conditions of patients that necessitates the utilization of health 
services (eg, comorbid conditons, severity of illness, use of other medications) &  
3) Enabling factors: include variables depicting patients’ ability to secure the healthcare 
services (eg, health insurance, drug coverage).  
The Andersen behavior model has been used to study utilization of healthcare services and 
subsequent outcomes in numerous studies in the literature (74-76). Based on these principles, 
we adapted this model to fit our research needs. Figure 2.1 shows the Andersen model with 
variables of interest for our analysis.  
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Figure 2.1: Andersen’s Emerging Behavioral Model of Health Services Use (Adapted) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
After identifying all the relevant variables in the Andersen model, it is equally 
important to consider their relation with the exposure and outcome of interest, as well as with 
one-another. In pharmacoepidemiology research, the biggest threat to the internal validity of 
any study is the issue of confounding. Confounding refers to a phenomenon where the 
relationship between the exposure and outcome of interest is due, completely or in part, to 
another variable that is associated independently with exposure and outcome.  This variable 
is defined as the confounder (77).The theory of directed acyclic graphs (DAG) provides a 
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theoretical framework for identifying the potential confounders based on subject-matter 
knowledge (78-80).  
In the past, various studies have successfully used the theory of DAG to identify 
relevant confounders and controlling for them through conditioning (81-83).  Weng et al. 
(84) compared DAG with change-in-estimate method, in which the confounders are selected 
based on their impact on exposure-outcome association, for their performance in covariate 
selection in a simulation analysis. The performance was measured by standard error, bias, 
square root of the mean-squared error, and 95% confidence interval coverage. This study 
concluded that under correct specifications, DAG outperformed change-in-estimate method. 
More recently, Cox et al. (85) have recommended the use of DAGs in identifying 
confounders in design of nonrandomized studies of treatment effects using secondary data 
sources. Therefore, we used the theory of DAG to identify relevant confounders based on 
information from the literature.   
A DAG is drawn as a network of exposure, outcome and all the other relevant 
variables that are associated with exposure and outcome independently. All the associations 
specified in the DAG must be directed, meaning the direction of the association between all 
the variables must be known. DAG must be acyclic, meaning there must not be any closed 
loops in the DAG. Any variable should not affect itself through other variables. Following all 
these rules, we constructed a DAG for the association between TNF-Is and CVD events 
(Figure 2.2). Within this framework, factors independently associated with TNF-Is 
(exposure) and CVD event (outcome) are shown along with the associations of interest, 
namely the association between TNF-I treatment and first CVD event.  
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Figure 2.2: Directed acyclic graph (DAG) for the association between TNF-I use and 
cardiovascular diseases 
 
*CCS: Combined Comorbidity Score 
** CVD risk factor includes diabetes mellitus, hyperlipidemia and hypertension 
 
Patient predisposing factors, age, sex and geogrpahic location, are considered as 
factors independently associated with exposure (TNF-I) and outcome (CVD events) in the 
DAG. This observation is supported by several studies in the literature. Bonafede et al. (62) 
reported that geographic location was associated with biologic medication initiation. Patient 
age has been consistently shown to be associated with prescription of biologic agents in RA 
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in the literature (63, 86-88).  Older age is also directly associated to higher risk of CVD 
events as established by the Framingham heart study (89). Gender differences in the 
incidence of CVD have also been well established (90).   
A number of clinical need factors including patients’ comorbidities, CVD risk factors, 
use of NSAIDs and use of corticosteroids were postulated to be associated with both 
exposure and outcome independetly. Analysis of a registry data suggested that prior 
treatment with steroids were significantly associated with inititation of TNF-Is (63). Another 
study reported an association between NSAIDs use and initiation of biologic treatment (62). 
Both NSAIDs and steroids have been shown to be associated independently with CVD 
events (91, 92). Literature suggests that patient co-morbid conditions play an important role 
in initiation of biologic treatment in RA (62, 63). Comorbid conditions including diabetes, 
high blood pressure and hyperlipidemia have been consistantly reported to be associated with 
higher risk of CVD (93-95). We also must account for the causal effect of various classes of 
CV medications, including beta-blokers, inhibitors of renin angiotensin system, calcium 
channel blockers, and lipid lowering agents, on prevention of CVD events.  
Finally, a set of enabling variables, including health plan type and patient co-pay are 
considered for their effect on the utilization of prescription medications including TNF-Is, 
NSAIDs, corticosteroids and CVD medications. Different plan types differ in their generosity 
of drug prescription coverage and the co-payments have been shown to be associated with 
prescription medication utilization (96). Therefore, it is important to consider impact of these 
variables on medication utilization while evaluating subsequent outcomes. Additionally, we 
also considered the impact of visit to rheumatologist on TNF-Is initiation because prior 
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research demonstrated higher likelihood of initiation of biologics if the patient visited a 
rheumatologist (62).  
Thus, DAG provided us with a systematic framework of all the relavent variables that 
should be considered for confounding control while evaluating the effects of TNF-Is on the 
risk of CVD events. We evaluated all the causal and non-causal paths in our Figure 2.2 and 
identified a minimal sufficient adjustment set to control for confounding in a multivariate 
model for our Aims 2 and 3.  
  
 CHAPTER 3 
3 METHODS 
 In section 3.1, the data source used for this dissertation is described. In section 3.2, 
methods used are described in detail by Specific Aims and finally in section 3.3, issues 
related to statistical power are discussed.  
3.1 Data-source:  
Data from the Truven’s MarketScan Commercial Claims And Encounters (CCAE) and 
Medicare Supplemental and Coordination of Benefits (COB) were analyzed for this study. 
This database contains de-identified, person-specific health data including clinical utilization, 
expenditures, insurance enrollment/plan benefit, inpatient, outpatient, and outpatient 
prescription information. The data include private sector health data from approximately 100 
payers, and can be linked to track detailed patient information across sites, types of 
providers, and over time (12). Over 35 million individuals were included in the 2008 CCAE, 
encompassing employees, their spouses, and their dependents. The Medicare Database 
contains the health care experiences of 2.5 million individuals annually with Medicare 
Supplemental insurance paid for by employers. Both the Medicare-covered portion of 
payment (represented as the COB amount) and the employer paid portion are included, as 
well as any out-of-pocket expenses to patients. These data have been used widely in health 
services research. Due to its substantial size, longitudinal integrity, and 
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unique data links, this database provides an ideal opportunity to conduct 
pharmacoepidemiology studies. For this particular analysis, data from inpatient services file, 
outpatient services file, outpatient drug claims file and enrollment file were merged using 
unique patient identifiers.  
3.2 Methods by Specific Aim:  
The plan for patient population, study design, measurement of variables and statistical 
analyses is detailed below by Specific Aim.  
3.2.1 Specific Aim 1:  To identify factors influencing biologic treatment initiation in RA 
patients 
Patient population: 
The total study period for our study was from Jan 1, 2007 to Dec 31, 2010. This time 
frame was selected because our dataset also contains Medicare enrollees and in 2006, 
Medicare part D was implemented extending drug benefit coverage to many beneficiaries. 
Therefore, it is likely that prescription medication utilization pattern may have changed 
between pre-2006 and post-2006. To avoid the threat of this history effect on our study’s 
internal validity, we began our study period from Jan 1, 2007. To allow for 12 months of 
baseline period for everyone, the subject identification period started from Jan 1, 2008 and 
ended at Oct 1, 2010. All patients with a recorded diagnosis in this subject identification 
period were eligible for inclusion in our cohort. Diagnoses of RA was defined by ICD-9-CM) 
code of 714.0 in our data source. This ICD-9-CM code has been shown to be highly sensitive 
in detecting RA in previous studies (97, 98). However, concerns have been raised about the 
specificity of this code because of the high false positive rate observed by Singh et al. (97). 
To ensure specificity of our criteria, while maintaining high sensitivity, we required the 
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patients to have at least 2 outpatient claims (not on the same day), or 1 inpatient claim with 
this diagnosis code. The earliest of these diagnoses dates was defined as the index diagnosis 
date. Further, we required patients to fill a prescription of a DMARD in the study period after 
diagnosis of RA because as suggested by Singh et al. (97), this criterion reduces the high 
false positive rate of RA identification obtained by only using ICD-9 codes.  
We excluded any patients with age <18 years at the time of their diagnoses because 
RA diagnosis under the age of 18 years is generally classified as juvenile rheumatoid arthritis 
(JRA), which differs systematically from RA in terms of disease progression and treatments 
used (99, 100). We further limited the inclusion to patients continuously enrolled in their 
health plan for at least 12 months prior to and 3 months after their index diagnosis date. This 
was done because intermittent enrollment may result in incompleteness of the data in our 
analytic dataset; which in turn could lead to misinterpretation of our effect estimates. The 12 
months of continuous enrollment period prior to the index diagnosis date was defined as the 
baseline period. Figure 3.1 summarizes the inclusion and exclusion criteria for our RA 
cohort.  
Study design: 
We designed a retrospective cohort study to evaluate factors influencing biologic 
treatment initiation for this particular aim. Patients included in the RA cohort (See Figure 
3.1) were followed for 3 months from the index diagnosis date for determining initiation of a 
biologic DMARD treatment. Figure 3.2 shows a schematic diagram of study design for Aim 
1. 
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Figure 3.1: Inclusion and exclusion criteria for Aim 1 cohort 
Disease identification: RA diagnosis (ICD-9 code 714.0) recorded on 1 inpatient or 2 
outpatient claims + atleast   1 DMARD prescription in drug claims or outpatient services 
claims between 1 Jan, 2008 to 31 Dec, 2010 
 
 
Exclude: Did not meet eligibility 
requirements 
 
Eligibility requirements: Patients with complete drug history and 15 months continuous 
enrollment (12 months pre-index+ 3 months post-index) in their health plan 
 
 
Exclude: Had contradiction to 
biologic use 
Exclude: Diagnosed with Crohn’s 
disease or psoriatic arthritis 
 
Patients with no contraindication to biologic use & no comorbid conditions in which 
biologics are indicated 
 
Patients who do not have any biologic DMARD use in 1 year pre-index period 
Final sample  
 
Exclude: Used biologics in pre-index 
period 
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Figure 3.2: Study design for Aim 1 
 
 
 
 
 
 
 
 
 
 
Measurement of variables:  
Independent (Predictor) variables:  
In this Specific Aim, we evaluated factors influencing biologic treatment initiation in RA 
patients. All the patient factors were independent variables of interest and were measured 
during the 12-month baseline period preceding their index diagnosis date. The details of 
variables to be measured are provided below, 
1) Predisposing factors: Patients’ age up to their index diagnosis date was measured as 
a continuous variable. Proportion of male and female patients in both the groups were 
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region, in which the patients were placed in one of the following groups based on US 
census region: Northeast, Midwest, South and West and 2) a metropolitan statistical 
area indicator.  
2) Clinical need factors: We measured the risk factors for CVD, patients’ comorbidity 
profile and severity of RA in the baseline period. Details for measurement are as 
follows,  
a. RA severity: To measure RA severity in our administrative claims data, we 
used the score developed by Ting et al. (101) This claims based index for 
rheumatoid arthritis severity (CIRAS) makes use of the information recorded 
in healthcare utilization claims to approximate RA severity through a 
composite score. CIRAS was calculated based on following information from 
administrative claims within past one year: patient age, gender, number of 
inflammatory marker tests ordered, rehabilitation visits, rheumatoid factor 
test, diagnosis of Felty’s syndrome, number of chemistry panel ordered, 
number of platelet counts ordered, and number of rheumatology visits. CIRAS 
was measured as a continuous variable with higher score meaning worse 
disease.  
b. Use of co-medications: We measured the utilization of NSAIDs, steroids and 
number of oral DMARDs used in the baseline period. These products were 
identified using the national drug code (NDC) numbers from the outpatient 
pharmacy files and appropriate J codes from Healthcare Common Procedure 
Coding System (HCPCS) code set for injectable products. 
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c. Comorbidity profile: We measured patients’ comprehensive comorbidity 
profile using the score proposed by Gagne et al., combined comorbidity score 
(CCS), which is reported to be superior in predicting mortality compared to 
the older scores (102). CCS was computed as a continuous variable using the 
algorithm proposed by these authors.  
d. CVD risk factors: Diabetes, hypertension and hyperlipidemia have long been 
recognized as the major risk factors for CVD (94). In our RA cohort, we 
identified the proportion of patients with these risk factors. Identification of 
dibetes, hypertension and hyperlipidemia was based on an inpatient of 
outpatient diagnosis recorded using ICD-9-CM codes. Following codes were 
used: hypertension- 401.X–405.X; hyperlipidemia- 272.X; and diabetes 
mellitus-250.x.  
3) Enabling variables: We included the following variables in this set: visit to a 
rheumatologist as a binary variable, health plan type as a binary variable indicating 
capitated plan (included HMO or capitated POS plans) or non-capitated plan 
(included Basic major medical, comprehensive, EPO, PPO, non-capitated POS, 
consumer driven health plan or high deductible health plan), type of insurance as a 
binary variable indicating either Medicare supplemental or commercial insurance and 
drug benefit generosity. Drug benefit generosity was approximated by creating a 
‘generosity index’ using payment information from all the prescriptions filled by 
patients. Similar methods have been successfully used in prior studies (14). This 
index was calculated as a continuous variable in the range of 0-1 and was defined as 
the proportion of total drug cost paid by the patient out of pocket (OOP) as copay or 
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coinsurance. Based on this index, patients were classified into quartiles of drug 
benefit generosity to facilitate interpretation. The quartiles were termed as poor drug 
benefit generosity (highest OOP costs, 4th quartile), average drug benefit generosity 
(3rd quartile), above average drug benefit generosity (2nd quartile) and most 
generous drug benefit (lowest OOP costs, 1st quartile).  
Dependent (Outcome) variable:  
The outcome variable of interest was initiation of a biologic DMARD during the 90 
days of follow up period beginning on the index diagnosis date.  The following biologic 
agents were available during the study period and pooled for this analysis: abatacept, 
adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab and 
tocilizumab. We did not categorize the biologics based on their mechanism of action because 
we assumed that due to similarities in costs and indications, the factors influencing treatment 
initiation might not differ across these classes and pooling them might give us better 
statistical power. The use of these agents was identified using both the NDC codes from 
outpatient pharmacy files for filled prescriptions and J codes using outpatient services files 
for injectable agents administered at physician’s office. 
Statistical analyses: 
Descriptive statistics were used to summarize patient factors in biologic initiators and 
non-initiators. For dichotomous and categorical variables, the results were presented as 
numbers and proportions. For continuous variables, the results were presented as mean (± 
SD). The patient factors were then compared between biologic initiators and non-initiators 
using standardized differences (17). This method was used to avoid statistically significant 
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but clinically meaningless differences between our two groups owing to the large sample 
size. The equation for calculation of standardized difference can be given as follows,   
  
            
√                   
 
 
; pT= the prevalence of the binary variable in treated subjects. 
pC = the prevalence of the binary variable in untreated subjects 
To understand the impact of various predictors on the initiation of a biologic agent 
after controlling for other predictors in a multivariate manner, hierarchical logistic regression 
models were used in which the predictors were entered in 3 sets. The first model included 
only predisposing variables.  The second model included predisposing and enabling 
variables.  The final model included predisposing, enabling and need variables.  
 Following is the multiple logistic regression equation, 
Ln (P/1-P) = β0 + βiΧPredisposing + βjΧEnabling + βkΧNeed + ε 
 P= probability of outcome (biologic treatment initiation) 
  β=Regression co-efficient for the independent variables 
  ε= Error  
The model fit was evaluated after entering each block using Akaike information criterion 
(AIC) and likelihood ratio tests.  
 42 
 
3.2.2 Specific Aim 2: To compare the effect of TNF-Is on the risk of CVD events to other 
disease modifying anti rheumatic drugs (DMARDs) in RA patients. 
Study design and patient population: 
For this aim, we designed a nested case-control study within our RA cohort to study 
the effect of TNF-I use on the risk of CVD events. Nested case-control is an alternative study 
design to the cohort design that improves efficiency by matching only a fixed number of 
controls to cases in a defined cohort and comparing the exposure distribution in these two 
groups instead of analyzing person-time data for everyone in the cohort (77). The nested 
case-control study design uses special type of control sampling, known as risk-set sampling 
(103). A risk set at a given event date consists of the case (who observes the event at that 
time) and the remaining members of the cohort who are alive and being observed at that time 
point. From that risk set, a fixed number of controls are selected for each case. Since the 
cases and controls are matched on the event date in the sampling process by design, the 
nested case-control design can be used to model complex exposures that are time-varying 
(104). This study design has been shown to be a comparable alternative to survival analysis 
techniques that are computationally complex while studying time-dependent exposures (105). 
Matching on important covariates also allows control for potential confounders. In addition, 
it offers the classical advantage of the ability to study rare outcomes with sufficient power of 
the case-control study design. CVD events have been reported to have an incidence rate of 
1.51 per 100 person years in RA patients in the US in previous research (106) . Therefore, to 
ensure sufficient power and to model our complex drug treatment appropriately over time, 
we selected the nested case-control study design to study the effect of TNF-α inhibitor use on 
CVD events.   
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All the patients identified as the members of the RA cohort as shown in figure 3.1 
comprised of the base cohort for Aim 2. Further, to be considered for our case-control 
sampling, patients in the base cohort had to meet the following inclusion criteria: 1) 
Continuous enrollment in their health plans during the 12 months of the baseline period to 
ensure completeness of data, 2) No diagnosis of RA in the baseline period to exclude 
prevalent RA cases, 3) No use of biologic agents in the baseline period because when the risk 
of outcome is altered with the course of treatment, the internal validity of the study is 
compromised if we fail to account for duration of the treatment. This problem can be 
circumvented by exclusion of prevalent drug users and constructing a clean cohort of only 
the incident drug users (107). 4) No history of tuberculosis (contraindication to biologics use) 
or psoriatic arthritis or Crohn’s disease (both comorbid conditions in which some of the 
biologics are indicated) during the baseline period, and 5) No history of any CVD in the 
baseline period to ensure the selected patients are at risk for the outcome. Thus our patient 
population consisted of incident RA patients who had no history of biologic use, who were 
eligible to receive biologics in the future and who were at risk for an incident CVD event.  
Nested case-control sampling: 
All the patients identified as eligible for sampling from the base cohort were 
followed-up from their index date to the earliest of the following: the outcome (CVD 
diagnosis), disenrollment from their health plan, switch between biologic treatments or study 
end date (Dec 31, 2010). If patients experienced a CVD event, they were defined as cases 
and the date of CVD diagnosis was defined as the event date. Once the cases were identified, 
twelve age, sex and cohort entry month-matched controls were sampled using an incident 
density sampling procedure from the remaining patients of the base cohort who were being 
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followed-up at the event date and who were free from CVD at that time (Figure 3.3). The 
main purpose of matching in case-control studies is to balance the number of cases and 
controls across the levels of the selected matching variables. This balance can reduce the 
variance in the parameters of interest, which improves statistical efficiency. However, one 
must be extremely cautious because if the matching confounder is highly correlated to the 
exposure then matching forces the exposure distribution of the controls to be similar to the 
cases and hence may introduce a bias which is termed as ‘control selection bias’ in the 
literature (77). Since the follow-up began on the first ever RA diagnosis date for these 
patients, our sampling also ensured the matching of cases and controls on the duration of RA. 
Figure 5 depicts the schematic diagram for the study design for Aim 2.  
Figure 3.3: Study design for Aims 2 and 3 
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Measurement of variables:  
1. Exposure: Following three unique exposure definition schemes were used,  
a. Scheme 1 (Ever/Never): First, we considered a dichotomous definition of 
exposure: ever-treated with a TNF-I (Monotherapy or in combination with 
non-biologic DMARDs) vs never-treated with a TNF-I prior to the event 
date.  
b. Scheme 2 (Current use indicators for TNF-Is and other RA treatments): To 
take into account the timing of TNF-I use and also the use of other 
DMARDs, we defined exposure into following mutually exclusive 
categories, 1) Current use of TNF-Is (Monotherapy or in combination with 
non-biologic DMARDs), 2) Current use of other biologics (Monotherapy 
or in combination with non-biologic DMARDs), 3) Current use of only 
non-biologic DMARDs, 4) No current DMARD use. Drug use in the time 
period of 6-month prior to the event date was defined as ‘current use’.  
c. Scheme 3 (Current and past use indicators for TNF-I and other RA 
treatments): In addition to the timing of TNF-I use and other DMARDs 
use, to account for the entire DMARD exposure history, we defined 
exposure into following mutually exclusive categories hierarchically: 1) 
No DMARD use, 2) Past use of only non-biologic DMARDs, 3) Current 
use of only non-biologic DMARDs, 4) Past use of TNF-Is (Monotherapy 
or in combination with non-biologic DMARDs), 5) Current use of TNF-Is 
(Monotherapy or in combination with non-biologic DMARDs), 6) Past use 
of other biologics (Monotherapy or in combination with non-biologic 
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DMARDs), and 7) Current use of other biologics (Monotherapy or in 
combination with non-biologic DMARDs). Drug use in the time period of 
6-month prior to the event date was defined as ‘current use’ and any use 
before the time period of 6-months prior to the event date was defined as 
‘past use’.  
TNF-Is included following agents: adalimumab, certolizumab, etanercept, 
golimumab and infliximab. Abatacept, anakinara, rituximab and tocilizumab were 
considered as ‘other biologics’. Methotrexate, hydroxychloroquin, auranofin, 
injectable gold, penicillamine, sulfasalazine, azathioprine, leflunamide, 
cyclophosphamide and cyclosporine were defines as ‘non-biologic DMARDs’. 
The use of these agents was identified using both the NDC codes from outpatient 
pharmacy files for filled prescriptions and J codes using outpatient services files 
for injectable/infusion agents administered at physician’s office. 
2. Measurement of duration of treatment: 
Duration of treatment with TNF-I was defined as a continuous variable 
representing the cumulative days of TNF-I use for the patients who filled at least 
one TNF-I prescription in the exposure measurement period. Similarly, duration 
of treatment with non-biologic DMARDs and other biologics were also measured 
as continuous variables. Significance of a quadratic term was tested for the 
continuous variables representing cumulative use for each treatment to check for 
any evidence of non-linearity in the association between the duration and the risk 
of an incident CVD event.  
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3. Outcome measurement: 
The outcome of interest was defined as a composite measure consisting of 
acute myocardial infarction (ICD-9 code 410), unstable angina (ICD-9 code 411), 
angina pectoris (ICD-9 code 413), chronic heart failure (ICD-9 codes 428.xx, 
398.91, 402.01, 402.11, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93), other 
forms of chronic heart diseases (ICD-9 code 414), ischemic stroke (ICD-9 code s 
433.x1, 434 [excluding 434.x0], or 436); and transient ischemic stroke (ICD-9 
code 435). 
4. Covariates: 
We identified the following covariates during the baseline period: CVD risk 
factors including hypertension, hyperlipidemia, and diabetes mellitus, CVD drug 
use including lipid lowering agents, beta-blockers, angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, and other CVD drugs, RA drug use 
including steroids, non-steroidal anti-inflammatory drugs and non-biologic 
DMARDs, and other comorbidities including chronic obstructive pulmonary 
disease and cancer.  
Statistical analysis:  
Descriptive statistics were used to summarize the patient characteristics for our cases 
and controls. Categorical variables were presented as numbers and percentages and 
continuous variables were presented as means (±standard deviations). The influence of the 
exposure definition on the absolute scale was assessed by calculating the estimates for the 
absolute risk of an incident CVD event during the 3 year follow-up period for all the three 
schemes using methods proposed by Langholz & Borgan (108). Based on this method, the 
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absolute risk of an incident CVD event at time t j in the time interval (s,t] with a specified 
treatment history X0(u); s< u≤ t is given by,  
 ̂           ∏ (   ̂ (     ))
      
 
;  ̂ (     ) is a Kaplan-Mier type estimator of baseline hazard and given by following 
equation 
 ̂ (     )  
   ̂         
∑    ̂                      
    
    ̂          is a relative risk function for individual with treatment history X0 at time t j 
      is the sampled risk set at time t j 
   ̂          is a relative risk function for individual l sampled in the risk set R with 
treatment history Xl at time t j 
       is sampling weights for individual l at time t j calculated as the ratio of total patients 
sample at time t j to total patients at risk set at time t j 
   = 1 if occurrence of a CVD event is observed at t j, 0 otherwise 
For the relative risk estimation, our alternative hypothesis for this aim was following,  
Ha: TNF-Is reduce the risk of CV events compared to no use of DMARDs in newly 
diagnosed RA patients. 
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For this Specific Aim, a matched sampling technique (incidence density sampling) 
was used in which cases and controls are matched on person-time at risk by design. As a 
result, our final sample consisted of numerous groups, termed as risk sets, each with 1 case 
and 12 controls matched on person-time at risk, sex, age and cohort entry month and year. 
Matching presents a unique challenge in modeling because it divides the sample in to 
different strata, with the strata defined by potential confounder or sets of confounders (for 
instance, age, sex, cohort entry month and year and person-time at risk for CVD) represented 
by risk sets (77). These risk sets differ from one-another in terms of the baseline risk of the 
patients that are sampled within each set. If there are total ‘n’ risk sets then an unconditional 
logistic regression model would need (n-1) dummy variables to account for differences 
across those risk sets. Such model would be tremendously unstable because of the number of 
parameters that are needed to be estimated. The appropriate way to handle stratified data is 
the use of a conditional logistic regression (CLR) model, which is a model for stratum-
specific regression. This model differs from unconditional model in which it conditions out 
the effects of each risk set instead of trying to model these effects. In other words, it does 
allow for the baseline risk to differ between the risk sets by fitting them as separate intercepts 
but does not estimate these baseline risks (or the nuisance parameters) (109).   
Therefore, CLR methods were used to estimate crude and adjusted odds ratio (OR) 
for the effect of TNF-Is on the risk of CVD compared to no use of DMARDs only. The 
covariates discussed above were used for risk adjustment. Following is the CLR equation, 
Vxxxxxxkk 7665544332211)(logit    

k = odds of CVD event given the exposure status and covariates  
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α k= intercepts for n strata (for n risk sets) 
x1, .., x6 = Exposure status indicators; 
 x1=1 if past exposure to traditional DMARDs, 0 otherwise 
           x2=1 if current exposure to traditional DMARDs, 0 otherwise 
x3=1 if past exposure to TNF-Is, 0 otherwise  
x4=1 if current exposure to TNF-Is, 0 otherwise 
x5=1 if past exposure to other biologics, 0 otherwise 
x6=1 if current exposure to other biologics, 0 otherwise 
V= Vector of covariates  
No use of DMARDs during the study period is the reference exposure category. 
Additionally, crude and adjusted estimates for the association between the duration of TNF-I 
use and incident CVD events were also estimated from separate CLR models. 
3.2.3 Specific Aim 3: To compare the effect of individual TNF-Is (adalimumab, 
etanercept, infliximab) on the risk of CVD events among RA patients.  
Study design:  
For this Aim, we used the nested case-control study design as well. All the patients 
identified as the members of the RA cohort as shown in figure 3.1 comprised of the base 
cohort for Aim 3. For this Aim, we used similar exclusion criteria and sampling scheme used 
for Aim 2.  
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Measurement of variables:  
1. Exposure: 
We created 7 mutually exclusive categories for drug use based on at least one filled 
prescription of these agents during the study period. 1) Infliximab, 2) Etanercept, 3) 
Adalimumab, 4) Newer TNF-α inhibitors (golimumab and certolizumab) 5) Non-biologic 
DMARDs (including methotrexate, hydroxychloroquin, auranofin, injectable gold, 
penicillamine, sulfasalazine, azathioprine, leflunamide, cyclophosphamide and 
cyclosporine), 6) Other biologic agents (Abatacept, anakinara, rituximab and 
tocilizumab) and 7) No use of DMARD during the study period. The use of these agents 
was identified using both the NDC codes from outpatient pharmacy files for filled 
prescriptions and J codes using outpatient services files for injectable agents administered 
at physician’s office. 
Additionally, duration of treatment with these agents was defined as continuous 
variable representing the cumulative days of use for the patients who filled at least one 
prescription in the study period. Significance of a quadratic term was tested for the 
continuous variables representing cumulative use for each treatment to check for any 
evidence of non-linearity in the association between the duration and the risk of an 
incident CVD event. 
2. Outcome: 
The outcome of interest was defined as a composite measure consisting of acute 
myocardial infarction (ICD-9 code 410), unstable angina (ICD-9 code 411), angina 
pectoris (ICD-9 code 413), chronic heart failure (ICD-9 codes 428.xx, 398.91, 402.01, 
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402.11, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93), other forms of chronic heart 
diseases (ICD-9 code 414), ischemic stroke (ICD-9 code s 433.x1, 434 [excluding 
434.x0], or 436); and transient ischemic stroke (ICD-9 code 435). 
3. Covariates: 
We identified following covariates during the baseline period: CVD risk factors 
including hypertension, hyperlipidemia, and diabetes mellitus, CVD drug use including 
lipid lowering agents, beta-blockers, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, and other CVD drugs, RA drug use including steroids, 
non-steroidal anti-inflammatory drugs and non-biologic DMARDs, and other 
comorbidities including chronic obstructive pulmonary disease and cancer.  
Statistical analyses: 
Descriptive statistics were used to summarize the patient characteristics for our cases 
and controls. Categorical variables were presented as numbers and percentages and 
continuous variables were presented as mean (±standard deviations).  
To account for the matched sampling, we used conditional logistic regression (CLR) 
models for the estimations of incident rate ratios (IRRs). Results from both unadjusted and 
adjusted models were presented. The reference group was comprised of patients did not use 
any DMARD during the study period. Following is the CLR equation 
Vxxxxxxkk 7665544332211)(logit    

k = odds of CVD event given the exposure status and covariates  
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α k= intercepts for n strata (for n risk sets) 
x1, .., x6 = Exposure status indicators; 
 x1=1 if exposed to infliximab, 0 otherwise 
           x2=1 if exposed to etanercept, 0 otherwise 
x3=1 if exposed to adalimumab, 0 otherwise  
x4=1 if exposed to newer TNF-Is, 0 otherwise 
x5=1 if exposed to non-biologic DMARDs, 0 otherwise 
x6=1 if exposed to other biologics, 0 otherwise 
V= Vector of covariates  
Additionally, crude and adjusted estimates for the association between the duration of 
infliximab, adalimumab and etanercept use and incident CVD events were also estimated 
from CLR. All analyses were conducted using SAS version 9.2 (SAS institute, Cary, NC).  
3.3 Statistical power consideration:  
Various authors have provided suggestions regarding the selection of number of 
controls per case in traditional case-control studies (110, 111) to achieve sufficient statistical 
power. The traditional dictum is to select four controls per case for traditional case-control 
analyses. Studies have shown that although the statistical power in case-control studies 
depends on exposure-outcome association strength, the gain in statistical power quickly 
diminishes after 4 controls per case (111). However, unlike the traditional case-control 
studies, nested case-control studies are conducted in a confined base cohort. Therefore, the 
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researchers have limited flexibility in the number of case-control pairs that can be selected. 
The maximum number of cases that can be selected in a nested case control study equals to 
the number of events observed in the base cohort. Therefore, the traditional dictum of four 
controls per case does not hold true in the case of nested case-control studies. Figure 3.4 is a 
chart representing approximate number of case-control sets needed to achieve 80% power 
with different effect size. As it can be seen, the curves platue after 12 controls per case. 
Therefore, we selected 12 matched control(s) per case.  If the highest true odds ratio for 
disease in exposed subjects relative to unexposed subjects is 1.5, 455 case patients with 12 
matched control(s) per case would be needed to be able to reject the null hypothesis that this 
odds ratio equals 1 with probability (power) 0.8.   The Type I error probability associated 
with this test of this null hypothesis is 0.05.  
Figure 3.4: Statistical power consideration 
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 CHAPTER 4 
4 FACTORS INFLUENCING TREATMENT INITIATION WITH BIOLOGIC 
DISEASE MODIFYING ANTIRHEUMATIC AGENTS IN PATIENTS WITH 
RHEUMATOID ARTHRITIS 
This chapter presents the first of three manuscript prepared from this dissertation. In 
this manuscript, we evaluated the factors influencing treatment initiation with biologics in 
rheumatoid arthritis patients using health insurance claims from Marketscan databases during 
the period of 2007 to 2010.  
4.1 Overview 
Background: Very little information is available in the literature specifically related to factors 
influencing treatment initiation with biologics in RA patients.  
Objectives: To evaluate the predictors of treatment initiation with biologics in RA patients 
Methods: A retrospective cohort study was designed using data for patients diagnosed with 
RA between Jan 1, 2008 and Oct 1, 2010 identified from Truven’s MarketScan Commercial 
Claims And Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits 
(COB). These patients were followed up for 3 months for the outcome of biologic initiation. 
The selection of predictors of biologic initiation was guided 
by the Andersen Behavior Model. Predictors were measured during 12 month pre-index 
period and were grouped into three sets: predisposing, enabling or need factors. To 
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understand the impact of various predictors on the initiation of a biologic agent after 
controlling for other predictors in a multivariate manner, hierarchical logistic regression 
models were used in which the predictors were entered in three sets.  
Results: Approximately 5% of the total sample (2,610 of 52,212) initiated treatment with a 
biologic agent during the 3-month follow-up period, of which 93.02% initiated treatment 
with an anti-TNF agent (n= 2,428). In our multivariate models, we observed that treatment 
initiation with biologics in RA patients was associated with predisposing factors patient age 
and region, enabling factors, health insurance type, and drug benefit generosity and need 
factors, RA severity, RA type, pre-index non-biologic DMARD and steroid use.  
Conclusion: We observed that treatment initiation with biologics is influenced by a mix of 
predisposing, enabling and need factors. Our findings suggest that interventions such as more 
generous drug coverage could promote timely initiation of biologic treatment. 
4.2 Introduction:  
Rheumatoid arthritis (RA) is an autoimmune disease that affects approximately 1.3 
million adults in the United States and is associated with substantial morbidity and mortality 
(2). The annual direct cost to treat patients with RA is estimated to be $9,519 per person (15), 
and the indirect costs of RA are approximately twice the direct costs associated with this 
condition (16). The average number of days absent from work due to RA has been reported 
to be in the range of 2.7 to 30 days annually (17). 
Diseases modifying anti-rheumatic agents (DMARDs) form the cornerstone of 
pharmacologic treatment in RA by controlling inflammation and preventing joint damage. 
DMARDs are generally classified into non-biologic and biologic DMARDs. Non-biologic 
 57 
 
DMARDs include agents, such as methotrexate, sulfasalazine, hydroxychloroquine, 
azathioprine, penicillamine and leflunomide. Although these medications halt the progression 
of the disease by suppressing inflammation, they do not interfere with the functioning of 
specific components of the immune system. On the other hand, biologic DMARDs (hereafter 
referred to as biologics) target specific components of the immune system, such as T cells, B 
cells, and cytokines (i.e., TNF- α and interleukins) that play an important role in the 
pathogenesis of RA (19). Currently, there are 10 biologics approved for the treatment of RA. 
Of these 10 agents, 5 are TNF-α inhibitors (e.g., adalimumab, etanercept), 2 are interleukin 
inhibitors (e.g., anakinra). The remaining agents include rituximab,an anti-CD20 antibody 
that causes depletion of B-cells, abatacept, a selective costimulation modulator that prevents 
full activation of T-cells, and tofacitinib, a janus kinase inhibitor.  
The American College of Rheumatology (ACR) advocates the use of non-biologic 
DMARDs in all RA patients and the use of biologics in patients with moderate to high 
disease activity with features of poor prognosis or in patients who fail to respond to non-
biologic DMARDs (112). Except for tofacitinib, the biologics are administered either 
subcutaneously or as an intravenous infusion, while most of the non-biologic agents are 
administered orally. The biologics are substantially more costly compared to non-biologic 
DMARDs. The mean annual direct costs for biologic treatment have been reported to be 
approximately five times greater than the annual direct costs for non-biologic DMARDs (15).  
Treatment with biologics is efficacious in achieving ACR response rates in patients 
whose RA is not well controlled with conventional DMARDs (113). Uncontrolled RA 
decreases quality of life in patients and increases comorbidities, notably cardiovascular 
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diseases (114), which in turn can result in escalation of total healthcare costs. Timely 
initiation of biologics may be able to prevent these unfavorable consequences in RA patients. 
Research surrounding the predictors of biologic treatment initiation is of special 
interest from a societal perspective because such research may provide an insight into 
potential strategies to improve access by identifying factors associated with lower likelihood 
of initiation of biologic agents. The current literature lacks studies that specifically evaluate 
the factors influencing biologic treatment initiation in RA. The 2 studies that examined this 
issue have important limitations. The study by Bonafede et al. (62) used insurance claims 
data to study the predictors of biologic and non-biologic DMARD treatment initiation in 
patients with newly diagnosed RA. This study provides limited information regarding 
biologics specifically since non-biologic and biologic DMARDs were pooled. It is well-
understood that these two subgroups of DMARDs differ drastically in their mechanism of 
actions, indications and cost of treatment and therefore factors that influence the initiation of 
non-biologic DMARDs may differ from factors that influence the initiation of biologics. So, 
to study those as a single group may not give us estimates that are relevant to biologic agents. 
DeWitt et al. (63) evaluated specific predictors of biologic initiation in 1,545 RA patients in 
an observational database. This study used patient self-reported data for medication use, 
which is subject to numerous biases and did not consider important predictors such as patient 
cost-sharing. In addition to the limitations of a relatively small sample size and limited 
generalizability, this study used data up to 2006, at which point there were only 5 biologics 
compared to 10 which are available currently.  
Therefore, we designed this study with the objective of evaluating the predictors of 
treatment initiation with biologics in RA patients. Our study adds new information to the 
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literature by evaluating factors specifically influencing biologic treatment initiation using a 
large nationally representative sample derived from health insurance claims. To 
systematically analyze the influence of sets of various population characteristics on biologic 
treatment initiation, we used Andersen’s behavioral model (ABM) for health services use 
(73), a  model that is helpful in understanding potential inequities in the use of healthcare 
services.  
4.3 Methods: 
Data source:  
Data from the Truven’s MarketScan Commercial Claims And Encounters (CCAE) 
and Medicare Supplemental and Coordination of Benefits (COB) were used for this study. 
This database contains de-identified, person-specific health data including clinical utilization, 
expenditures, insurance enrollment/plan benefit, inpatient, outpatient, and outpatient 
prescription information. The CCAE contains healthcare data for nearly 40 Million 
individuals, encompassing employees, their spouses, and their dependents. The COB data 
contains the health care experiences of 3.8 million Medicare-eligible retirees with employer-
sponsored Medicare Supplemental plans. These data have been used widely in health 
services research due to its substantial size, longitudinal integrity, and unique data links 
(115). For this particular analysis, data from inpatient services file, outpatient services file, 
outpatient drug claims file and enrollment file were merged using unique patient identifiers.  
Study design: 
A retrospective cohort study was designed to evaluate factors influencing biologic 
treatment initiation in RA patients. The total study period was from Jan 1, 2007 to Dec 31, 
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2010. To allow for a 12-month baseline period for everyone in order to obtain stable baseline 
measurements and sufficient wash out period to identify prevalent biologic users, we began 
patient identification on Jan 1, 2008 and continued until Oct 1, 2010. All patients 18 years of 
age and older with recorded ICD-9-CM diagnosis code of 714.0 on at least 2 outpatient 
claims or 1 inpatient claim and at least 1 DMARD prescription in drug claims or outpatient 
services claims between Jan 1, 2008 and Dec 31, 2010 were identified as having RA. This 
algorithm has been validated for its use in identifying RA patients in electronic healthcare 
databases (97). The earliest diagnosis claim was defined as the index diagnosis. Patients who 
were not continuously enrolled in their health plan for 12 months pre-index and 3 months 
post-index or did not have complete drug history recorded in the database were excluded. We 
also excluded patients who had history of tuberculosis (contraindication to biologics use) or 
psoriatic arthritis or Crohn’s disease (both comorbid conditions in which some biologic 
DMARDs are indicated) during the baseline period to ensure the included RA patients were 
eligible to receive biologics and the biologics initiated were for RA treatment. Finally, we 
excluded all the patients who used any biologic agent during the baseline period since we 
only were interested in incident users. Once the eligible RA patients were identified, they 
were followed for 3-months beginning from their index diagnosis for the initiation of a 
biologic agent (Figure 4.1). 
Measures: 
To evaluate factors influencing biologic treatment initiation in RA patients,  we 
organized the patient factors into the following 3 distinct sets of predictors based on the 
ABM (73) 1) Predisposing factors 2) Enabling factors and 3) Need factors. ABM posits a 
process of health care use in which predisposing factors influence the ability (measured 
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through enabling factors) of a person to obtain health care which, when adding the need for 
treatment, predicts the use of health care services. We measured following sets of patient 
factors during the 12 month baseline period pre-index.  
Predisposing factors: 
Predisposing factors included the variables that may influence the likelihood of need 
for health services. Patients’ age, gender and geographic location were included in this set. 
Age was defined as a continuous variable; gender was defined as a dichotomous variable and 
geographic location was defined as a categorical variable consisting of the following 
categories: Northeast, north central, west and south.  
Enabling factors: 
Enabling factors included variables suggesting patients’ ability to secure healthcare 
services. We included the following variables in this set: visit to a rheumatologist as a binary 
variable, health plan type as a binary variable indicating capitated plan (included HMO or 
capitated POS plans) or non-capitated plan (included Basic major medical, comprehensive, 
EPO, PPO, non-capitated POS, consumer driven health plan or high deductible health plan), 
type of insurance as a binary variable indicating either Medicare supplemental or commercial 
insurance and drug benefit generosity. Drug benefit generosity was approximated by creating 
a ‘generosity index’ using payment information from all the prescriptions filled by patients. 
Similar methods have been successfully used in prior studies (116). This index was 
calculated as a continuous variable in the range of 0-1 and was defined as the proportion of 
total drug cost paid by the patient out of pocket (OOP) as copay or coinsurance. Based on 
this index, patients were classified into quartiles of drug benefit generosity to facilitate 
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interpretation. The quartiles were termed as poor drug benefit generosity (highest OOP costs, 
4th quartile), average drug benefit generosity (3rd quartile), above average drug benefit 
generosity (2nd quartile) and most generous drug benefit (lowest OOP costs, 1st quartile).  
Need factors: 
Need factors included health conditions of patients that necessitate the utilization of 
health services. In this set, we included RA related factors such as RA type as a binary 
variable (incident or prevalent diagnosis) and RA severity as a continuous variable, 
calculated as a claims based index proposed and validated by Ting et al. (101). Other need 
factors included patients’ comorbidity profile, which was calculated as a continuous score 
based on methods proposed by Gagne et al. (102), steroid use as a binary variable and use of 
non-biologic DMARDs as a categorical variable indicating whether patients used 0,1, 2 or 
more than 2 agents in the baseline period. Methotrexate, hydroxychloroquin, auranofin, 
injectable gold, penicillamine, sulfasalazine, azathioprine, leflunamide, cyclophosphamide 
and cyclosporine were included as non-biologic DMARDs. 
The outcome variable of interest was initiation of a biologic DMARD during the 90 
days of follow up period beginning on the index diagnosis date.  The following biologic 
agents were available during the study period and pooled for this analysis: abatacept, 
adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab and 
tocilizumab. We did not categorize the biologics based on their mechanism of action because 
we assumed that due to similarities in costs and indications, the factors influencing treatment 
initiation might not differ across these classes and pooling them might give us better 
statistical power. The use of these agents was identified using both the NDC codes from 
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outpatient pharmacy files for filled prescriptions and J codes using outpatient services files 
for injectable agents administered at physician’s office. 
Statistical analyses: 
Descriptive statistics were used to summarize patient factors in biologic initiators and 
non-initiators. For dichotomous and categorical variables, the results were presented as 
numbers and proportions. For continuous variables, the results were presented as mean (± 
SD). The patient factors were then compared between biologic initiators and non-initiators 
using standardized differences (117). This method was used to avoid statistically significant 
but clinically meaningless differences between our two groups owing to the large sample 
size. The proportion of individual biologic agents initiated also was reported.  
To understand the impact of various predictors on the initiation of a biologic agent 
after controlling for other predictors in a multivariate manner, hierarchical logistic regression 
models were used in which the predictors were entered in 3 sets. First only predisposing 
variables were added to the multivariate model, then enabling variables were added and 
finally need variables were added. All analyses were conducted using SAS version 9.2 (SAS 
institute, Cary, NC). 
Sensitivity analyses: 
To determine the robustness of our findings, we conducted several sensitivity analyses. 
First, we considered the initiation of biologic agents into two groups using two separate 
multivariate models, first model evaluating predictors of TNF-I initiation and second model 
evaluating predictors of other non-TNF-I biologics initiation. In another set of sensitivity 
analyses, we used follow-up periods for the length of 6 months and 12 months instead of the 
 64 
 
original definition of 3 months. Finally, we conducted a stratified analysis based on the data 
source, commercial claims and Medicare supplemental claims, and reported findings.   
4.4 Results: 
A total of 52,212 patients were included in our cohort who were diagnosed with RA, 
had no history of biologic use, and could plausibly receive a biologic in the future (Figure 
4.2). Approximately 5% of the total sample (2,610 of 52,212) initiated treatment with a 
biologic agent during the 3-month follow-up period. Table 4.1 compares the baseline 
characteristics of the biologic initiators and biologic non-initiators. Comparison of the 
predisposing variables suggested that the biologic initiators were more frequently younger 
(Mean age 51.6 years vs 59.2 years, Standardized difference (SD)=56.88), more likely to live 
in the south region (50.96% vs 41.40%, Standardized difference=19.25), less likely to live in 
the north central region (23.22% vs 30.30%, Standardized difference=16.05). For the 
enabling variables, type of insurance was less likely to be Medicare among the biologic 
initiators (12.07% vs 31.07%, Sd=47.48). Among need variables, the severity of RA was 
found to be significantly greater among biologic initiators (mean CIRAS 4.91 vs 4.10, 
Sd=16.05). Prevalence of certain comorbid conditions including any tumor (3.79% vs 6.99%, 
SD=14.19) and hypertension (32.61% vs 40.84%, Sd=17.14) was found to be lower in the 
biologic initiator group.  Biologic initiators were more likely to use steroids (69.66% vs 
61.46%, SD=17.25), more likely to have no use of any non-biologic DMARD (42.26% vs 
30.77%, SD=24.03), while less likely to use only one non-biologic DMARD (37.01% vs 
49.9%, SD=26.22) in the pre-index period.  
Figure 4.3 shows the proportion of the 9 individual biologic agents that were initiated. 
Of 2,610 patients who initiated treatment with a biologic agent, most initiated treatment with 
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an anti-TNF agent (n= 2,428 or 93.02%). The patients most often initiated treatment with 
etanercept (47.32%) or adalimumab (37.47%), and initiated infliximab, golimumab, and 
certolizumab less frequently (5.48%, 1.76%, 1.00% respectively). Among other biologics, 
rituximab, abatacept, anakinara and tocilizumab were initiated by 3.95%, 2.34%, 0.61% and 
0.08% of the patients, respectively. 
The results of our multivariate model that evaluated the influence of various 
predictors on treatment initiation with biologics are presented in Table 4.2. The predisposing 
variables patient age and geographic region were found to be significant predictors of 
biologic initiation. Each year increase in age reduced the odds of biologic initiation by 2% 
(OR 0.98, 95% CI 0.97-0.98). Patients in the north central region had significantly lower 
likelihood of treatment initiation with biologics compared to patients in the south (OR 0.81, 
95% CI 0.73-0.90).  
Several of the enabling variables were found to be associated with biologic initiation. 
Medicare patients and patients with a capitated health plan had lower likelihood of biologic 
treatment initiation (Medicare vs commercial insurance OR 0.74, 95% CI 0.63-0.87, 
Capitated vs non-capitated health plan OR 0.81, 95% CI 0.71-0.91). On the other hand, 15% 
and 31% higher odds of biologic initiation were observed for above average and the most 
generous benefit generosity compared to poor benefit generosity (OR 1.15 95% CI 1.03-1.30 
& OR 1.31 95% CI 1.17-1.47 respectively). 
Among the need variables, RA severity, RA status, pre-index steroid and non-
biologic DAMRD use were found to be significant predictors of biologic treatment initiation. 
With each unit increase in RA severity measure (CIRAS), the odds of biologic initiation 
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increased by 16% (OR 1.16 95% CI 1.12-1.21). Previous use of steroids raised the odds of 
biologic initiation by 51% (OR 1.51, 95% CI 1.38-1.66). Compared to no use of a non-
biologic DMARD in the pre-index period, use of 1 non-biologic DMARD and 2 non-biologic 
DMARD decreased the odds of biologic initiation by 36% and 18% respectively (OR 0.64 
95% CI 0.58-0.72 & OR 0.82 95% CI 0.72-0.93). Also, patients who had newly diagnosed 
RA at the index date had 34% greater odds of biologic initiation compared to those who had 
prevalent RA (OR 1.34 95% CI 1.16-1.56). Results and model fit statistics for our 
hierarchical models are reported in Appendix Table 4.1.  
In our sensitivity analyses where we considered initiation of TNF-Is and other 
biologics as separate outcomes, findings similar to original model were observed for majority 
of the predictors but due to decreased power, some results were no longer statistically 
significant (Table 4.3). However, the need factor of patient comorbidity status (approximated 
by a combined comorbidity score (CCS)) was found to be a significant predictor of other 
biologic initiation but not TNF-I initiation. Each unit increase in CCS resulted in 25% 
increased odds of other biologic initiation (OR 1.25 95% CI 1.16-1.34). The results of other 
set of sensitivity analyses where follow-up periods were changed to 6 months and 12 months 
were very similar to the original results (Appendix Table 4.2). Finally, when we stratified our 
sample based on the data source into commercial and Medicare supplemental claims, we 
observed findings similar to our original results for all the variables except for the drug 
benefit generosity variable, which was a non-significant predictor among Medicare 
supplemental enrollees (Appendix Table 4.3).  
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4.5 Discussion: 
In this nationally representative large sample of patients diagnosed with RA, we 
observed that treatment initiation with biologics is influenced by a mix of predisposing, 
enabling and need factors. When use of healthcare services is solely governed by patients’ 
health related need factors, equity in healthcare use is demonstrated. However, when 
predisposing and enabling factors significantly explain the use of healthcare services 
independent of need factors, potential inequity in access of healthcare use is exhibited (75). 
In our analyses, in addition to the need factors such as RA severity, RA diagnosis type and 
pre-index use of non-biologic treatments for RA, the predisposing factor age, and the 
enabling factors of insurance type and drug benefit generosity were found to be significant 
predictors of treatment initiation with biologics suggesting potential issues with access to 
these agents. 
The finding that age is inversely associated with biologic treatment initiation is 
consistent with a prior study by DeWitt et al. (63). A number of other studies have also 
reported a similar finding for DMARDs as a class and not only specific to biologics (62, 86, 
87). Although there is no evidence in the literature suggesting differential efficacy of 
biologics in different age groups, evidence of their differential use is concerning because it 
may lead to less aggressive RA management and hence uncontrolled RA in older patients. 
One of the factors leading to less aggressive treatment in older RA patient may be physician 
preference (118). Future research should be conducted to examine the efficacy and safety of 
biologic agents in elderly patients to address physician concerns.   
The significant association of higher RA severity score with biologic treatment 
initiation is an expected finding based on the ACR recommendations for the treatment of RA 
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(112). However, we also noted that incident RA cases were more likely than prevalent cases 
to initiate biologics and patients who used 1 or 2 non-biologic DMARDs in the pre-index 
period were less likely than patients who did not use any non-biologic DMARD to initiate 
biologics. These findings may seem counterintuitive at first glance. However, we postulate 
that this phenomenon may be attributed to the fact that combination therapy with biologics 
has been found to be superior to oral DMARD monotherapy for remission in early RA 
patients (119). Therefore physicians may start treatment with biologics at a very early stage 
of the disease to achieve remission in these patients.   
We further observed that patients with drug benefit plans that had lower cost sharing 
were more likely to initiate treatment with biologics. Greater patient cost sharing has been 
known to delay or reduce the odds of initiation of treatments in a variety of disease 
conditions (120), including RA (121). The coverage of biologics under a higher or specialty 
formulary tier of pharmacy benefits has become increasingly common (122). Research 
suggests that this practice has substantially increased the OOP costs for biologics (122, 123). 
Insurers must be mindful of the fact that higher cost sharing may deter patients from 
initiation of timely pharmaceutical care, which may result in uncontrolled RA and eventual 
increase in total healthcare cost. Patients enrolled in capitated health plans were found to be 
less likely to initiate biologic treatment. However, since we did not have precise information 
about what services were capitated within these health plans, it is difficult to interpret this 
finding. We also found that Medicare supplemental enrollees were less likely to initiate 
biologics compared to the commercial enrollees, even after controlling for their age and other 
patient demographics. This may be attributed to differential patient and plan profiles between 
commercial and Medicare supplemental enrollees. To further examine this issue, we 
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conducted a stratified analysis in these two groups (Appendix Table 4.3). All the findings 
were found to be similar across the two data sources used, except for the drug benefit 
generosity. Among Medicare supplemental enrollees, drug benefit generosity did not 
significantly predict biologic initiation. We caution our readers trying to interpret this finding 
because our sample represents a special group of Medicare enrollees, those with employer 
sponsored health plans. These plans are seen as gold standards for drug benefits among all 
the Medicare patients.   
Results from our sensitivity analyses, where we considered initiation of TNF-Is and 
other biologics as separate outcomes, suggested that patients with worse comorbidity profile 
were more likely to initiate non-TNF-I biologics (Table 4.3). This finding may reflect the fact 
that TNF-Is are contraindicated in a variety of comorbid conditions including congestive 
heart failure, multiple sclerosis, and lymphoproliferative diseases, while abatacept and 
rituximab are not (22). Therefore, it is likely that physicians may avoid TNF-I treatment in 
RA patients with a higher burden of comorbidities and hence sicker RA patients are 
channeled towards non TNF-I biologics. This finding is important for researchers evaluating 
associations between biologic treatments and various outcomes in RA patients in an 
observational setting. Appropriate measures should be taken to address this channeling bias 
in observational studies in order to ensure unbiased interpretation of the estimates.  
This is the largest study of its kind to provide estimates on the influence of population 
characteristics on biologic treatment initiation. However, there are several limitations of this 
study that deserve discussion. As with any other study using administrative claims, we were 
not able to validate the diagnoses of the disease condition (RA) as well as co-morbid 
conditions. Further, the administrative claims contain very limited information on clinical 
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conditions of RA patients, such as disease activity and swollen joint count. Therefore, we 
were not able to capture the exact severity of RA in patients in our cohort. However, as a 
proxy, we used the validated claims-based index for getting an approximation of RA severity 
(101). We also did not have any specific information about the drug coverage criteria for our 
patients and therefore had to rely on a calculated generosity index that approximated the drug 
benefit generosity for the patients in our cohort. Next, because of the unavailability of 
information on patient race, our study cannot explain potential racial disparities in biologics 
initiation. Finally, the insurance claims data only represent employed individuals and their 
dependents and the Medicare supplemental data only represent retirees whose insurance are 
paid by their employers limiting generalizability.  
4.6 Conclusion: 
The results from our study suggest that treatment initiation with biologics in RA 
patients is associated with patient age, RA severity, RA type, pre-index non-biologic 
DMARD and steroid use, health insurance type, and drug benefit generosity. From a policy 
point of view, the finding that more generous drug coverage facilitated biologic initiation is 
of significance. Our findings also highlight potential age bias in the initiation of biologics.  
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Figure 4.1: Timeline of the study 
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Figure 4.2: Sample derivation flow-chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†The contraindications to biologic use considered were: Tuberculosis (ICD-9 codes: 010-018). The other conditions in 
which also biologics are indicated were Crohn’s disease (ICD-9 code: 555) and Psoriatic arthritis (ICD-9 code: 696) 
 
 
Disease identification: RA diagnosis (ICD-9 code 714.0) recorded on 1 inpatient or 2 
outpatient claims + atleast   1 DMARD prescription in drug claims or outpatient services 
claims between 1 Jan, 2008 to 31 Dec, 2010 
Included n=168,594 
 
 
Did not meet eligibility requirements 
Excluded n= 89,004 
Eligibility requirements: Patients with complete drug history and 15 months continuous 
enrollment (12 months pre-index+ 3 months post-index) in their health plan 
Included n=79,590 
 
 
Had contradiction to biologic use 
Excluded n=184 
Diagnosed with Crohn’s disease or 
psoriatic arthritis 
Excluded n=4,356 
Patients with no contraindication to biologic use & no comorbid conditions in which 
biologics are indicated
†
 
Included n=75,050 
 
 
Patients who do not have any biologic DMARD use in 1 year pre-index period 
Final sample n=52,212 
 
 
Used biologics in pre-index period 
Excluded n= 22,838 
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Table 4.1: Baseline characteristics of the biologic initiator and non-initiator patients 
with rheumatoid arthritis identified from Marketscan database, 2008-2010 
Variable Biologic 
initiators 
(n=2,610) 
Biologic non-
initiators 
(n=49,602) 
Standardized 
difference
†
 
 n(%) n(%)  
Predisposing    
Patient age (Mean(SD)) 51.63(12.8) 59.18(13.72) 56.88 
Female 1985(76.05)  37182(74.96)  2.54 
MSA 2121(81.55)  39997(81.01)  1.37 
Region    
Northeast Region 220(8.43)  4739(9.55)  3.93 
North Central Region 606(23.22)  15031(30.3)  16.05 
South Region 1330(50.96)  20537(41.4)  19.25 
West Region 442(16.93)  9045(18.24)  3.42 
Unknown region 12(0.46)  250(0.5)  0.64 
Enabling    
Capitation    
Non-capitated health plan 2193(86.14)  40966(84.38)  4.96 
Capitated health plan 353(13.86)  7585(15.62)  4.96 
Seeing a rheumatologist 1281(49.98)  22688(46.1)  7.77 
Payer type    
Commercial 2295(87.93)  34190(68.93)  47.48 
Medicare 315(12.07)  15412(31.07)   
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Drug benefit generosity
‡
    
Most generous drug benefit 687(26.32)  12338(24.87)  3.32 
Better than average drug benefit 609(23.33)  12416(25.03)  3.97 
Average drug benefit 603(23.1)  12423(25.05)  4.54 
Below average drug benefit 685(26.25)  12340(24.88)  3.13 
Need    
Incident RA 976(37.39)  16636(33.54)  8.07 
CIRAS* (Mean(SD)) 4.91(2.09) 4.10(1.92) 16.05 
Combined comorbidity score (CCS or Gagne 
Score) (Mean(SD)) 
0.40(1.26) 0.48(1.42) 6.47 
Individual comorbid conditions from CCS    
Metastatic cancer 6(0.23)  292(0.59)  5.62 
Congestive heart failure 116(4.44)  2996(6.04)  7.16 
Dementia 6(0.23)  297(0.6)  5.75 
Renal failure 64(2.45)  1540(3.1)  3.97 
Weight loss 10(0.38)  188(0.38)  0.07 
Hemiplegia 7(0.27)  193(0.39)  2.11 
Alcohol abuse 10(0.38)  171(0.34)  0.64 
Any tumor 99(3.79)  3467(6.99)  14.19 
Cardiac arrhythmias 150(5.75)  3874(7.81)  8.21 
Chronic pulmonary disease 302(11.57)  7025(14.16)  7.75 
Coagulopathy 46(1.76)  857(1.73)  0.26 
Complicated diabetes 66(2.53) 1603(3.23) 4.2 
Deficiency anemia 331(12.68) 6331(12.76) 0.24 
Fluid and electrolyte disorders 129(4.94)  2983(6.01)  4.71 
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Liver disease 78(2.99)  905(1.82)  7.6 
Peripheral vascular disorder 93(3.56)  2642(5.33)  8.56 
Psychosis 129(4.94) 2156(4.35) 2.83 
Pulmonary circulation disorders 20(0.77)  488(0.98)  2.34 
HIV/AIDS 0(0)  36(0.07)  3.81 
Hypertension 851(32.61)  20256(40.84)  17.14 
Steroids use in pre-index period 1818(69.66) 30501(61.49) 17.25 
Non-biologic DMARD use in pre-index period    
No use 1103(42.26) 15264(30.77) 24.03 
Used 1 agent 966(37.01) 24750(49.9) 26.22 
Used 2 agents 440(16.86) 8338(16.81) 0.13 
Used more than 2 agents 101(3.87) 1250(2.52) 7.68 
 
† A standardized difference of 10 (approximately equivalent to P<.05) indicates significant imbalance of a baseline 
covariate. 
‡Drug benefit generosity was classified according to the quartiles of calculated generosity index. This index was calculated 
as a continuous variable and defined as the proportion of total drug cost paid by the patient out of pocket. The quartiles were 
termed as poor drug benefit generosity (highest out of pocket costs, 4th quartile), average drug benefit generosity (3rd 
quartile), above average drug benefit generosity (2nd quartile) and most generous drug benefit (lowest out of pocket costs, 
1st quartile). Because of no prescription drug use, generosity index in 111 patients (26 and 85 respectively in biologic 
initiators and non-initiators) was missing.  
 
*CIRAS: Claims based index of rheumatoid arthritis severity  
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Table 4.2: Multivariate predictors of treatment initiation with biologic agents in RA 
patients 
Variables OR (95% CI) 
Predisposing  
Patient age 0.98 (0.97-0.98) 
Region  
South region 1 
North Central Region 0.81 (0.73-0.90) 
Northeast Region 0.89 (0.76-1.03) 
West Region 0.92 (0.82-1.04) 
Metropolitan statistical area  
Non-MSA 1 
MSA 1.04 (0.94-1.16) 
Gender  
Female 1 
Male 1.08 (0.98-1.19) 
Enabling  
Capitation  
Non-capitated health plan 1 
Capitated plan  0.81 (0.71-0.91) 
Visit to rheumatologist in the pre-index 
period 
 
No visit 1 
At least one visit 1.03 (0.94-1.13) 
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Drug benefit generosity†  
Poor  1 
Average 1.00 ( 0.89-1.13) 
Better than average 1.15 (1.03-1.30) 
Most generous  1.31 (1.17-1.47) 
Insurance type  
Commercial 1 
Medicare  0.74 (0.63-0.87) 
Need  
RA factors  
CIRAS
‡
 1.16 (1.12-1.21) 
Prevalent RA 1 
Incident RA 1.34 (1.16-1.56) 
Medication use in the pre-index period  
No steroid use 1 
Steroid use 1.51 (1.38-1.66) 
No non-biologic DMARD use 1 
1 non-biologic DMARD use  0.64 (0.58-0.72) 
2 non-biologic DMARDs use  0.82 (0.72-0.93) 
> 2 non-biologic DMARDs use  1.13 (0.90-1.41) 
Combined comorbidity score  1.00 (0.97-1.04) 
 
† Drug benefit generosity was classified according to the quartiles of calculated generosity index. This index was calculated 
as a continuous variable and defined as the proportion of total drug cost paid by the patient out of pocket. The quartiles were 
termed as poor drug benefit generosity (highest out of pocket costs, 4th quartile), average drug benefit generosity (3rd 
quartile), above average drug benefit generosity (2nd quartile) and most generous drug benefit (lowest out of pocket costs, 
1st quartile).  
 
‡ CIRAS: Claims based index of rheumatoid arthritis severity 
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Table 4.3: Sensitivity analyses: Multivariate predictors of treatment initiation with 
TNF-Inhibitors and other biologics in RA patients 
Variables OR (95% CI) 
 TNF-Inhibitors
†
 Other Biologics
†
 
Predisposing   
Patient age 0.98 (0.97-0.98) 0.99 (0.97-1.01) 
Region   
South region 1 1 
North Central Region 0.80 (0.72-0.89) 0.94 (0.65-1.37) 
Northeast Region 0.89 (0.76-1.04) 0.84 (0.47-1.5) 
West Region 0.93 (0.82-1.05) 0.81 (0.5-1.31) 
Metropolitan statistical area   
Non-MSA 1 1 
MSA 1.05 (0.94-1.17) 0.96 (0.65-1.42) 
 
Gender   
Female 1 1 
Male 1.07 (0.97-1.18) 1.15 (0.81-1.64) 
Enabling   
Capitation   
Non-capitated health plan 1 1 
Capitated plan  0.83 (0.73-0.93) 0.47 (0.26-0.86) 
Visit to rheumatologist in the 
pre-index period 
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No visit 1 1 
At least one visit 1.02 (0.92-1.12) 1.25 (0.89-1.76) 
Drug benefit generosity
‡
   
Poor  1 1 
Average 0.96 (0.85-1.09) 1.89 (1.17-3.05) 
Better than average 1.13 (1.00-1.27) 1.72 (1.06-2.81) 
Most generous  1.31 (1.17-1.48) 1.36 (0.82-2.25) 
Insurance type   
Commercial 1 1 
Medicare  0.67 (0.57-0.80) 0.66 (0.39-1.12) 
Need   
RA factors   
CIRAS
*
 1.17 (1.12-1.22) 1.07 (0.92-1.24) 
Prevalent RA 1 1 
Incident RA 1.30 (1.12-1.52) 1.86 (1.07-3.2) 
Medication use in the pre-index 
period 
  
No steroid use 1 1 
Steroid use 1.50 (1.36-1.65) 1.66 (1.15-2.41) 
No non-biologic DMARD use 1 1 
1 non-biologic DMARD use  0.64 (0.58-0.72) 0.71 (0.48-1.06) 
2 non-biologic DMARDs use  0.82 (0.71-0.93) 0.89 (0.54-1.46) 
> 2 non-biologic DMARDs use  1.10 (0.87-1.39) 1.52 (0.70-3.30) 
Combined comorbidity score  0.97 (0.94-1.00) 1.25 (1.16-1.34) 
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† For the other biologic model, the total number of events was 161(other biologic initiators) and for the TNF-Inhibitor 
model, the total number of events was 2,308 (TNF-inhibitor initiators). Other biologic agents include abatacept, anakinara, 
rituximab and tocilizumab and TNF-inhibitors include adalimumab, certolizumab, etanercept, golimumab and infliximab. 
 
‡ Drug benefit generosity was classified according to the quartiles of calculated generosity index. This index was calculated 
as a continuous variable and defined as the proportion of total drug cost paid by the patient out of pocket. The quartiles were 
termed as poor drug benefit generosity (highest out of pocket costs, 4th quartile), average drug benefit generosity (3rd 
quartile), above average drug benefit generosity (2nd quartile) and most generous drug benefit (lowest out of pocket costs, 
1st quartile).  
 
*CIRAS: Claims based index of rheumatoid arthritis severity 
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Figure 4.3: Proportion of individual biologics initiated in RA patients  
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Appendix Table 4.1: Results of hierarchical models for prediction initiation of biologics 
Variable OR (95% CI) 
Model 1 
(Predisposing 
factors) 
Model 2 
(Predisposing+ 
Enabling 
factors) 
Model 3 
(Predisposing+ 
Enabling+ Need 
factors) 
Patient age 0.96(0.96-0.97) 0.98(0.97-0.98) 0.98(0.97-0.98) 
Region    
South region 1 1 1 
North Central Region 0.74(0.67-0.81) 0.79(0.72-0.88) 0.81(0.73-0.90) 
Northeast Region  0.79(0.68-0.91) 0.85(0.73-0.98) 0.89(0.76-1.03) 
West Region 0.81(0.72-0.9) 0.88(0.79-0.99) 0.92(0.82-1.04) 
Metropolitan statistical area    
Non-MSA 1 1 1 
MSA 1.06(0.96-1.18) 1.05(0.94-1.16) 1.04(0.94-1.16) 
Gender     
Female 1 1 1 
Male 1.08(0.99-1.19) 1.06(0.96-1.16) 1.08(0.98-1.19) 
Capitation    
Non-capitated health plan  1 1 
Capitated plan   0.79(0.70-0.90) 0.81(0.71-0.91) 
Visit to rheumatologist in the pre-
index period 
   
No visit  1 1 
At least one visit  1.13(1.04-1.23) 1.03(0.94-1.13) 
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Drug benefit generosity†    
Poor   1 1 
Average  1.01(0.90-1.13) 1.00(0.89-1.13) 
Better than average  1.15(1.02-1.29) 1.15(1.03-1.30) 
Most generous   1.31(1.17-1.47) 1.31(1.17-1.47) 
Insurance type    
Commercial  1 1 
Medicare   0.66(0.56-0.77) 0.74(0.63-0.87) 
RA factors    
CIRAS
‡
   1.16(1.12-1.21) 
Prevalent RA   1 
Incident RA   1.34(1.16-1.56) 
Medication use in the pre-index 
period 
 
 
 
No steroid use   1 
Steroid use   1.51(1.38-1.66) 
No non-biologic DMARD use   1 
1 non-biologic DMARD use    0.64(0.58-0.72) 
2 non-biologic DMARDs use    0.82(0.72-0.93) 
> 2 non-biologic DMARDs use    1.13(0.90-1.41) 
Combined comorbidity score    1.00(0.97-1.04) 
Model Fit statistics 
c-statistic 0.64 0.67 0.69 
AIC 19856.7 18892.1 18654.7 
 
† Drug benefit generosity was classified according to the quartiles of calculated generosity index. This index was calculated 
as a continuous variable and defined as the proportion of total drug cost paid by the patient out of pocket. The quartiles were 
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termed as poor drug benefit generosity (highest out of pocket costs, 4th quartile), average drug benefit generosity (3rd 
quartile), above average drug benefit generosity (2nd quartile) and most generous drug benefit (lowest out of pocket costs, 
1st quartile).  
 
‡ CIRAS: Claims based index of rheumatoid arthritis severity 
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Appendix Table 4.2: Sensitivity analyses: Multivariate predictors of treatment initiation 
with biologics in RA patients, 6 months and 12 months follow-up period 
Variables OR (95% CI) 
 6 month follow-up period
†
 12 month follow-up period
†
 
Predisposing   
Patient age 0.98 (0.97-0.98) 0.98 (0.97-0.98) 
Region   
South region 1 1 
North Central Region 0.83 (0.76-0.9) 0.85 (0.78-0.92) 
Northeast Region 0.89 (0.78-1.01) 0.85 (0.76-0.97) 
West Region 0.99 (0.9-1.09) 0.93 (0.84-1.02) 
Metropolitan statistical area   
Non-MSA 1 1 
MSA 1.06 (0.97-1.16) 1.04 (0.95-1.13) 
Gender   
Female 1 1 
Male 1.07 (0.99-1.16) 1.03 (0.95-1.11) 
Enabling   
Capitation   
Non-capitated health plan 1 1 
Capitated plan  0.84 (0.76-0.92) 0.88 (0.81-0.97) 
Visit to rheumatologist in the 
pre-index period 
  
No visit 1 1 
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At least one visit 1.01 (0.93-1.09) 0.94 (0.87-1.01) 
Drug benefit generosity
‡
   
Poor  1 1 
Average 1.03 (0.93-1.13) 1.01 (0.92-1.11) 
Better than average 1.13 (1.03-1.25) 1.08 (0.99-1.19) 
Most generous  1.29 (1.17-1.41) 1.21 (1.1-1.33) 
Insurance type   
Commercial 1 1 
Medicare  0.77 (0.68-0.88) 0.79 (0.7-0.89) 
Need   
RA factors   
CIRAS
*
 1.18 (1.15-1.22) 1.19 (1.15-1.22) 
Prevalent RA 1 1 
Incident RA 1.5 (1.33-1.7) 1.52 (1.35-1.71) 
Medication use in the pre-index 
period 
  
No steroid use 1 1 
Steroid use 1.58 (1.46-1.7) 1.57 (1.46-1.69) 
No non-biologic DMARD use 1 1 
1 non-biologic DMARD use  0.54 (0.49-0.59) 0.48 (0.44-0.52) 
2 non-biologic DMARDs use  0.68 (0.61-0.76) 0.6 (0.54-0.67) 
> 2 non-biologic DMARDs use  0.89 (0.73-1.08) 0.8 (0.66-0.97) 
Combined comorbidity score  0.98 (0.95-1) 0.97 (0.94-1) 
 
† For the 6 month follow-up period model, the sample size was 45,901 total patients (3,821 biologic initiators) and for the 
12 month follow-up period model, the sample size was 34,112 total patients (4,368 biologic initiators).   
 
‡ Drug benefit generosity was classified according to the quartiles of calculated generosity index. This index was calculated 
as a continuous variable and defined as the proportion of total drug cost paid by the patient out of pocket. The quartiles were 
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termed as poor drug benefit generosity (highest out of pocket costs, 4th quartile), average drug benefit generosity (3rd 
quartile), above average drug benefit generosity (2nd quartile) and most generous drug benefit (lowest out of pocket costs, 
1st quartile) 
 
* CIRAS: Claims based index of rheumatoid arthritis severity 
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Appendix Table 4.3 Sensitivity analyses: Multivariate predictors of treatment initiation 
with biologics in RA patients, Medicare supplemental and commercial enrollees 
Variable OR (95% CI) 
Combined 
data 
Medicare 
Supplemental
†
 
Commercial
†
  
Predisposing    
Patient age 0.98(0.97-0.98) 0.95(0.93-0.97) 0.98(0.97-0.98) 
Region    
South region 1 1 1 
North Central Region 0.81(0.73-0.90) 0.77(0.58-1.03) 0.82(0.73-0.92) 
Northeast Region  0.89(0.76-1.03) 1.20(0.81-1.76) 0.84(0.71-1.00) 
West Region 0.92(0.82-1.04) 1.32(0.95-1.83) 0.87(0.77-0.99) 
Metropolitan statistical area    
Non-MSA 1 1 1 
MSA 1.04(0.94-1.16) 0.81(0.60-1.09) 1.08(0.97-1.22) 
Gender     
Female 1 1 1 
Male 1.08(0.98-1.19) 0.86(0.66-1.12) 1.12(1.00-1.24) 
Enabling    
Capitation    
Non-capitated health plan 1 1 1 
Capitated plan  0.81(0.71-0.91) 0.74(0.50-1.10) 0.81(0.70-0.93) 
Visit to rheumatologist in the pre-
index period 
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No visit 1 1 1 
At least one visit 1.03(0.94-1.13) 1.13(0.87-1.46) 1.02(0.92-1.13) 
Drug benefit generosity
‡
    
Poor  1 1 1 
Average 1.00(0.89-1.13) 0.98(0.67-1.42) 1.00(0.88-1.30) 
Better than average 1.15(1.03-1.30) 0.86(0.60-1.24) 1.18(1.04-1.34) 
Most generous  1.31(1.17-1.47) 0.97(0.68-1.38) 1.35(1.19-1.52) 
Insurance type    
Commercial 1 - - 
Medicare  0.74(0.63-0.87) - - 
Need    
RA factors    
CIRAS
*
 1.16(1.12-1.21) 1.13(1.01-1.27) 1.16(1.11-1.20) 
Prevalent RA 1 1 1 
Incident RA 1.34(1.16-1.56) 1.49(1.04-2.14) 1.29(1.09-1.52) 
Medication use in the pre-index 
period 
   
No steroid use 1 1 1 
Steroid use 1.51(1.38-1.66) 1.36(1.05-1.77) 1.53(1.39-1.59) 
No non-biologic DMARD use 1 1 1 
1 non-biologic DMARD use  0.64(0.58-0.72) 0.44(0.32-0.60) 0.68(0.61-0.76) 
2 non-biologic DMARDs use  0.82(0.72-0.93) 0.70(0.49-1.01) 0.83(0.72-0.95) 
> 2 non-biologic DMARDs use  1.13(0.90-1.41) 1.04(0.56-1.92) 1.13(0.88-1.44) 
Combined comorbidity score  1.00(0.97-1.04) 1.05(0.98-1.11) 0.99(0.96-1.03) 
 
† For the commercial model, the sample size was 35052 total patients (2,174 biologic initiators) and for the Medicare 
supplemental model, the sample size was 15,276 total patients (295 biologic initiators) 
 90 
 
‡ Drug benefit generosity was classified according to the quartiles of calculated generosity index. This index was calculated 
as a continuous variable and defined as the proportion of total drug cost paid by the patient out of pocket. The quartiles were 
termed as poor drug benefit generosity (highest out of pocket costs, 4th quartile), average drug benefit generosity (3rd 
quartile), above average drug benefit generosity (2nd quartile) and most generous drug benefit (lowest out of pocket costs, 
1st quartile).   
 
* CIRAS: Claims based index of rheumatoid arthritis severity 
 
 
  
 CHAPTER 5 
5 TNF-ALPHA INHIBITOR TREATMENT AND THE RISK OF INCIDENT 
CARDIOVASCULAR EVENTS IN PATIENTS NEWLY DIAGNOSED WITH 
RHEUMATOID ARTHRITIS 
This chapter presents the second of three manuscripts prepared from this dissertation. 
In this manuscript, we evaluated the association between TNF-alpha inhibitor treatments and 
the risk of incident cardiovascular events in patients newly diagnosed with rheumatoid 
arthritis using health insurance claims from Marketscan databases during the period of 2007 
to 2010. 
5.1 Overview:  
Objective: There is little evidence on the association between use of TNF-α inhibitors (TNF-
Is) and the risk of CVD events in patients newly diagnosed with RA. Our study evaluated 
this association in this previously unstudied population.  
Methods: A nested case-control study was designed using data for patients newly diagnosed 
with RA between Jan 1, 2008 and Dec 31, 2010 identified from the Marketscan claims 
database. These patients were followed up for the outcome of a composite cardiovascular 
disease (CVD) event. Patients who experienced the outcome were defined as cases on their 
event date and 12 age-, sex-, and cohort entry month-matched controls were selected on the 
same date. Exposure to TNF-I was defined using three unique definition schemes that 
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accounted for timing and use of other RA treatments. Duration of treatment was defined as a 
continuous variable representing cumulative days use. Conditional logistic regression (CLR) 
models were used to derive estimates for incidence rate ratios (IRR).  
Results: Of the 15,951 patients of the base cohort, 466 cases of an incident CVD event were 
identified during follow-up, who were matched with 5,592 controls (12 cases per control) 
using incidence density sampling. In our multivariate CLR models, which adjusted for 
baseline factors as well as treatment history with other DMARDs, current use of TNF-I and 
current use of non-biologic DMARDs were found to be associated with a reduced risk of an 
incident CVD events compared to no DMARD use (IRR 0.62 95% CI 0.40-0.98 & IRR 0.66 
95% CI 0.48-0.89 respectively). Duration of use for both TNF-I and non-biologic DMARDs 
was found to be associated with a reduced risk of CVD in a linear manner.  
Conclusion: Treatment with TNF-Is and non-biologic DMARDs may help in reducing the 
risk of incident CVD events in patients newly diagnosed with RA compared to no treatment 
with DMARDs.
5.2 Introduction: 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of 
the synovium, a membrane that lines the joint capsule and produces lubricating fluid in the 
joint, leading to disability (1). The association between RA and cardiovascular diseases 
(CVD) has been the focus of recent attention, primarily because of the increasing recognition 
of the major role that inflammation plays in the development of atherosclerosis (7, 23, 24). 
Several epidemiological studies indicate that RA patients have an increased risk of CVD-
related morbidity and mortality compared to the general population (4, 5, 41). The 
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proinflammatory cytokine, TNF-α, may play an important role in the development and 
acceleration of atherosclerosis in RA patients (25). Therefore, it is plausible to hypothesize 
that treatment with TNF- α inhibitors (TNF-Is) in RA patients may slow the progression of 
atherosclerosis and reduce the risk of CVD events. 
Several observational studies have evaluated the association between CVD and TNF-Is 
in established RA patients (49, 52, 53, 55-60), but few focus on incident RA cases (51, 61). 
This is important because structural damage to joints occur aggressively within first few 
years of RA diagnosis (8, 9), so it is possible that development of atherosclerosis may also 
accelerate during the early stages of RA. Two small studies indicate that atherogenic lipid 
profile and subclinical atherosclerosis are features of early RA (10, 11). The epidemiological 
evidence of the effect of TNF-Is on CVD events among early RA patients is limited to only 
two studies, one limited to modest sample size (198 CVD events) (61) and the second mixed 
treatment exposure with TNF-Is and other biologics, which could bias the results (51).  
The primary objective of this study is to examine the effect of TNF-I treatment on 
incident CVD event among patients newly diagnosed with RA. We extend previous analyses 
by studying a large sample of patients with a new diagnosis of RA, isolating treatment 
exposure to only TNF-I biologic treatment, and by using several different definitions of 
treatment exposure to account for the timing and history of treatment with disease modifying 
anti-rheumatic agents (DMARDs).  The results from this study should help better understand 
the potential benefits of TNF-I medication use on cardiovascular risk in patients with RA. 
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5.3 Methods: 
Data source:  
Data from the Truven’s MarketScan Commercial Claims And Encounters (CCAE) 
and Medicare Supplemental and Coordination of Benefits (COB) was used for this study. 
This database contains de-identified, person-specific health data including clinical utilization, 
expenditures, insurance enrollment/plan benefit, inpatient, outpatient, and outpatient 
prescription information. The CCAE contains healthcare data for nearly 40 million 
individuals, encompassing employees, their spouses, and their dependents. The COB data 
contains the health care experiences of 3.8 million Medicare-eligible retirees with employer-
sponsored Medicare Supplemental plans. These data have been used widely in health 
services research due to its substantial size, longitudinal integrity, and unique data links (12). 
For this particular analysis, data from inpatient services file, outpatient services file, 
outpatient drug claims file and enrollment file were merged using unique patient identifiers.  
Study design and patient population: 
The nested case-control study design was selected to evaluate the association between 
TNF-Is and CVD because of its ability to efficiently deal with time varying nature of 
exposures without substantial loss in power (104).  Many researchers in the past have 
preferred this study design while evaluating treatment-outcome associations in RA patients 
(49, 52, 56, 124). From the Marketscan data files, a base cohort of RA patients 18 years and 
older who had at least 2 outpatient or 1 inpatient diagnosis of RA (ICD-9 code: 714.0) and at 
least one prescription record for a DMARD between Jan 1, 2008 and Dec 31, 2010 was 
identified. The earliest of these diagnoses was defined as the index diagnosis and the 12 
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month period pre-index was defined as the baseline period (Figure 5.1). To be considered for 
our case-control sampling, patients in the base cohort had to meet the following inclusion 
criteria during the 12-month baseline period: 1) continuous enrollment in their health plans, 
2) no diagnosis of RA in the baseline period, 3) No use of biologic agents, 4) no history of 
tuberculosis (contraindication to biologics use) or psoriatic arthritis or Crohn’s disease 
(inflammatory conditions for which biologic treatment is indicated), and 5) not diagnosed 
with the outcome of interest in the baseline period. Thus our sample consisted of patients 
with an incident diagnosis of RA who had no history of biologic use but were eligible to 
receive biologics in the future and at risk for an incident CVD event.  
Nested case-control sampling: 
All of the patients identified as eligible for sampling from the base cohort were 
followed from their index date to the earliest occurrence of the following events: the outcome 
(CVD diagnosis), disenrollment from their health plan, switch between biologic treatments, 
or the study end date (Dec 31, 2010). If patients experienced a CVD event, they were defined 
as “cases” and the date of CVD diagnosis was defined as the event date. Once the cases were 
identified, twelve age, sex and cohort entry month-matched controls were sampled using an 
incident density sampling procedure from the remaining patients of the base cohort at the 
event date who were free from CVD at that time (Figure 5.1) (77). Because the index 
diagnosis of RA was the starting point for follow-up of all patients in the base cohort, our 
sampling strategy also ensured the matching of cases and controls on the duration of RA.  
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Exposure definition schemes: 
While evaluating treatment-outcome association in RA, a precise exposure definition, one 
that accounts for both timing and history of the treatment, is vital because patients are known 
to start, stop and switch treatments often. There are several approaches used for exposure 
measurement by studies conducted in the past to evaluate the association between CVD and 
TNF-Is. One previously used approach (51, 55) is to define the use of TNF-Is or biologic 
DMARDs as ever-treated vs never-treated, meaning once a patient begins therapy with TNF-
Is he or she is considered to be treated for the entire follow-up period. Another approach used 
by several studies (49, 54, 56) is to classify the use of TNF-Is as ‘current use’ vs ‘no current 
use’ based on the use of medications within a certain time period prior to the event. In 
addition to using the two commonly used approaches, we developed a unique third approach 
that accounted for both the timing and the history of the treatment to measure antirheumatic 
medication use in RA patients. We evaluated the impact of three exposure definitions 
described below on the observed estimates:  
1) Scheme 1 (Ever/Never): First, we considered a dichotomous definition of exposure: 
ever-treated with a TNF-I (Monotherapy or in combination with non-biologic 
DMARDs) vs never-treated with a TNF-I prior to the event date. This over-simplified 
definition of exposure into a binary variable leads to non-differential misclassification 
of exposure by ignoring the timing of exposure and use of other treatments during 
that time. Although, some authors argue that such non-differential misclassification of 
the exposure would produce a bias towards the null and hence provide a conservative 
estimate of the treatment-outcome association (47), there is also evidence in the 
literature suggesting that this may not be true under all circumstances (64). 
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2) Scheme 2 (Current use indicators for TNF-Is and other RA treatments): To take 
into account the timing of TNF-I use and also the use of other DMARDs, we defined 
exposure into the following mutually exclusive categories: 1) current use of TNF-Is 
(monotherapy or in combination with non-biologic DMARDs), 2) current use of other 
biologics (monotherapy or in combination with non-biologic DMARDs), 3) current 
use of only non-biologic DMARDs, 4) no current DMARD use. Drug use in the time 
period of 6-months prior to the event date was defined as ‘current use’. Compared to 
Scheme 1, this approach addresses some of the misclassification by considering the 
timing of the exposure, which may be closely associated with the outcome. 
3) Scheme 3 (Current and past use indicators for TNF-I and other RA treatments): 
In addition to the timing of TNF-I use and other DMARDs use, to account for the 
entire DMARD exposure history, we defined exposure into the following mutually 
exclusive categories hierarchically: 1) no DMARD use, 2) past use of only non-
biologic DMARDs, 3) current use of only non-biologic DMARDs, 4) past use of 
TNF-Is (monotherapy or in combination with non-biologic DMARDs), 5) current use 
of TNF-Is (monotherapy or in combination with non-biologic DMARDs), 6) past use 
of other biologics (monotherapy or in combination with non-biologic DMARDs), and 
7) current use of other biologics (monotherapy or in combination with non-biologic 
DMARDs). Drug use in the time period of 6-months prior to the event date was 
defined as ‘current use’ and any use before the time period of 6-months prior to the 
event date was defined as ‘past use’. This definition is advantageous compared to 
Scheme 2 because if a patient has used the treatment in the past before discontinuing 
it and the reason for discontinuation is associated with the outcome, that patient 
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would not be classified as drug users and would be misclassified into the reference 
group (no current DMARD use) in Scheme 2, which ignores treatment history. So, we 
are likely to miss out on this important finding in Scheme 2. However, in Scheme 3, 
such patients would be classified into separate groups based on their past use of 
DMARDs and the reference group would only be comprised of patients not exposed 
to any DMARDs during the study period.  
TNF-Is included the following agents: adalimumab, certolizumab, etanercept, golimumab 
and infliximab. Abatacept, anakinara, rituximab and tocilizumab were considered as ‘other 
biologics’. Methotrexate, hydroxychloroquine, auranofin, injectable gold, penicillamine, 
minocycline, sulfasalazine, azathioprine, leflunamide, cyclophosphamide and cyclosporine 
were defined as ‘non-biologic DMARDs’. The use of these agents was identified using both 
the NDC codes from outpatient pharmacy files for filled prescriptions and J codes using 
outpatient services files for injectable/infusion agents administered at physician’s office. 
Measurement of duration of treatment: 
Duration of treatment with TNF-I was defined as a continuous variable representing 
the cumulative days of TNF-I use for the patients who filled at least one TNF-I prescription 
in the exposure measurement period. Similarly, duration of treatment with non-biologic 
DMARDs and other biologics were also measured as continuous variables. Significance of a 
quadratic term was tested for the continuous variables representing cumulative use for each 
treatment to check for any evidence of non-linearity in the dose response relationship 
between the duration and the risk of an incident CVD event (125).  
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Outcome measurement: 
The outcome of interest was defined as a composite measure consisting of acute 
myocardial infarction (ICD-9 code 410), unstable angina (ICD-9 code 411), angina pectoris 
(ICD-9 code 413), chronic heart failure (ICD-9 codes 428.xx, 398.91, 402.01, 402.11, 
404.01, 404.03, 404.11, 404.13, 404.91, 404.93), other forms of chronic heart diseases (ICD-
9 code 414), ischemic stroke (ICD-9 code s 433.x1, 434 [excluding 434.x0], or 436); and 
transient ischemic stroke (ICD-9 code 435). 
Covariates: 
In addition to matching with age and gender, we identified the following covariates 
during the baseline period and added them to our multivariate model for risk adjustment: 
CVD risk factors including hypertension, hyperlipidemia, and diabetes mellitus; CVD drug 
use including lipid lowering agents, beta-blockers, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, and other CVD drugs; RA drug use including steroids, non-
steroidal anti-inflammatory drugs and non-biologic DMARDs; and other comorbidities 
including chronic obstructive pulmonary disease and cancer.  
Statistical Analyses: 
Descriptive statistics were used to summarize the patient characteristics for our cases 
and controls.  Categorical variables were presented as numbers and percentages and 
continuous variables were presented as means (±standard deviations). The influence of the 
exposure definition on the absolute scale was assessed by calculating the estimates for the 
absolute risk of an incident CVD event during the 3 year follow-up period for all the three 
schemes using methods proposed by Langholz & Borgan (108). The influence of the 
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exposure definition on the relative scale was assessed by comparing incident rate ratios 
(IRRs) for the three schemes. The IRRs were estimated by odds ratios calculated from 
conditional logistic regression (CLR) models. Results from both crude and adjusted models 
were presented for the three schemes. Additionally, crude and adjusted estimates for the 
association between the duration of TNF-I use and incident CVD events were also estimated 
from CLR. All analyses were conducted using SAS version 9.2 (SAS institute, Cary, NC). 
Sensitivity analyses: 
Multiple sensitivity analyses were conducted to evaluate the robustness of the findings. 
First, we varied the definition of current use to 3 months and 12 months from the 6 months 
definition used in the original analysis. Second, we repeated the entire analysis in a subgroup 
of the patients who were not exposed to any non-biologic DMARDs in the pre-index period. 
Next, for the duration of treatments we considered the cumulative use only in those patients 
who used TNF-I continuously, without interruption in the treatment for more than three 
months. Finally, we created separate categories for the use of TNF-I as monotherapy or 
combination therapy with non-biologic DMARDs.  
5.4 Results: 
The base-cohort consisted of 15,951 patients who were incident RA cases, had no 
history of biologic use, were eligible to receive biologics in the future and were at risk for an 
incident CVD event. Figure 5.2 shows the sample derivation flow chart along with the 
exclusion criteria. Of the 15,951 patients of the base cohort, 466 cases of an incident CVD 
event were identified during follow-up. These cases were age, sex, and cohort entry month-
matched with 5,592 controls (12 cases per control) using incidence density sampling. Table 
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5.1 compares the case and control patients’ baseline characteristics. CVD cases and their 
matched controls were 61 years old at the index date and 79% of the cases and controls were 
females. The mean follow-up time was 246 days for the cases and controls. Cases had higher 
prevalence of CVD risk factors (hyperlipidemia, hypertension and diabetes mellitus), other 
comorbid conditions (COPD and cancer) and used CV medications more often in the pre-
index period compared to controls.  
Table 5.2 shows patient disposition into categorical exposure groups based on the 
exposure definition scheme used. Scheme 1, which considered a binary exposure definition, 
classified 586 patients into ‘ever use of TNF-I’ and 5,427 patients into ‘never use of TNF-I’ 
category. Scheme 2, which considered current use of TNF-Is and other DMARDs, 
reclassified patients from the ‘never use of TNF-I’ category of scheme 1 into three separate 
categories (current use of non-biologic DMARDs (n=4,181), current use of other biologics 
(n=71), or no current DMARD use (n=1,249) ) based on their current use of other DMARDs. 
Scheme 3, that considered current use as well as past use of all the DMARDs, reclassified 
patients from the ‘no current DMARD use’ category of scheme 2 into 4 separate categories 
(past use of TNF-I (n=29), past use of non-biologic DMARDs (n=351), past use of other 
biologics (n=15), and no use of any DMARD (n=854) based on patients’ history of DMARD 
use.  
Table 5.3 shows the estimates for absolute risk of an incident CVD event by exposure 
classification schemes. Finer exposure definitions (schemes 2 & 3) that classified users based 
on the use and timing of each class of DMARD use led to a decrease in exposure 
misclassification and hence more accurate absolute risk estimates compared to the broad 
exposure definition (scheme 1) that lumped the users of all the non-TNF-I biologics and non-
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DMARD users into a single category (never use of TNF-I). The estimates for the category of 
TNF-I use were found to be similar across all the 3 definitions.  
Table 5.3 shows results from our multivariate analysis.. In scheme 1, we observed no 
statistically significant difference in the risk of incident CVD event between ‘ever use of 
TNF-I’ and ‘never use of TNF-I’ (IRR 0.86, 95% CI 0.60-1.21). Similarly, in scheme 2, the 
risk of an incident CVD event after ‘current use of TNF-I’ was found to be no different than 
‘no current DMARD use’ (IRR 0.74 95% CI 0.49-1.10). However, compared to ‘no current 
DMARD use’, ‘current use of a non-biologic DMARD’ was found to be associated with a 
decreased risk (IRR 0.76 95% CI 0.59-0.97) and ‘current use of other biologics’ was found to 
be associated with an increased risk (IRR 2.22 95% CI 1.14-4.33) of an incident CVD event. 
In scheme 3, ‘current use of TNF-I’ and ‘current use of non-biologic DMARDs’ were found 
to be associated with a reduced risk of an incident CVD events compared to ‘no DMARD 
use’ (IRR 0.62 95% CI 0.40-0.98 & IRR 0.66 95% CI 0.48-0.89 respectively). No other drug 
groups were found to have a significantly different risk of an incident CVD event compared 
to ‘no DMARD use’.  
We also observed significant association between duration of treatment and incident 
CVD events (Table 5.4). Each additional month of TNF-I use was found to reduce the risk of 
an incident CVD event by 5% (IRR 0.95, 95% CI 0.90-1.00, p=0.048). Each additional 
month of non-biologic DMARD use was found to reduce the risk by 3% (IRR 0.97 95% CI 
0.94-1.00, p=0.041). The cumulative use of other biologics was not found to be significantly 
associated with CVD events. The quadratic terms for all the treatments were not statistically 
significant (p>0.05), indicating that the duration of use was associated with the risk of 
incident CVD events in a linear fashion.  
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Estimates from our sensitivity analyses, in which we evaluated the impact of ‘current 
use’ definition, duration of treatment definition, excluding prevalent users of non-biologic 
DMARDs, and type of TNF-I therapy on our original results, were found to be consistent 
with the primary model (Appendix Tables 5.1 and 5.2). While estimates for some exposure 
categories were no longer statistically significant potentially due to loss of power with 
smaller sample size in those categories, the estimates trended in the direction of the original 
results.      
5.5 Discussion: 
In this observational study of incident RA patients, we observed that the risk of 
incident CVD event was significantly reduced by current treatment with TNF-Is and non-
biologic DMARDs compared to no treatment with any DMARD. Further, we observed that 
this protective effect was found to be associated with the duration of TNF-I and non-biologic 
DMARD use in a linear manner.  
This is the largest study to our knowledge evaluating the association between TNF-I 
use and risk of incident CVD event in patients newly diagnosed with RA. Our findings 
suggest that beginning treatment with TNF-Is or non-biologic DMARDs early in the course 
of RA may represent a potential strategy to reduce the risk of an incident CVD event. Our 
findings are supported by results from several previous studies conducted in a similar 
population (new RA patients) (10, 11, 51). Georgiadis et al. (10) demonstrated that treatment 
with methotrexate in early RA patients resulted in a statistically significant increase in the 
levels of high density lipoprotein-C (HDL-C or ‘good cholesterol’), which is a marker of 
improvement in atherogenic profile. Another study showed a significant decrease in the 
common carotid artery intima-media thickness, which is an early indicator for 
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atherosclerosis, after treatment with methotrexate in early RA patients (11). Hochberg et al. 
(51) reported a statistically significant risk reduction in the risk of a composite CVD endpoint 
after treatment with methotrexate, but not with biologics in incident RA patients. Our study 
differs from theirs in that we separated the biologics into TNF-Is and other biologics while 
evaluating their association with CVD, which they did not. However, Ljung et al.  (61) did 
not observe any statistically significant risk reduction in acute coronary syndrome (ACS) 
after TNF-I treatment in early RA patients. One reason for the difference between our results 
and results from Ljung et al. may be the lack of power in their study due to smaller sample 
size (198 ACS events). 
Our findings also highlight the importance of a precise and time specific definition of 
exposure. As observed in our exposure definition schemes 1 (Ever/Never TNF-I use) & 2 
(Current use indicators for TNF-Is and other RA treatments), broad definitions lead to non-
differential misclassification of exposure and result in a reference group consisting of a 
heterogeneous mix of patients (Table 5.2). When relying on relative measures of 
associations, such misclassification may lead to masking of important differences in 
treatment-outcome associations (Table 5.3). In our case, scheme 1 lumped the users of all 
non-TNF DMARDs along with non-users of DMARDs into the reference category ‘Never 
use of TNF-Is’. In scheme 2, users of other DMARDs were separated but past users of these 
DMARDs got classified into the reference category ‘No current DMARD use’. This 
misclassification may lead to an inappropriate conclusion that TNF-I use has no impact on 
incident CVD events. In reality, as reflected in scheme 3, the appropriate inference would be 
that compared to ‘No DMARD use’, current use of TNF-Is may have a potential protective 
effect against incident CVD events in patients newly diagnosed with RA. However, since 
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non-biologic DMARDs also have a similar protective effect and schemes 1 and 2 fail to 
account for the treatment history with these agents, this important finding is masked in these 
two definition schemes. Although several authors have highlighted this problem in the past 
using examples of different drug classes,(65, 126) unfortunately this remains a largely 
ignored issue in pharmacoepidemiology studies. 
Our study has some important limitations. As with any other study using administrative 
claims, we were not able to validate the diagnoses of the disease condition (RA) as well as 
the outcome. However, to address this limitation we used algorithms that have been validated 
for their use in identifying these conditions in electronic databases (97, 127, 128)  Further, 
the administrative claims contain very limited information on clinical status of RA patients, 
such as disease activity and swollen joint count. Therefore, we were not able to capture and 
control for the exact severity of RA in our cohort of patients. However, our sampling 
technique matched cases and controls on the duration of RA, which is used as an 
approximation for severity of RA. Additionally, since the claims data do not have reliable 
information on patient vital status, our study is limited by the competing risk of death. 
Certain exposure categories in our scheme 3 had small numbers of patients, which may lead 
to limited power to detect differences between the groups. Finally, our database did not 
contain information on important variables such as tobacco use, which is a risk factor for 
both RA and CVD. We were also not able to capture the over-the-counter use of certain pain 
relievers, which are commonly used by RA patients. Therefore, there may be some residual 
confounding in our exposure-outcome association even after multivariate risk adjustment. 
We postulate that the widespread problem of channeling bias affecting observational studies 
may explain the higher trend for increased CVD risk in users of other biologics because 
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patients with a higher baseline cardiovascular risk may be preferentially treated with non 
TNF-α inhibitor biologic agents. We caution the readers to interpret our findings in light of 
these limitations.     
5.6 Conclusion: 
We observed that treatment with TNF-Is and non-biologic DMARDs may help in 
reducing the risk of incident CVD events in patients newly diagnosed with RA compared to 
no treatment with DMARDs. Early treatment with a non-biologic DMARD or a TNF-I agent 
may represent a beneficial strategy for clinicians trying to manage the increased CVD risk in 
RA. Accurate measurement of exposure is important while evaluating treatment outcome 
association in RA to avoid inappropriate conclusions owing to non-differential 
misclassification of the exposure.  
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Figure 5.1: Timeline of the study 
 
 
 
 
 
 
 
 
 
 
  
Dec 31, 2010 
Total study period: 1 Jan, 2007 to 31 Dec, 2010 
Subject identification period: 1 Jan, 2008 to 31 Dec, 2010 
Jan 1, 2007 
Incident RA 
diagnosis 
 
Event Date for Cases: Controls 
selected at this point 
Exposure measurement 
period 
12 months Baseline 
period (continuous 
enrollment) 
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Figure 5.2: Sample derivation flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Incident CVD cases 
n=466 
 
Disease identification: RA diagnosis (ICD-9 code 714.0) recorded on 
1 inpatient or 2 outpatient claims + at least 1 DMARD prescription in 
drug claims or outpatient services claims between 1 Jan, 2008 to 31 
Dec, 2010 
n=168,594 
 
 Not continuously enrolled in the baseline period 
or complete drug data not available 
Excluded n= 87,398 
Diagnosed with comorbid conditions in which 
biologics are indicated (Chrohn’s disease or 
psoriatic arthritis)               
Excluded n=4,454 
Contraindication to biologics use (Tuberculosis)  
Excluded n=189 
Used a biologic agent in pre-index period 
Excluded n=23,213 
Not at risk for outcome (ie diagnosed with a 
CVD event prior to the index date)  
Excluded n=7,955 
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Excluded n=29,434 
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Table 5.1: Baseline comparison of cases of incident cardiovascular diseases and controls 
sampled from a cohort of incident RA patients 
Variable Cases
†
 (n=466) Controls (n=5,592) 
n % n % 
Matching variables     
Patient age (Mean±SD) 61.21 ± 10.49 61.13 ± 10.46 
Mean duration of RA, days (Mean±SD) 249.61 ± 211.23 249.61 ± 211.02 
Female gender 368 78.97 4416 78.97 
Cardiovascular risk factors     
Diabetes Mellitus 125 26.82 794 14.20 
Hyperlipidemia 163 34.98 1674 29.94 
Hypertension 264 56.65 2254 40.31 
Other comorbid conditions     
Chronic obstructive pulmonary disease (COPD) 103 22.1 790 14.13 
Cancer 36 7.73 340 6.08 
RA medications in the pre-index period     
Coxib 51 10.94 590 10.55 
NSAIDs 214 45.92 2507 44.83 
Steroids 302 64.81 3128 55.94 
Non-biologic DMARDs
‡
 204 43.78 2246 40.16 
CV medications in the pre-index period     
ACE-Inhibitors 112 24.03 1047 18.72 
Beta-blockers 144 30.9 1080 19.31 
Lipid lowering agents 216 46.35 1797 32.14 
 110 
 
 
† 466 cases included 23 patients with acute myocardial infarction (ICD-9 code 410), 16 patients with unstable angina (ICD-
9 code 411), 43 patients with angina pectoris (ICD-9 code 413), 98 patients with chronic heart failure (ICD-9 codes 428.xx, 
398.91, 402.01, 402.11, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93), 156 patients with other forms of chronic heart 
diseases (ICD-9 code 414), 98 patients with cerebrovascular accident (ischemic stroke, ICD-9 codes 433.x1, 434 [excluding 
434.x0], or 436, and transient ischemic stroke, ICD-9 code 435), and 32 patients with multiple diagnoses from this list.  
‡ Non-biologic DMARDs include methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, sulfasalazine, 
azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine  
*Other CV drugs include cardiac glycosides, antiarrhythmic agents, hypotensive agents, vasodilating agents and 
phosphodiesterase inhibitors  
Calcium channel blockers 121 25.97 892 15.95 
Other CV drugs* 150 32.19 1166 20.85 
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Table 5.2: Patient disposition into categorical exposure groups based on the exposure 
definition scheme used  
 
†Total number of patients in the cohort=6,058 
‡TNF-inhibitors include infliximab, etanercept, adalimumab, certolizumab and golimumab. Non-biologic DMARDs include 
methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, sulfasalazine, azathioprine, leflunamide, 
minocycline, cyclophosphamide and cyclosporine. Other biologic agents include abatacept, anakinara, rituximab and 
tocilizumab.
Exposure 
definition 
Scheme 
Number of patients classified in exposure categories
†
 
Scheme 1 
Ever use 
of TNF-I
‡
 
 
Never use of TNF-I  
N=586 N=5,427 
Scheme 2 
Current 
use of 
TNF-I
‡
 
Current use 
of non-
biologic 
DMARDs
‡
 
Current use 
of other 
biologics
‡
 
No current DMARD use 
N=557 N=4,181 N=71 N=1,249 
Scheme 3 
Current 
use of 
TNF-I
‡
 
Current use 
of non-
biologic 
DMARDs
‡
 
Current use 
of other 
biologics
‡
 
Past use 
of TNF-
I 
Past use 
of non-
biologic 
DMARDs 
Past use of 
other 
biologics 
No use 
of any 
DMARD 
N=557 N=4,181 N=71 N=29 N=351 N=15 N=854 
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Table 5.3: Absolute CVD risk & relative measures of association of an incident CVD event by exposure status 
Exposure
†
 n 
(cases) 
n 
(controls) 
Absolute CVD risk 
estimates for 3 year 
period 
(95% CI) 
 
Unadjusted 
IRR (95% CI) 
Adjusted
‡
 IRR  
(95% CI) 
Scheme 1      
TNF-use never 426 5046 0.012 (0.011-0.014) Ref. Ref. 
TNF-use ever 40 546 0.010 (0.0071-0.014) 0.86 (0.61-1.22) 0.86 (0.60-1.21) 
Scheme 2      
No current DMARD 111 1138 0.014 (0.011-0.017) Ref. Ref. 
Current TNF-I 39 518 0.011 (0.0072-0.014) 0.75 (0.51-1.11) 0.74 (0.49-1.10) 
Current non-biologic DMARD 302 3879 0.011 (0.0095-0.013) 0.78 (0.61-0.99) 0.76 (0.59-0.97) 
Current other biologic 14 57 0.033 (0.014-0.051) 2.48 (1.33-4.65) 2.22 (1.14-4.33) 
      
Scheme 3      
No DMARD use 79 775 0.015 (0.011-0.020) Ref. Ref. 
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Current TNF-I 39 518 0.011 (0.0072-0.014) 0.68 (0.44-1.05) 0.62 (0.4-0.98) 
Current non-biologic DMARD 302 3879 0.011 (0.0096-0.013) 0.71 (0.53-0.96) 0.66 (0.48-0.89) 
Current other biologic 14 57 0.034 (0.015-0.052) 2.28 (1.19-4.39) 1.93 (0.96-3.87) 
Past TNF-I 1 28 0.0051 (0-0.015) 0.32 (0.04-2.43) 0.24 (0.03-1.85) 
Past non-biologic DMARD 28 323 0.012 (0.0074-0.017) 0.78 (0.47-1.28) 0.68 (0.4-1.13) 
Past other biologic 3 12 0.035 (0-0.076) 2.31 (0.63-8.44) 2.32 (0.61-8.84) 
 
† TNF-inhibitors include infliximab, etanercept, adalimumab, certolizumab and golimumab. Non-biologic DMARDs include methotrexate, hydroxychloroquin, auranofin, 
injectable gold, penicillamine, sulfasalazine, azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine. Other biologic agents include abatacept, anakinara, 
rituximab and tocilizumab. 
‡Adjusted for pre-index NSAID use, steroid use, non-biologic DMARD use, cardiovascular medication use, Diabetes, Hypertension, Hyperlipidemia, chronic obstructive 
pulmonary disease and cancer in addition to matching with age, gender, duration of RA and cohort entry month and year. Unadjusted associations are estimated in age, 
gender, duration of RA and cohort entry month and year matched sample  
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Table 5.4: Association between duration of RA treatments and incident CVD event 
Exposure
†
 Adjusted
‡
 IRR  
(95% CI) 
p-values 
Each additional month of cumulative TNF-I use 0.95 (0.90-1.00) 0.048 
Each additional month of cumulative non-biologic 
DMARD use 
0.97 (0.94-1.00) 0.041 
Each additional month of cumulative other biologics 
use 
1.06 (0.99-1.13) 0.12 
 
†TNF-inhibitors include infliximab, etanercept, adalimumab, certolizumab and golimumab. non-biologic DMARDs include 
methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, sulfasalazine, azathioprine, leflunamide, 
minocycline, cyclophosphamide and cyclosporine, & Other biologic agents include abatacept, anakinara, rituximab and 
tocilizumab 
‡Adjusted for pre-index NSAID use, steroid use, non-biologic DMARD use, cardiovascular medication use, Diabetes, 
Hypertension, Hyperlipidemia, chronic obstructive pulmonary disease and cancer in addition to matching with age, gender, 
duration of RA and cohort entry month and year. Unadjusted associations are estimated in age, gender, duration of RA and 
cohort entry month and year matched sample  
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Appendix Table 5.1: Sensitivity analyses set 1 
Exposure
†
 Original results 
Adjusted
‡
 IRR (95% CI) 
Sensitivity 
analysis 1* 
Adjusted
‡
 IRR  
(95% CI) 
Sensitivity 
analysis 2** 
Adjusted
‡
 IRR 
(95% CI) 
Sensitivity 
analysis 3
§
 
Adjusted
‡
 IRR 
(95% CI) 
Sensitivity 
analysis 4
¶ 
Adjusted
‡
 IRR 
(95% CI) 
Scheme 1      
TNF-I use never 
TNF-I use ever 
1.0 
0.86 (0.60-1.21) 
- - 1.0 
0.80 (0.50-1.26) 
- 
Scheme 2      
No current DMARD 
Current TNF-I 
Current nbDMARD 
Current other biologic 
1.0 
0.74 (0.49-1.1) 
0.76 (0.59-0.97) 
2.22 (1.14-4.33) 
1.0 
0.65 (0.43-0.97)  
0.70 (0.56-0.87) 
2.23 (1.08-4.59) 
1.0 
0.66 (0.43-1.01) 
0.69 (0.52-0.92) 
2.14 (1.14- 4.02) 
1.0 
0.69 (0.41-1.17) 
0.74 (0.53-1.02) 
1.86 (0.79-4.37) 
- 
Scheme 3      
No DMARD use ever 
Current TNF-I 
Current nbDMARD 
1.0 
0.62 (0.40-0.98) 
0.66 (0.48-0.89) 
1.0 
0.61 (0.38-0.98) 
0.67 (0.49-0.90) 
1.0 
0.62 (0.39-0.98) 
0.66 (0.49-0.90) 
1.0 
0.57 (0.31-1.03) 
0.62 (0.42-0.93) 
- 
  
 
1
1
6
 
 
† TNF-inhibitors include infliximab, etanercept, adalimumab, certolizumab and golimumab. Non-biologic (nb) DMARDs include methotrexate, hydroxychloroquin, 
auranofin, injectable gold, penicillamine, sulfasalazine, azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine. Other biologic agents include abatacept, 
anakinara, rituximab and tocilizumab. 
‡Adjusted for pre-index NSAID use, steroid use, non-biologic DMARD use, cardiovascular medication use, Diabetes, Hypertension, Hyperlipidemia, chronic obstructive 
pulmonary disease and cancer in addition to matching with age, gender, duration of RA and cohort entry month and year. Unadjusted associations are estimated in age, 
gender, duration of RA and cohort entry month and year matched sample  
*Sensitivity analysis 1: Current use defined as any use in past 3 months 
** Sensitivity analysis 2: Current use defined as any use in past 12 months 
§ Sensitivity analysis 3: Excluded all the patients who used a non-biologic DMARD in the pre-index period 
¶ Sensitivity analysis 4: Cumulative use considered only in patients who use biologic agents without any interruption of >3 months since starting the therapy
Current other biologic 
Past TNF-I 
Past nbDMARD 
Past other biologic 
1.93 (0.96-3.87) 
0.24 (0.03-1.85) 
0.68 (0.40-1.13) 
2.32 (0.61-8.84) 
2.14 (1.01-4.54) 
0.78 (0.33-1.83) 
0.88 (0.58-1.32) 
3.08 (1.11-8.56) 
2.04 (1.07-3.87) 
0.81 (0.09-6.83) 
0.68 (0.31-1.52) 
3.06 (0.32-29.46) 
1.56 (0.64-3.81) 
0.27 (0.0-2.25) 
0.67 (0.35-1.26) 
2.50 (0.44-14.09) 
Duration of TNF-I use      
Each additional month of 
TNF-I use 
0.95 (0.9-1.00) - -  0.96 (0.91-1.01) 
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Appendix Table 5.2: Sensitivity analysis set 2, TNF-I monotherapy and combination 
therapy considered separately 
 
† TNF-inhibitors include infliximab, etanercept, adalimumab, certolizumab and golimumab. Non-biologic DMARDs 
include methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, sulfasalazine, azathioprine, leflunamide, 
minocycline, cyclophosphamide and cyclosporine. Other biologic agents include abatacept, anakinara, rituximab and 
tocilizumab. 
‡Adjusted for pre-index NSAID use, steroid use, non-biologic DMARD use, cardiovascular medication use, Diabetes, 
Hypertension, Hyperlipidemia, chronic obstructive pulmonary disease and cancer in addition to matching with age, gender, 
Exposure
†
 Adjusted
‡
 IRR (95% CI) 
Definition 1  
TNF-I use never 
TNF-I use ever 
- 
Definition 2  
No current DMARD 
Current TNF-I Monotherapy 
Current TNF-I combination therapy* 
Current non-biologic DMARD 
Current other biologic 
1.0 
0.88 (0.47-1.63) 
0.68 (0.43-1.09) 
0.76 (0.59-0.97) 
2.23 (1.14-4.34) 
 
Definition 3  
No DMARD use ever 
Current TNF-I monotherapy 
Current TNF-I combination therapy 
Current non-biologic DMARD 
Current other biologic 
Past TNF-I monotherapy** 
Past TNF-I combination therapy 
Past non-biologic DMARD 
Past other biologic 
1.0 
0.76 (0.40-1.45) 
0.57 (0.34-0.95) 
0.65 (0.48-0.89) 
1.93 (0.97-3.88) 
- 
0.41 (0.05-3.27) 
0.67 (0.40-1.13) 
2.35 (0.62-8.96) 
 
Duration of TNF-I treatment  
Each additional month of TNF-I monotherapy 
Each additional month of TNF-I combination 
0.91 (0.80-1.04) 
0.96 (0.90-1.01) 
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duration of RA and cohort entry month and year. Unadjusted associations are estimated in age, gender, duration of RA and 
cohort entry month and year matched sample  
* Patients who begin TNF-inhibitor therapy within 30 days of beginning any non-biologic DMARD therapy or whose 
prescription at hand for these two classes overlap for more than 30 days were defined as using TNF-inhibitor combination 
therapy. 
**Unable to provide estimates because none of the cases were classified as ‘Past TNF-I monotherapy’ users. 
 CHAPTER 6 
6 ASSESSMENT OF INDEPENDENT EFFECT OF INFLIXIMAB, ETANERCEPT 
AND ADALIMUMAB ON THE RISK OF INCIDENT CARDIOVASCULAR 
EVENTS IN PATIENTS NEWLY DIAGNOSED WITH RHEUMATOID 
ARTHRITIS 
This chapter presents the last of three manuscripts prepared from this dissertation. In 
this manuscript, we evaluated the association between individual TNF-alpha inhibitor 
treatments, infliximab, adalimumab and etanercpet, and the risk of incident cardiovascular 
events in patients newly diagnosed with rheumatoid arthritis using health insurance claims 
from Marketscan databases during the period of 2007 to 2010. 
6.1 Overview: 
Objective: No study in the past has evaluated the independent effects of individual TNF-α 
inhibitors (TNF-Is), etanercept, adalimumab and infliximab, and the risk of CVD events in 
patients newly diagnosed with RA. The objective of our study was to provide estimates of 
this association.  
Methods: A nested case-control study was designed using data for patients newly diagnosed 
with RA between Jan 1, 2008 and Dec 31, 2010 identified from the Marketscan claims 
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database. These patients were followed up for the outcome of a composite cardiovascular 
disease (CVD) event. Patients who experienced the outcome were defined as cases on their 
event date and 12 age-, sex-, and cohort entry month-matched controls were selected on the 
same date. Following mutually exclusive exposure categories were created based on at least 
one filled prescription of these agents during the study period: 1) Infliximab, 2) Etanercept, 
3) Adalimumab, 4) Newer TNF-Is (golimumab and certolizumab) 5) Non-biologic 
DMARDs, 6) Other biologic agents and 7) No use of DMARD during the study period. 
Conditional logistic regression (CLR) models were used to derive estimates for incidence 
rate ratios (IRR).  
Results: Of the 15,951 patients of the base cohort, 466 cases of an incident CVD event were 
identified during follow-up, who were matched with 5,592 controls (12 cases per control) 
using incidence density sampling. In our multivariate CLR models, treatment with 
adalimumab (adjusted IRR 0.40, 95% CI 0.18-0.87) and non-biologic DMARDs (adjusted 
IRR 0.66, 95% CI 0.48-0.89) was found to be associated with a reduced risk of incident CVD 
events compared to no treatment with DMARDs. No differences were found between 
individual TNF-Is.  
Conclusion: Treatment with adalimumab and non-biologic DMARDs may help in reducing 
the risk of incident CVD events in patients newly diagnosed with RA compared to no 
treatment with DMARDs
6.2 Introduction: 
The association between rheumatoid arthritis (RA) and cardiovascular diseases (CVD) 
has been the recent focus of research because of the increasing recognition of atherosclerosis 
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as an inflammatory condition (7, 23, 24). The chronic systematic inflammatory process in 
RA may initiate or accelerate atherosclerosis (129). Several epidemiological studies have 
provided data that indicate an increased burden of CVD in RA patients compared to the 
general population (4, 5, 41). The disease modifying antirheumatic drugs (DMARDs) control 
inflammation in RA and therefore may help in reducing CV burden. Because of the role 
tumor necrosis factor (TNF)- α plays in the cascade of atherosclerotic events (25), TNF- α 
inhibitors (TNF-Is) are of special interest as the agents most likely to reduce CVD events in 
RA patients.  
TNF- Is are a heterogeneous class of drugs. First TNF-I agent, infliximab, was 
approved for treating adults with RA in 1998; 4 additional agents have been approved since 
that time: etanercept (1998), adalimumab (2002), certolizumab pegol (2008), and golimumab 
(2009).These agents differ from each other in terms of their molecular structure, route of 
administration and pharmacokinetic parameters (20, 66). No randomized controlled trials 
(RCTs) have compared these agents head-to-head for their efficacy in RA. However, recent 
evidence from a mixed treatment comparison using data from RCTs suggests differences 
between these agents on efficacy endpoints in RA patients (130). The odds of achieving 
ACR50 response (American College of Rheumatology response criteria for 50% 
improvement in joint function) were found to be higher with etanercept compared to both 
infliximab and adalimumab (etanercept vs infliximab OR: 4.17, 95% Credible Interval (CrI) 
2.00-11.17, etanercept vs adalimumab OR: 3.50, 95% CrI 1.37-7.63) (130). Individual TNF-
Is also differ with respect to their effectiveness in treating other rheumatologic diseases. 
Unlike adalimumab and infliximab, etanercept lacks efficacy in treating other auto-immune 
diseases, such as Crohn's disease, Wegener's granulomatosis and sarcoidosis (69, 70).  
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Differences in the safety profiles of individual TNF-Is have also been reported. 
Infliximab, but not etanercept, is found to be associated with an increased risk of infections 
such as mycobacterium tuberculosis and histoplamosis (71). Evidence from indirect 
comparisons using withdrawals due to adverse events reported in randomized controlled 
trials as an outcome suggest that etanercept has a more favorable tolerability profile 
compared to infliximab and adalimumab in RA patients (etanercept versus infliximab 
OR:0.30, 95% CrI 0.16-0.62, etanercept versus adalimumab OR: 0.50, 95% CrI 0.25-0.91) 
(72).  
Several observational studies have evaluated the association between CVD and TNF-Is 
in RA patients (49, 52, 53, 55-60), but no study has evaluated independent effects of 
individual TNF-I agents. Because these agents differ with respect to their pharmacological 
properties, effectiveness profiles in various rheumatologic diseases and tolerability, we 
believe that it is not appropriate to assume a class effect in terms of these agents’ effect on 
the risk of CVD events in RA patients. Therefore, we designed this study to examine the 
effects of non-biologic and biologic DMARDs on the risk of CVD with a special focus on 
individual TNF-Is, infliximab, adalimumab and etanercept, in patients newly diagnosed with 
RA. 
6.3 Methods: 
Data source:  
Data from the Truven’s MarketScan Commercial Claims And Encounters (CCAE) 
and Medicare Supplemental and Coordination of Benefits (COB) was used for this study. 
This database contains de-identified, person-specific health data including clinical utilization, 
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expenditures, insurance enrollment/plan benefit, inpatient, outpatient, and outpatient 
prescription information. The CCAE contains healthcare data for nearly 40 million 
individuals, encompassing employees, their spouses, and their dependents. The COB data 
contains the health care experiences of 3.8 million Medicare-eligible retirees with employer-
sponsored Medicare Supplemental plans. These data have been used widely in health 
services research due to its substantial size, longitudinal integrity, and unique data links (12). 
For this particular analysis, data from inpatient services file, outpatient services file, 
outpatient drug claims file and enrollment file were merged using unique patient identifiers.  
Study design and patient population: 
The nested case-control study design was selected to evaluate the association between 
individual TNF-inhibitors and CVD because of its ability to efficiently deal with the time 
varying nature of drug exposure. This study design has been used commonly to evaluate 
treatment-outcome associations in RA patients (49, 52, 56, 124). From the Marketscan data 
files, a base cohort of RA patients 18 years and older who had at least 2 outpatient or 1 
inpatient diagnosis of RA (ICD-9 code: 714.0) and at least one prescription record for a 
DMARD between Jan 1, 2008 and Dec 31, 2010 was identified (97). The earliest of these 
diagnoses was defined as the index diagnosis and the 12 month period pre-index was defined 
as the baseline period (Figure 6.1). To be considered for our case-control sampling, patients 
in the base cohort had to meet the following inclusion criteria: 1) continuous enrollment in 
their health plans during the 12 month baseline period, 2) no diagnosis of RA in the baseline 
period, 3) no use of biologic agents in the baseline period, 4) no history of tuberculosis 
(which is a contraindication to biologics use), psoriatic arthritis or Crohn’s disease (comorbid 
conditions in which some of the biologics are indicated) during the baseline period, and 5) 
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not diagnosed with the outcome of interest in the baseline period. Thus our patient population 
consisted of incident RA patients who had no history of biologic use, who were eligible to 
receive biologics in the future and who were at risk for an incident CVD event.  
Nested case-control sampling: 
All the patients identified as eligible for sampling from the base cohort were 
followed-up from their index date to the earliest of the following: the outcome (CVD 
diagnosis), disenrollment from their health plan, switch between biologic treatments or study 
end date (Dec 31, 2010). If patients experienced a CVD event, they were defined as cases 
and the date of CVD diagnosis was defined as the event date. Once the cases were identified, 
12 age, sex and cohort entry month-matched controls were sampled from the remaining 
patients of the base cohort at the event date who were free from CVD at that time (Incidence 
density sampling) (Figure 6.1). Based on our power calculations, selecting more than 12 
controls per case provided no benefit in statistical power. Therefore, we selected 12 controls 
per case. Since the follow-up began on the first ever RA diagnosis date for these patients, our 
sampling also ensured the matching of cases and controls on the duration of RA.  
Measures: 
1. Exposure measurement: 
To comprehensively categorize antirheumatic drug use, we considered exposure to 
both non-biologic and biologic DMARDs. Because of our special interest in 
individual TNF-I agents, biologic DMARDs were classified in the following 
categories: infliximab, etanercept, adalimumab, and newer TNF-Is (golimumab and 
certolizumab) or other biologic agents. As a result, the following mutually exclusive 
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categories were created based on at least one filled prescription of these agents during 
the study period: 1) Infliximab, 2) Etanercept, 3) Adalimumab, 4) Newer TNF-Is 
(golimumab and certolizumab) 5) Non-biologic DMARDs (including methotrexate, 
hydroxychloroquine, auranofin, injectable gold, penicillamine, sulfasalazine, 
minocycline, azathioprine, leflunamide, cyclophosphamide and cyclosporine), 6) 
Other biologic agents (Abatacept, anakinara, rituximab and tocilizumab) and 7) No 
use of DMARD during the study period. The use of these agents was identified using 
both the NDC codes from outpatient pharmacy files for filled prescriptions and J 
codes using outpatient services files for injectable agents administered at physician’s 
office. 
Additionally, duration of treatment with these agents was defined as a continuous 
variable representing the cumulative days of use for the patients who filled at least 
one prescription in the study period. Significance of a quadratic term was tested for 
the continuous variables representing cumulative use for each treatment to check for 
any evidence of non-linearity in the association between the duration and the risk of 
an incident CVD event. 
2. Outcome: 
The outcome of interest was defined as a composite measure consisting of acute 
myocardial infarction (ICD-9 code 410), unstable angina (ICD-9 code 411), angina 
pectoris (ICD-9 code 413), chronic heart failure (ICD-9 codes 428.xx, 398.91, 
402.01, 402.11, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93), other forms of 
chronic heart diseases (ICD-9 code 414), ischemic stroke (ICD-9 code s 433.x1, 434 
[excluding 434.x0], or 436); and transient ischemic stroke (ICD-9 code 435). A 
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patient was defined as a case if he/she experienced any one of these events during the 
follow-up period.  
3. Covariates: 
We identified the following covariates during the baseline period: CVD risk factors 
including hypertension, hyperlipidemia, and diabetes mellitus; CVD drug use 
including lipid lowering agents, beta-blockers, angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, and other CVD drugs; RA drug use 
including steroids, non-steroidal anti-inflammatory drugs and non-biologic 
DMARDs; and other comorbidities including chronic obstructive pulmonary disease 
and cancer.  
Statistical analyses: 
Descriptive statistics were used to summarize the patient characteristics for our cases 
and controls. Categorical variables were presented as numbers and percentages and 
continuous variables were presented as means (±standard deviations). To account for the 
matched sampling, we used conditional logistic regression (CLR) models for the estimations 
of incident rate ratios (IRRs). Results from both unadjusted and adjusted models were 
presented. We used two distinct reference groups for this analysis. Firstly, to estimate the 
effectiveness of various agents, we used all the patients who did not use any DMARD in the 
study period as the reference group. Next, to estimate the comparative effectiveness, we used 
the users of etanercept as the reference group.  
 127 
 
Additionally, crude and adjusted estimates for the association between the duration of 
infliximab, adalimumab and etanercept use and incident CVD events were also estimated 
from CLR. All analyses were conducted using SAS version 9.2 (SAS institute, Cary, NC). 
6.4 Results: 
The base-cohort consisted of 15,951 patients who were incident RA cases, had no 
history of biologic use, were eligible to receive biologics in the future and were at risk for an 
incident CVD event. Figure 6.2 shows the sample derivation flow chart along with the 
exclusion criteria. Of the 15,951 patients of the base cohort, 466 cases of an incident CVD 
event were identified during follow-up. These cases were age, sex, and cohort entry month-
matched with 5,592 controls (12 cases per control) using incidence density sampling. Table 
6.1 compares the case and control patients’ baseline characteristics. CVD cases and their 
matched controls were 61 years old at the index date and 79% of the cases and controls were 
females. The mean follow-up time was 246 days for the cases and controls. Cases had higher 
prevalence of CVD risk factors (hyperlipidemia, hypertension and diabetes mellitus), other 
comorbid conditions (COPD and cancer) and used CV medications more often in the pre-
index period compared to controls.  
A total of 40 cases (8.58%) and 518 controls (9.26%) were exposed to a TNF-α 
inhibitor. Of those, 12 cases and 160 controls were exposed to infliximab, 8 cases and 167 
controls were exposed to adalimumab and 20 cases and 191 controls were exposed to 
etanercept treatment. Because 27 controls but none of the cases were exposed to the newer 
TNF- α inhibitors (golimumab and certolizumab), this drug category was not further 
 128 
 
analyzed. Appendix Tables 6.1 and 6.2 summarize covariate distribution by exposure to 
various DMARDs for our sample.  
Table 6.2 shows the crude and adjusted estimates of the associations between the use of 
various DMARDs and CVD events. Compared to no DMARD use, adalimumab treatment 
significantly reduced the risk of incident CVD event (adjusted IRR 0.40, 95% CI 0.18-0.87). 
Other TNF- α inhibitors, infliximab and etanercept were not found to be significantly 
associated with a similar risk reduction. However, the use of non-biologic DMARDs was 
also found to be associated with a reduced risk of an incident CVD event compared to no 
DMARD use (adjusted IRR 0.66, 95% CI 0.48-0.89). On the other hand, the use of other 
biologic treatment was found to be associated with a significantly increased risk of an 
incident CVD event compared to no DMARD use (adjusted IRR 2.01, 95% CI 1.06-3.82).  
Compared to etanercept, use of adalimumab showed a trend towards a lower 
cardiovascular risk, which was not statistically significant (adjusted IRR 0.45, 95% CI 0.29-
1.06).  Treatment with infliximab and non-biologic DMARDs were found to be no different 
in reducing the risk of CVD events compared to etanercept. Treatment with other biologics 
was found to be associated with a higher risk of CVD events compared to etanercept 
(adjusted IRR 2.27 95% CI 1.08-4.76).  
When exposure to DMARDs was defined as cumulative exposure duration in number 
of days, use of each additional month of adalimumab therapy was found to significantly 
reduce the risk of an incident CVD event by 15% (adjusted IRR 0.85 95% CI 0.73-1.00, 
p=0.048). Cumulative use of none of the other treatments was found to be associated with a 
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reduction in incidence of CVD events. Table 6.3 summarizes the association between 
duration of DMARD treatments and the risk of incident CVD events.  
6.5 Discussion: 
In this observational study of incident RA patients, treatment with adalimumab and 
non-biologic DMARDs was found to be associated with a reduced risk of incident CVD 
events compared to no treatment with DMARDs. We also observed that each additional 
month of treatment with adalimumab resulted in 15% reduction in the risk of an incident 
CVD event. Comparing adalimumab and infliximab head to head with etanercept, we did not 
observe any statistically significant differences between these agents.  
Given the cost and clinical consequences of high CVD burden in RA patients, proper 
CV risk management is extremely important. This is the first study to our knowledge that 
estimates the independent effects of individual TNF-α inhibitors on the risk of incident CVD 
events using clinical endpoints. Several previous studies have evaluated the impact of these 
agents on subclinical endpoints. For instance, other studies estimated the associations 
between use of TNF-α inhibitors with endpoints such as carotid intima media thickness 
(cIMT), flow mediated dilation (FMD) and pulse wave velocity (PWV) (131, 132). A recent 
review summarizing these studies concluded that treatment with adalimumab, infliximab and 
etanercept generally results in improvement in vasodilating functions, endothelial functions 
and arterial stiffness (131). However, no study examined if these agents differed with respect 
to their effects on the aforementioned subclinical endpoints. Some studies have also 
evaluated the effects of these agents on atherogenic index, which is a strong predictor of CV 
events, in RA patients. A review summarizing these studies concluded that treatment with 
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adalimumab and etanercept, but not infliximab, may result in favorable changes in patients’ 
atherogenic index (132). Our study provides further evidence, specifically in favor of 
adalimumab and non-biologic DMARDs, for their potential protective effects on the risk of 
CVD events compared to no DMARD use. For the head to head comparison, we did observe 
a trend favoring adalimumab compared to etanercept but this trend was statistically non-
significant. Because of the limited sample size, our study may be underpowered to detect 
these differences. We call for future studies with more conclusive sample sizes to compare 
differences between these agents for their cardiovascular outcomes.  
The finding that the use of other biologics is associated with an increased risk of 
incident CVD events compared to no DMARD use is puzzling. We postulate that the 
widespread problem of channeling bias affecting observational studies may explain this 
finding because patients with a higher baseline cardiovascular risk may be preferentially 
treated with non TNF-α inhibitor biologic agents. The fact that TNF-α inhibitors are 
contraindicated in New York Heart Association class III and IV CHF patients may deter 
physicians from prescribing these agents in patients with a higher cardiovascular risk profile 
altogether. We were not able to adequately control for this because of the unavailability of 
RA-specific cardiovascular risk factors such as smoking, obesity and RA disease activity in 
our data. Further studies that account for these differences are necessary to understand the 
impact of other biologic treatments on the risk of CVD events.  
There are several other limitations that deserve mention. We were not able to validate 
the diagnoses of the disease condition (RA) as well as the outcome. However, to address this 
limitation we used algorithms for detection of RA and CVD events that were validated 
previously for their sensitivity and specificity (97, 127, 128). Additionally, since the claims 
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data do not have reliable information on patient vital status, our study is limited by the 
competing risk of death. In the definition of exposure, it is assumed that filling of 
prescription equates with the use of medication. This assumption is untestable. Our study had 
very small sample sizes for golimumab and certolizumab owing to their late market entry. 
Future studies that have sufficient data on the use of these agents should be planned to 
evaluate their effects on CVD. We caution the readers to interpret our findings in light of 
these limitations.     
Our study also has several unique strengths. Our sample represents the real world 
experiences of RA patients from the entire country. We conducted the study exclusively in 
incident RA patients and matched our cases and controls on the duration of the disease to 
reduce unmeasured confounding. Finally, we used a study design that is known to account 
for the time varying nature of RA treatments (104).  
6.6 Conclusion: 
Early treatment with adalimumab and non-biologic DMARDs may help in reducing the 
risk of incident CVD events in patients newly diagnosed with RA compared to no DMARD 
use. Our data should serve as hypothesis generating for further studies.    
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Figure 6.1: Timeline of the study  
 
 
 
 
 
 
 
 
 
 
  
Dec 31, 2010 
Total study period: 1 Jan, 2007 to 31 Dec, 2010 
Subject identification period: 1 Jan, 2008 to 31 Dec, 2010 
Jan 1, 2007 
Incident RA 
diagnosis 
 
Event Date for Cases: Controls selected 
at this point 
Exposure measurement 
period 
12 months Baseline 
period (continuous 
enrollment) 
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Figure 6.2: Sample derivation flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Incident CVD cases 
n=466 
 
Disease identification: RA diagnosis (ICD-9 code 714.0) recorded on 
1 inpatient or 2 outpatient claims + at least 1 DMARD prescription in 
drug claims or outpatient services claims between 1 Jan, 2008 to 31 
Dec, 2010 
n=168,594 
 
 Not continuously enrolled in the baseline period 
or complete drug data not available 
Excluded n= 87,398 
Diagnosed with comorbid conditions in which 
biologics are indicated (Chrohn’s disease or 
psoriatic arthritis)               
Excluded n=4,454 
Contraindication to biologics use (Tuberculosis)  
Excluded n=189 
Used a biologic agent in pre-index period 
Excluded n=23,213 
Not at risk for outcome (ie diagnosed with a 
CVD event prior to the index date)  
Excluded n=7,955 
Prevalent RA cases 
Excluded n=29,434 
 
 
Base cohort: Patients eligible for nested case control sampling 
n=15,951 
 
 
Exclusion 
criteria 
Age, sex and cohort 
entry month-matched 
controls 
n=5,592 
 
Incidence density sampling 
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Table 6.1: Baseline comparison of cases of incident cardiovascular diseases and controls 
sampled from a cohort of incident RA patients 
Variable Cases
†
 (n=466) Controls (n=5,592) 
n % n % 
Matching variables     
Patient age (Mean±SD) 61.21 ± 10.49 61.13 ± 10.46 
Mean duration of RA, days (Mean±SD) 249.61 ± 211.23 249.61 ± 211.02 
Female gender 368 78.97 4416 78.97 
Cardiovascular risk factors     
Diabetes Mellitus 125 26.82 794 14.2 
Hyperlipidemia 163 34.98 1674 29.94 
Hypertension 264 56.65 2254 40.31 
Other comorbid conditions     
COPD 103 22.1 790 14.13 
Cancer 36 7.73 340 6.08 
RA medications in the pre-index period     
Coxib 51 10.94 590 10.55 
NSAIDs 214 45.92 2507 44.83 
Steroids 302 64.81 3128 55.94 
Non-biologic DMARDs
‡
 204 43.78 2246 40.16 
CV medications in the pre-index period     
ACE-Inhibitors 112 24.03 1047 18.72 
Beta-blockers 144 30.9 1080 19.31 
Lipid lowering agents 216 46.35 1797 32.14 
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† 466 cases included 23 patients with acute myocardial infarction (ICD-9 code 410), 16 patients with unstable angina (ICD-
9 code 411), 43 patients with angina pectoris (ICD-9 code 413), 98 patients with chronic heart failure (ICD-9 codes 428.xx, 
398.91, 402.01, 402.11, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93), 156 patients with other forms of chronic heart 
diseases (ICD-9 code 414), 98 patients with cerebrovascular accident (ischemic stroke, ICD-9 codes 433.x1, 434 [excluding 
434.x0], or 436, and transient ischemic stroke, ICD-9 code 435), and 32 patients with multiple diagnoses from this list.  
‡ Non-biologic DMARDs include methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, sulfasalazine, 
azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine  
* Other CV drugs include cardiac glycosides, antiarrhythmic agents, hypotensive agents, vasodilating agents and 
phosphodiesterase inhibitors   
Calcium channel blockers 121 25.97 892 15.95 
Other CV drugs* 150 32.19 1166 20.85 
 136 
 
Table 6.2: Estimates of the association between the use of individual TNF-Is, non-
biologic DMARDs and other biologics and the risk of an incident CVD event compared 
to no DMARD use or etanercept use 
Exposure
†
 N 
 (cases) 
N 
 (controls) 
Unadjusted IRR (95% CI) Adjusted‡
 
IRR  
(95% CI) 
No DMARD use 79 776 Reference Reference 
Infliximab 12 160 0.68 (0.35-1.30) 0.61 (0.31-1.20) 
Adalimumab 8 167 0.43 (0.20-0.93) 0.40 (0.18-0.87) 
Etanercept 20 191 0.94 (0.55-1.63) 0.89 (0.50-1.56) 
Other biologics* 17 69 2.27 (1.24-4.18) 2.01 (1.06-3.82) 
Non-biologic DMARDs* 330 4,202 0.71 (0.53-0.96) 0.66 (0.48-0.89) 
Etanercept 20 191 Reference Reference 
Infliximab 12 160 0.72 (0.34-1.52) 0.69 (0.32-1.50) 
Adalimumab 8 167 0.46 (0.20-1.06) 0.45 (0.29-1.06) 
Other biologics‡ 17 69 2.41 (1.19-4.91) 2.27 (1.08-4.76) 
Non-biologic DMARDs‡ 330 4,202 0.76 (0.47-1.22) 0.74 (0.45-1.22) 
 
† 27 controls but none of the cases were exposed to newer TNF-inhibitors (certolizumab and golimumab). 
Therefore we were not able to estimate the association between the use of these agents and an incident CVD 
event 
‡ Adjusted for pre-index NSAID use, steroid use, non-biologic DMARD use, cardiovascular medication use, 
Diabetes, Hypertension, Hyperlipidemia, chronic obstructive pulmonary disease and cancer in addition to 
matching with age, gender, duration of RA and cohort entry month and year. Unadjusted associations are 
estimated in age, gender, duration of RA and cohort entry month and year matched sample  
*Non-biologic DMARDs include methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, 
sulfasalazine, azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine, & Other biologic 
agents include abatacept, anakinara, rituximab and tocilizumab 
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Table 6.3: Association between duration of RA treatments and incident CVD event 
Exposure Adjusted† IRR 
(95% CI) 
p-value 
Each additional month of cumulative infliximab use 0.97 (0.89-1.04) 0.37 
Each additional month of cumulative adalimumab use 0.85 (0.73-1.00) 0.048 
Each additional month of cumulative etanercept use 0.99 (0.93-1.07) 0.86 
Each additional month of cumulative other biologics use‡   1.06 (0.99-1.14) 0.099 
Each additional month of cumulative non-biologic DMARD 
use‡ 
0.97 (0.95-1.00) 0.092 
 
† Adjusted for pre-index NSAID use, steroid use, non-biologic DMARD use, cardiovascular medication use, 
Diabetes, Hypertension, Hyperlipidemia, chronic obstructive pulmonary disease and cancer in addition to 
matching with age, gender, duration of RA and cohort entry month and year. Unadjusted associations are 
estimated in age, gender, duration of RA and cohort entry month and year matched sample Non-biologic  
‡ DMARDs include methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, sulfasalazine, 
azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine, & Other biologic agents include 
abatacept, anakinara, rituximab and tocilizumab  
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Appendix Table 6.1 Distribution of covariates by DMARD use status 
Variable 
No 
DMARDs 
TNF-Is† 
Other 
biologics† 
Non-Biologic 
DMARDs † 
N % N % N % N % 
Females 694 81.17 432 73.72 68 79.07 3590 79.21 
Age (Mean (SD)) 61.41 10.52 58.25 9.49 62.29 9.21 61.44 10.53 
CVD risk factors        
Diabetes Mellitus 112 13.10 108 18.43 12 13.95 687 15.16 
Hyperlipidemia 278 32.51 145 24.74 22 25.58 1392 30.71 
Hypertension 369 43.16 207 35.32 50 58.14 1892 41.75 
Other comorbidties        
COPD 147 17.19 79 13.48 18 20.93 649 14.32 
Cancer 67 7.84 19 3.24 16 18.60 274 6.05 
RA medications in the pre-
index period 
       
Coxib 69 8.07 80 13.65 14 16.28 478 10.55 
NSAIDs 305 35.67 269 45.90 27 31.40 2120 46.78 
Steroids 477 55.79 352 60.07 45 52.33 2556 56.40 
Did not use  nbDMARD 584 68.30 387 66.04 61 70.93 2576 56.84 
Used 1 nbDMARD 243 28.42 153 26.11 18 20.93 1580 34.86 
Used 2 nbDMARDs 26 3.04 38 6.48 3 3.49 346 7.63 
Used more than 2 
nbDMARDs 
2 0.23 7 1.19 4 4.65 30 0.66 
CV medications in the pre-
index period 
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Beta-blocker use 193 22.57 96 16.38 16 18.60 919 20.28 
Lipid lowering agents use 274 32.05 173 29.52 26 30.23 1540 33.98 
Calcium channel blockers 
use 
129 15.09 81 13.82 17 19.77 786 17.34 
Other CV drug use
‡
 181 21.17 108 18.43 26 30.23 1001 22.09 
ACE-I use 151 17.66 99 16.89 12 13.95 897 19.79 
 
†TNF-inhibitors include infliximab, etanercept, adalimumab, certolizumab and golimumab. Non-biologic (nb) DMARDs 
(nbDMARDs) include methotrexate, hydroxychloroquin, auranofin, injectable gold, penicillamine, sulfasalazine, 
azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine. Other biologic agents include abatacept, 
anakinara, rituximab and tocilizumab 
‡ Other CV drugs include cardiac glycosides, antiarrhythmic agents, hypotensive agents, vasodilating agents and 
phosphodiesterase inhibitors   
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Appendix Table 6.2 Distribution of covariates among users of individual TNF-
inhibitors 
Variable Infliximab Adalimumab Etanercept 
N % N % N % 
Females 126 73.26 130 74.29 161 76.30 
Age (Mean (SD)) 62.69 10.33 56.26 8.62 55.94 8.23 
CVD risk factors       
Diabetes Mellitus 46 26.74 29 16.57 31 14.69 
Hyperlipidemia 27 15.70 48 27.43 56 26.54 
Hypertension 48 27.91 62 35.43 84 39.81 
Other comorbidties       
COPD 31 18.02 11 6.29 28 13.27 
Cancer 8 4.65 6 3.43 5 2.37 
RA medications in 
the pre-index period 
      
Coxib 20 11.63 22 12.57 34 16.11 
NSAIDs 49 28.49 102 58.29 111 52.61 
Steroids 99 57.56 110 62.86 124 58.77 
Did not use 
nbDMARD
†
 
94 54.65 123 70.29 151 71.56 
Used 1 nbDMARD 68 39.53 34 19.43 45 21.33 
Used 2 nbDMARDs 9 5.23 14 8.00 13 6.16 
Used more than 2 
nbDMARDs 
1 0.58 4 2.29 2 0.95 
CV medications in       
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the pre-index period 
Beta-blocker use 34 19.77 29 16.57 31 14.69 
Lipid lowering agents 
use 
55 31.98 49 28.00 58 27.49 
Calcium channel 
blockers use 
28 16.28 18 10.29 29 13.74 
Other CV drug use
‡
 37 21.51 24 13.71 39 18.48 
ACE-I use 35 20.35 26 14.86 35 16.59 
 
† non-biologic DMARDs (nbDMARDs) include methotrexate, hydroxychloroquin, auranofin, injectable gold, 
penicillamine, sulfasalazine, azathioprine, leflunamide, minocycline, cyclophosphamide and cyclosporine,  
‡ Other CV drugs include cardiac glycosides, antiarrhythmic agents, hypotensive agents, vasodilating agents and 
phosphodiesterase inhibitors 
  
 CHAPTER 7 
7 SUMMARY 
7.1 Key Findings: 
This dissertation research focused on the determinants of use of biologic treatments, 
including TNF- α inhibitors (TNF-Is), and the cardiovascular (CV) outcomes of the use of 
TNF-I treatment in patients with rheumatoid arthritis (RA). In specific Aim 1, we evaluated 
the predictors of treatment initiation with biologics in RA patients. This study added new 
information to the literature by evaluating factors specifically influencing biologic treatment 
initiation using a large nationally representative sample derived from health insurance claims. 
We used data up to 2010 for this study and systematically evaluated the impact of various 
population characteristics on biologic treatment initiation with Andersen’s behavioral model 
(ABM) for health services use (73), a model that is helpful in understanding potential 
inequities in the use of healthcare services. We observed that treatment initiation with 
biologics was influenced by a mix of predisposing, enabling and need factors. In addition to 
the need factors such as RA severity, RA diagnosis type and pre-index use of non-biologic 
treatments for RA, the predisposing factor age, and the enabling factors of insurance type and 
drug benefit generosity were found to be significant predictors of treatment initiation with 
biologics. Neither the presence of cardiovascular risk factors, hypertension, hyperlipidemia
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or diabetes nor the history of cardiovascular diseases, including acute myocardial infarction, 
chronic heart failure, stroke or other cardiovascular diseases (CVD), were found to be 
significantly associated with the initiation of biologic treatments.  
The primary objective of Aim 2 was to examine the effect of TNF-I treatment on 
incident CVD event in patients newly diagnosed with RA. We assembled a large cohort that 
included cases with newly diagnosed RA that were not exposed to any biologic treatment 
prior to the onset of the disease. Thus, we assessed TNF-I exposure over the entire course of 
the disease. We used several different definitions of treatment exposure to account for the 
timing and history of treatment to gain a better understanding of prior medication use and 
length of treatment on CVD outcomes. We observed that the risk of incident CVD event was 
significantly reduced by current treatment with TNF-Is and non-biologic DMARDs 
compared to no treatment with any DMARD. Further, we observed that this protective effect 
was found to be associated with the duration of TNF-I and non-biologic DMARD use in a 
linear manner. Our findings also highlighted the importance of a precise and time specific 
definition of exposure by providing and comparing estimates of the risk of an incident CVD 
event using 3 unique exposure definitions with varying degrees of non-differential exposure 
misclassification.  
Because the individual TNF-I agents differ with respect to their pharmacological 
properties, effectiveness profiles in various rheumatologic diseases and tolerability, we 
examined the independent effects of infliximab, adalimumab and etanercept on the risk of 
CVD in patients newly diagnosed with RA in our specific Aim 3. We observed that treatment 
with adalimumab, but not with infliximab and etanercept, and non-biologic DMARDs was 
found to be associated with a reduced risk of incident CV events compared to no treatment 
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with DMARDs. We also observed that each additional month of treatment with adalimumab 
resulted in 15% reduction in the risk of n an incident CVD event. 
7.2 Implications: 
We undertook this analysis to provide meaningful answer to the important clinical 
question related to the best strategies of reducing CVD risk in patients with RA. Because of 
the increased burden of CVD in RA patients, the potential of various antirheumatic 
treatments for CV benefits has been the focus of attention in recent years. Numerous 
observational studies have provided estimates for the associations between TNF-I treatment 
and the risk of CVD in RA patients. Most of these studies point towards potential beneficial 
effects of TNF-Is, however estimates from some studies lack statistical significance. A meta-
analysis that pooled data form 11 observational studies, reported that the use of TNF-I was 
associated with a reduced risk of all CV events, MI and stroke (133). However, all of these 
11 studies included patients with established RA, with disease duration ranging from 5 to 15 
years, in their cohort. Because of recent reports suggesting an increased atherosclerosis in 
RA patients since very early stages of the disease (10, 11), we hypothesized that early 
treatment with TNF-Is may be able to translate into clinical benefits by hindering the 
acceleration of atherosclerosis. To test this hypothesis, we designed our study using 
insurance claims data that represented real-world early RA patients. 
First, we evaluated the association between TNF-Is as a class and the incidence of 
cardiovascular events in early RA patients, while controlling for the use of other treatments 
including non-biologic DMARDs and other biologics as well as other relevant patient 
covariates. Our finding that treatments with TNF-Is as well as non-biologic DMARDs are 
associated with a statistically significant risk reduction of CVD events in early RA patients 
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compared to no treatment with any DMARD is an important clinical finding. In this 
previously unstudied patient population, our estimates provide new insights for the clinicians 
who face the challenge of managing increased CV risk in RA patients. The American 
College of Rheumatology (ACR) advocates the use of DMARDs, both non-biologic or TNF-
Is, depending upon the duration of symptoms and features of prognosis in early RA patients 
as early as possible to maximize the chances of remission by arresting the disease 
progression. Our findings further highlight the importance of early DMARD treatment in RA 
patients by providing evidence for their potential CV benefit. Additionally, we also observed 
that the reduction in CVD risk with both TNF-I and non-biologic DMARD treatment is 
linearly duration dependent. Longer treatment with both agents appeared to be more 
beneficial for reducing the incidence of CVD events. This finding is important because it 
emphasizes the importance of treatment persistence with non-biologic DMARDs and TNF-I 
patients with early RA.  
Further, we also undertook the evaluation of independent effects of the three most 
commonly used TNF-Is on incident CVD events in the same cohort. We observed that 
adalimumab treatment appears to be significantly beneficial in reducing the risk of incident 
CVD events in early RA patients. Ours is the first study to report this important finding. 
Because our results are generated in an observational setting with a limited sample size, we 
call for further research to confirm these findings. If specific DMARDs with superior CVD 
benefit could be identified, maximum benefits could be obtained by targeting treatment with 
these agents in patient subgroups of RA patients who are at a greater risk of CVD events.  
In addition to these important clinical implications, our study also offers some policy 
implications. In our specific Aim 1, we observed that generous drug benefit was associated 
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with increased likelihood of biologic initiation. This finding supports the earlier observations 
by Karaca-Mandic et al. (121). The coverage of biologics under a higher or specialty 
formulary tier of pharmacy benefits has become increasingly common (25). Research 
suggests that this practice has substantially increased the out of pocket costs for biologics 
(25, 26). Insurers must be mindful of the fact that higher cost sharing may deter patients from 
initiation of timely pharmaceutical care, which may result in uncontrolled RA and eventual 
increase in RA-related healthcare cost. In addition, RA patients with co-morbid CVD have 
been known to incur higher overall costs than RA patients without co-morbid CVD (134). In 
our specific Aim 2, we observed that early treatment with TNF-Is and non-biologic 
DMARDs may be able to help in preventing incident CVD events in RA patients. Together 
these findings suggest that promoting early treatment with TNF-Is and non-biologic 
DMARDs by reducing patient cost sharing may result in ultimate cost savings for the 
insurers. 
Finally, our study also has methodological implications. We used 3 unique definitions 
to evaluate the impact of exposure definition on the observed estimates in our specific Aim 2. 
As observed in our exposure definition schemes 1 (Ever/Never TNF-I use) & 2 (Current use 
indicators for TNF-Is and other RA treatments), broad definitions lead to non-differential 
misclassification of exposure and resulted in a reference group consisting of a heterogeneous 
mix of patients. When relying on relative measures of associations, such misclassification 
may lead to masking of important differences in treatment-outcome associations. In our case, 
scheme 1 lumped the users of all non-TNF DMARDs along with non-users of DMARDs into 
the reference category ‘Never use of TNF-Is’. In scheme 2, users of other DMARDs were 
separated but past users of these DMARDs got classified into the reference category ‘No 
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current DMARD use’. This misclassification may lead to an inappropriate conclusion that 
TNF-I use has no impact on incident CVD events. In reality, as reflected in scheme 3, the 
appropriate inference would be that compared to no DMARD use, current use of TNF-Is may 
have a potential protective effect against incident CVD events in patients newly diagnosed 
with RA. However, since non-biologic DMARDs also have a similar protective effect and 
schemes 1 and 2 fail to account for the treatment history with these agents, this important 
finding is masked in these two definition schemes. Although several authors have highlighted 
this problem in the past using examples of different drug classes,(65, 126) unfortunately this 
is still a largely ignored issue in pharmacoepidemiology studies. Based on our findings, we 
recommend that researchers evaluating treatment-outcome associations in RA patients should 
create exposure groups after considering patients’ history of DMARD use. Based on the 
composition of the exposure group, the inference may change due to non-differential 
exposure misclassification.   
Some authors (56) in the past have suggested that patients who do not receive 
DMARDs may not be the most appropriate reference group while evaluating impact of 
biologic treatments in CVD outcomes in RA because of the issues related to confounding by 
indication. Briefly, this phenomenon occurs if the reason behind prescribing biologics is 
related to the outcome (CVD in our case). However, based on our Aim 1 results, in which we 
observed that neither CVD risk factors nor CVD history was related to the initiation of 
biologic treatment, we believe that our results do not merely reflect confounding by 
indication. In addition, our reference group may be comprised of any combination of three 
clinically distinct types of patients, 1) Patients with less severe RA whose conditions do not 
require immediate DMARD initiation in their physician’s opinion, 2) Patients not suitable for 
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DMARD initiation because of the concerns of adverse events from the use of these agents 
due to their generally poor health and 3) Patients similar to our comparator groups but who 
did not start timely DMARD therapy. If a large proportion of our reference group is 
comprised of patients type 1) discussed above, then arguably they should be at a lower risk of 
CVD events because severity of RA is associated with CVD risk. In that case, our estimates 
present a conservative estimate of the benefits of TNF-Is and non-biologic DMARDs. If a 
large proportion of our reference group is comprised of patients type 2) discussed above, then 
our findings may not represent the accurate estimates of benefits of TNF-Is and non-biologic 
DMARDs and may just be an artifact of the baseline CVD risk differences between the 
reference group and the comparator group. However, we strongly argue that this is unlikely 
because to be included in our cohort all the patients had to have at least one prescription of 
DMARDs during our study period. That means that the patients in our reference group 
represent the person-time experiences of new RA patients prior to starting their DMARDs. 
So clearly, these patients cannot be considered unsuitable for DMARD treatment. If a large 
proportion of our reference group is comprised of patients type 3) discussed above, then we 
think that our estimates present the most accurate relative risk estimates for the benefits of 
TNF-Is and non-biologic DMARDs. We believe that our findings should be interpreted as 
evidence in favor of using TNF-Is and non-biologic DMARDs for their CVD benefits 
compared to not using any DMARDs and should not be used to represent comparative 
differences between classes.  
7.3 Strengths and Limitations:   
Our study has several unique strengths. This is the largest study of its kind to provide 
the estimates of the association between TNF-Is and the risk of CVD events in newly 
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diagnosed RA patients. Our sample represents the real world experiences of RA patients 
from the entire country. We conducted the study exclusively in incident RA patients and 
matched our cases and controls on the duration of the disease to reduce unmeasured 
confounding. We used a study design that is known to account for the time varying nature of 
RA treatments (104). Additionally, we tested multiple definitions of exposure and provided 
estimates using the definition that accounted for the entire treatment history of the patients. 
Our specific Aim 3 is the only study to our knowledge that represents the estimates for the 
independent effects of individual TNF-Is on the risk of incident CVD events.  
However, there are certain limitations of this study that deserve discussion. As with 
any other study using administrative claims, we were not able to validate the diagnoses of the 
disease condition (RA), outcomes as well as co-morbid conditions. Several issues in coding 
of disease diagnoses in administrative claims data, which are collected for reimbursement 
purposes, have been identified. One such issue is that of upcoding of claims, in which the 
recorded diagnosis codes are entered to reflect a more complex disease condition than the 
actual condition to maximize reimbursement (135). However, to address this limitation we 
used algorithms for detection of RA and CVD events that were validated previously for their 
sensitivity and specificity (97, 127, 128).  
Further, the administrative claims contain very limited information on clinical 
conditions of RA patients, such as disease activity and swollen joint count. Therefore, we 
were not able to capture the exact severity of RA in patients of our cohort. However, as a 
proxy, we used the validated claims based index for getting an approximation of RA severity 
(101) for specific Aim 1. For specific Aims 2 and 3, our sampling technique matched cases 
and controls on the duration of RA, which is used as an approximation for severity of RA.  
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Additionally, since the claims data do not have reliable information on patient vital status, 
our Aims 2 and 3 are limited by the competing risk of death. To minimize that, we identified 
ICD-9 codes related to death (sudden death (798), instantaneous death (798.1), or death 
occurring in less than 24 hours from onset of symptoms, not otherwise explained (798.2)) 
and censored patients at their insurance disenrollment date.  
Measurement of exposure also presents unique challenges in pharmacoepidemiology 
studies using administrative claims data. We had to rely on prescription refill records to 
estimate the exposure. In this definition of exposure, it has to be assumed that filling of 
prescription equates with the use of medication. This assumption is untestable. We would 
also like to acknowledge that our database did not contain information on important variables 
such as tobacco consumption of the patients, which is a risk factor for both RA and CVD. 
We were also not able to capture the over-the-counter use of certain pain relievers, which are 
commonly used by RA patients. Therefore, there may have been some residual confounding 
in our exposure-outcome association even after multivariate risk adjustment.  
Because of the small number of patients using individual TNF-Is, our Aim 3 may be 
underpowered to detect the differences between these agents for the CVD outcomes. Some 
readers may argue that if conducting the study in a dataset that had information on healthcare 
experiences of over 35 Million unique individuals is unable to provide sufficient sample size 
for our research question, it may be difficult for future researchers to assemble a larger 
sample than ours. We acknowledge and share this concern. To gain a better understanding of 
this issue, it is imperative to discuss some of the major constraints limiting the sample size of 
our study. Firstly, our research interest of uncovering differences between individual TNF-Is 
led us to create exposure categories based on patients’ use of adalimumab, etanercept or 
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infliximab instead of combining them as a single group in Aim 3. Secondly, very few 
patients who belong to the population of our interest (early RA patients) begin treatment with 
these agents.  Finally, in order to improve the internal validity of the study, we excluded all 
the patients exposed to any biologics in the 12-months of pre-index period and conducted the 
study exclusively among the new users of these agents. Taken together, our exposure of 
interest, population of interest and the restrictions employed to improve the internal validity 
of the study resulted in small samples for the exposure groups of our Aim 3. If we were to 
relax some of these criteria, for example including prevalent users of these medications or 
defining the baseline period as a 6-month interval, we are likely to assemble a larger sample. 
However, in doing so the internal validity of the study may be compromised.  
The finding that the use of other biologics is associated with an increased risk of 
incident CVD events compared to no DMARD use in our Aims 2 and 3 is puzzling. We 
postulate that the widespread problem of channeling bias affecting observational studies may 
explain this finding. It may be possible that patients with a higher baseline cardiovascular 
risk may be channeled towards the use of non TNF-I biologic agents. The fact that TNF-Is 
are contraindicated in New York Heart Association class III and IV CHF patients may deter 
physicians from prescribing these agents in patients with a higher cardiovascular risk profile 
altogether. The risk of CVD at baseline was found to be higher for these patients as 
evidenced by a higher IRR while defining the use of these agents categorically, but when the 
duration of use was accounted for this higher risk was no longer observed suggesting 
potential for channeling bias.  We were not able to adequately control for this because of the 
unavailability of RA specific cardiovascular risk factors such as smoking, obesity and RA 
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disease activity in our data. Further studies that account for these differences are necessary to 
understand the impact of other biologic treatments on the risk of CVD events.  
Additionally, since the claims data do not have reliable information on patient vital 
status, our study is limited by the competing risk of death. Patients who experience sudden 
cardiac death are likely to go unrecorded in our database. Therefore, the patients may either 
be censored because after their death, they would no longer be enrolled in the health plan or 
may still keep contributing person time to our study if somehow their health insurance 
enrollment is active after their death. Such patients should ideally be classified as cases, but 
because of unavailability of their data, our study could not accurately classify them as cases.  
We caution the readers to interpret our findings in light of these limitations.    
7.4 Implication for future research:  
Our study paves the way for future research in several meaningful ways. In our specific 
Aim 1, we observed that age was inversely associated with biologic initiation. We postulate 
that this finding may be explained by factors including but not limited to physician 
preference, patients’ concerns related to the safety of biologics and patients’ co-morbid 
conditions. Future research should be conducted to examine the efficacy and safety of 
biologic agents in elderly patients and patients with co-morbid conditions to address some of 
these issues. If safe and effective biologic agents are identified in this specific patient 
population, both patients and payers could be benefited.  We also observed that lower patient 
cost sharing results in increased likelihood of biologic initiation. Further research examining 
whether this increased likelihood translates into improved outcomes and resultant cost 
savings should be conducted.   
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As discussed in section 7.3, our estimates from Aims 2 and 3 may suffer from residual 
confounding. Therefore, we call for future studies evaluating the association between TNF-Is 
and CVD events in this specific population using data sources that has sufficient covariate 
information to control for baseline CV risk. Additionally, because very limited data is 
available in the literature evaluating the associations between non TNF-I biologics including 
abatacept, rituximab, tocilizumab and certolizumab and CVD risk, future studies should be 
conducted with an exclusive focus on these agents to ensure sufficient power.  Our study 
used a composite endpoint of all CVD events. Evaluation of association between TNF-I and 
separate cardiovascular endpoints should be planned to better understand the full potential of 
benefits of these treatments.  
Cardiovascular risk reduction in RA patients after TNF-Is and non-biologic DMARDs 
as observed in our study involves complex biologic mechanisms. This risk reduction may be 
attributed either to the favorable changes in traditional cardiovascular risk factors, such as 
insulin resistance, blood pressure and atherogenic index, or to the favorable changes in 
inflammatory processes leading to acceleration of atherosclerosis. In order to maximize the 
treatment benefits in specific subpopulations of RA patients, an understanding of the 
mechanisms by which CV risk reduction occurs is very important. Studies conducted using 
subclinical endpoints such as high density lipoprotein levels and low density lipoprotein 
levels have their merits but provide little information related to the actual clinical benefits. 
Therefore, observational studies designed with clinical endpoints, such as development of 
diabetes, hyperlipidemia or hypertension, to evaluate the association between these 
treatments and traditional CVD risk factors are required. A recent evaluation using 
development of diabetes as an endpoint in RA or psoriasis patients after TNF-I treatment 
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presented encouraging findings that patients using these agents were nearly 40% less likely 
to develop diabetes than patients using certain non-biologic DMARDs (136). Further studies 
similar to this will provide very important insights in proper CV risk management in RA. The 
societal benefit of proper CV risk management is illustrated by the decline in CV mortality in 
patients with diabetes over last two decades (137). The medical community should strive for 
a similar decline in CV burden in RA patients and more research targeted towards 
understanding the potential role of antirheumatic agents in CV risk reduction represents a 
great opportunity to achieve this.  
Finally, our Aim 3 finding of adalimumab showing a protective effect in terms of its 
CV risk reduction in new RA patients should be treated as hypothesis generating. No study in 
the literature has been conducted to evaluate independent CVD effects of individual TNF-Is. 
We call for more studies with larger sample size to confirm this finding.  
7.5 Conclusion: 
The results from this dissertation suggest that early treatment with TNF-Is and non-
biologic DMARDs may help in reducing the risk of incident CVD events in patients newly 
diagnosed with RA. Among available TNF-Is, adalimumab showed the largest clinical 
benefit for CVD risk reduction. Future studies with larger sample size are recommended to 
confirm findings from our study.  
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